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Summary
Protease enzymes are responsible for the catalytic hydrolysis of peptides and 
therefore play vital roles in the biochemistry of organisms. Serine proteases, 
which achieve proteolytic cleavage by a mechanism involving an activated 
serine residue, are numerous in mammalian systems while only a limited number 
of the analogous cysteine proteases are to be found. Cysteine protease 
enzymes are however, widespread in parasitic species and often essential to the 
functioning of the organism. Thus the use of inhibitors for the treatment of 
parasitic infestation may be possible if the subtle differences between these two 
enzyme families can be exploited.
The opportunity exists in using modified substrates (peptides) to effect the 
inhibition of protease enzymes. In this case the required modification must 
induce the irreversible binding of the peptide to the active site of cysteine, but 
not serine, proteases. Indeed, A/-protected dipeptides bearing the fluoromethyl 
ketone or diazomethyl ketone modifications of the carboxy terminus have been 
shown to be particularly effective in this respect. Unfortunately, little is known 
about the substrate specificity of individual parasite cysteine protease enzymes.
The therapeutic use of dipeptide based inhibitors is limited by the vulnerability of 
the peptide linkage itself to proteolytic cleavage. Pseudo peptides containing 
the non-hydrolysable (E)-ethene linkage in place of the amide group have been 
shown to possess biological activities similar to those of the parent compounds 
in some systems. This concept has not, however, been applied to the field of 
parasite cysteine protease inhibition.
The aim of this study was to synthesise a selection of A/-protected pseudo 
peptides bearing the (E)-ethene isosteric linkage and a modified carboxy 
terminus (preferably as the more selective fluoromethyl ketone). The biological 
activity of these compounds could then be evaluated against a battery of 
cysteine protease containing parasitic species. Thus further clues as to the
substrate selectivity of these enzymes may be obtained in addition to the 
assessment of the suitability of the chosen isosteric linkage.
A selection of A/-phthaloyl protected amino acids was formed and used as model 
systems to test the carboxy terminus modification methodology. While the 
generation of the diazomethyl ketone derivatives of these via an intermediate 
mixed carbonate was successful, the subsequent conversion to the fluoromethyl 
ketone was found to be inefficient and impractical. The use of bromomethyl 
ketones as intermediates was therefore investigated.
The problems initially experienced during the attempted formation of 
bromomethyl ketones were overcome by the use of dry hydrogen bromide gas 
as a reagent. Thus it was shown that these materials could be formed in 
excellent yield. It was also found that the subsequent halogen exchange 
reaction could be performed successfully with triethylamine trishydrofluoride to 
give the desired fluoromethyl ketones.
Despite several important questions concerning this synthesis remaining 
unanswered and alternative methods untested, studies in this area were halted 
due to recent developments in end group technology. It was decided that the 
less selective, but more easily prepared, diazomethyl ketones would suffice as 
end groups for initial testing of the isostere concept with respect to parasite 
cysteine proteases.
Studies were initiated with the aim of synthesising the (E)-ethene isostere of N- 
BOC-(L)-Phe-(L)-Ala. Preparation of the A/-BOC protected (L)-phenylalaninal 
required for the first route chosen was effected using literature procedure. The 
subsequent addition of vinylmagnesium bromide to this aldehyde resulted in the 
generation of a pair of diastereomers from which the less abundant product was 
required. As the isolation of this material was found to be inefficient, studies in 
this area were not continued and an alternative route to the target compound 
was investigated. This strategy, which would utilise the Julia olefin synthesis as
the key synthetic step, required the prior generation of a sulfone derived from 
the appropriate A/-BOC protected (L)-amino acid. The four step sequence for 
the formation of this species was carried out successfully and reliably, on both 
large and small scales, on A/-BOC protected (L)-phenylalanine, (L)-valine and 
(L)-leucine. Purification of the intermediate compounds involved was found to 
be straightforward.
The chiral aldehyde required for the generation of a position-2 alanine mimic 
was formed, after some degree of experimentation, by the action of 
diisobutylaluminium hydride on the corresponding methyl ester. In contrast, for a 
glycine mimic, ozonolysis of an olefin was employed as the key aldehyde 
generating reaction.
The sulfone to aldehyde coupling reaction was initially the source of some 
problems. Conditions were eventually developed where the coupling could be 
effected and a quantitative estimate made on the extent of product formation. 
The p-hydroxysulfones produced by this coupling were converted into the 
corresponding trans olefins by reductive elimination. Removal of the C-terminus 
protection and generation of the required carboxylic acid was then effected in a 
single step by the use of Jones’ reagent. Thus the (E)-ethene isosteres of N- 
BOC-(L)-Phe-(L)-Ala, A/-BOC-(L)-Val-(L)-Ala and A/-BOC-(L)-Val-Gly were 
successfully synthesised and shown to possess the desired stereochemistry.
With a view to the synthesis of further intermediate aldehydes, studies on 3- 
pentenoic acid indicated that a-alkylation could be carried out without inducing a 
shift in the position of the double bond. This result also indicated that the 
synthesis of 4-methyl-3-pentenoic acid, a starting material employed in the 
literature route to alternative aldehydes, would be superfluous. Investigations 
into the generation of this material were therefore halted.
The standard method for the synthesis of diazomethyl ketones, as tested earlier, 
was applied to one of the completed isosteres but met with failure. A full scale
investigation into the factors influencing this result and possible alternative 
methods for activation of the carboxylic acid, allowed a plausible explanation for 
the reaction failure to be proposed. A technique was then developed, using 3- 
pentenoic acid as a model system, which allowed the successfull generation of 
diazomethyl ketones from Py-unsaturated carboxylic acids. The application of 
this methodology to the three completed isosteres allowed the synthesis of the 
desired diazomethyl ketones with the corresponding methyl esters being 
produced as the main by-products. An investigation into the use of methyl 
esters as starting materials in diazomethyl ketone syntheses proved to be fruitful 
with methyl 3-pentenoate. Unfortunately the application of this methodology to 
an (E)-ethene isostere methyl ester resulted in destruction of the olefin.
Thus the diazomethyl ketones of the A/-BOC-(L)-Phe-(L)-Ala, A/-BOC-(L)-Val-(L)- 
Ala and A/-BOC-(L)-Val-Gly (E)-ethene isosteres were successfully synthesised. 
Molecular mechanics calculations were carried out on the diazomethyl ketone of 
both amide and (E)-ethene linked A/-BOC-(L)-Val-(L)-Ala, the results of which 
suggested the isosteric nature of these groups.
The three isostere diazomethyl ketones, the corresponding methyl esters and 
also the diazomethyl ketone of the amide linked dipeptide A/-CBZ-(L)-Phe-(L)- 
Ala, were screened for activity against a variety of parasitic species. Results 
indicate that the diazomethyl ketone of A/-BOC-(L)-Phe-(L)-Ala possesses some 
form of growth inhibiting activity against Leishmania mexicana. This effect was 
not observed with either the isostere methyl ester or the diazomethyl ketone of 
the amide linked material. Similarly the diazomethyl ketone of A/-BOC-(L)-Val- 
(L)-Ala caused some degree of growth inhibition on several species of 
Trichomonas. It was not proven however, that these observed effects were due 
to cysteine protease inhibition.
Surprisingly, the methyl ester of A/-BOC-(L)-Val-Gly proved to be a powerful anti­
protease. Both this compound and the corresponding diazomethyl ketone 
showed the ability to inhibit parasitic growth.
Thus it can be concluded that (E)-ethene isosteres of A/-protected dipeptide 
diazomethyl ketones are capable of restricting the growth of specific parasitic 
species. It is as yet unknown if this effect is due to cysteine protease inhibition.
This thesis is dedicated to 
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"...in battle, use the normal force to engage; 
use the extraordinary to win. ” 
(translation)
- Sun Tzu
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1General Preamble
Terminology
Amino Acids
Throughout this study amino acids may be referred to by the recognised three 
letter abbreviations.
Alanine Ala Leucine Leu
Arginine Arg Lysine Lys
Asparagine Asn Methionine Met
Aspartic acid Asp Phenylalanine Phe
Cysteine Cys Proline Pro
Glutamine Gin Serine Ser
Glutamic acid Glu Threonine Thr
Glycine Gly Tryptophan Trp
Histidine His Tyrosine Tyr
Isoleucine lie Valine Val
In addition to these, the abbreviation Xxx will be used to represent an 
unspecified amino acid.
Peptides
The composition of peptides constructed from the above amino acids will be 
described using the recognised amino to carboxy terminus convention. For 
example, the peptide formed by the condensation of the carboxyl group of 
phenylalanine with the amino group of alanine would be given the abbreviation 
Phe-Ala.
Stereochemistry
The stereochemistry of each amino acid will be indicated by either an (L)- or (D)- 
prefix with (L)- being the natural configuration. Racemic centres will be assigned
2the prefix (DL)-. For example, the dipeptide formed by the condensation of 
natural phenylalanine with racemic alanine would be given the abbreviation (L)- 
Phe-(DL)-Ala.
Amino Acid Position
The position of each amino acid in a peptide may be indicated by a numbering 
system which follows the amino to carboxy terminus convention. Thus, in the 
dipeptide (L)-Phe-(DL)-Ala, phenylalanine would be described as occupying 
position 1. The associated benzyl side chain may also be described as the 
position 1 or AMerminal amino acid side chain. Similarly, alanine would be 
described as occupying position 2 with the associated methyl side chain termed 
the position 2 or C-terminal amino acid side chain.
Amide Link Replacement
In cases where the amide link of a dipeptide has been replaced by an isosteric 
group this will be stated. For example, the variant of (L)-Phe-(DL)-Ala where the 
central amide link has been replaced by an (E)-ethene group would be termed 
as the (E)-ethene isostere of (L)-Phe-(DL)-Ala.
A/-Terminus Protection
The A/-, or amino, terminus of a peptide may possess a protecting group such as 
(abbreviations indicated in brackets) benzyloxycarbonyl (CBZ), tert- 
butoxycarbonyl (BOC), phthaloyl (phth) or tosyl (Tos). For example, the 
dipeptide (L)-Phe-(DL)-Ala bearing an A/-terminus fe/f-butoxycarbonyl protection 
would be shown as A/-BOC-(L)-Phe-(DL)-Ala. Modifications to amino acid side 
chains will be indicated by a suffix enclosed in square brackets. For example, a 
benzyl protection of the hydroxyl group of tyrosine would be indicated by Tyr[0- 
Bz].
C-Terminus Modifications
Modifications to the carboxy terminus will be indicated in the following manner.
In cases where the modification results in the generation of a new carbon to
3carbon bond, this will be indicated by the placing of the modifying group directly 
after the amino acid designation. For example, the compound produced by the 
conversion of the carboxyl group of alanine into a diazomethyl ketone would be 
shown as AlaCHN2. Similarly, the corresponding chloromethyl ketone would be 
given the designation AlaCH2CI. However, in cases where the modification does 
not result in the generation of a new carbon to carbon bond, this will be indicated 
by inclusion of a hyphen. For example, the methyl ester of alanine would be 
given the designation Ala-OMe. Similarly, a C-terminal amide would be 
indicated by Ala-NH2.
Exception to the Above Rules
When illustrating the mechanism of enzyme action, functional groups or part side 
chains of interest will be shown linked to the parent amino acid in the peptide 
sequence which constitutes the enzyme. For example, Ser95-OH may be used 
to indicate the side chain hydroxyl function of a serine residue which occupies 
position 95 in the linear amino acid sequence of an enzyme.
Additional Abbreviations
The following abbreviations may also be used throughout this study.
B
cat.
Diazald®
DIBAL-H
DMAP
DME
DMF
DMSO
E or Enz
El
G.
HPLC
I
L
L
LDA
Ms
NMO
Nu
T.
THP
base
catalytic
A/-methyl-A/-nitroso-p-toluenesulphonamide 
Diisobutylaluminium hydride 
4-Dimethylaminopyridine 
Dimethoxyethane 
A/./V-Dimethylformamide
Dimethylsulfoxide (deuteriated form indicated by d6-) 
Enzyme
Enzyme-inhibitor complex 
Giardia
High pressure liquid chromatography
Inhibitor
Ligand
Leishmania
Lithium diisopropylamide 
Mesyl
A/-Methylmorpholine A/-oxide 
Nucleophile 
Trichomonas 
Tetrahydropyranyl
Any other abbreviations used will be defined as required within the main text.
5INTRODUCTION
Chapter 1: Protease Enzymes
Four main classes of protease enzymes have been detected, aspartic, metallo-, 
cysteine and serine proteases, the common feature of which is that they all 
possess the ability to catalyse the hydrolysis of amide links within peptides and 
proteins. These enzymes therefore play vital roles in the biochemistry of 
organisms.
It is the aim of this study to develop compounds which will disrupt the 
biochemical processes of parasitic organisms by inhibiting essential protease 
enzymes. Since proteolytic cleavage is also a vital part of the biochemistry of 
the host, it is imperative that the inhibiting action is highly selective. In order to 
gain an insight as to how this effect can be achieved, it is first essential that the 
general mechanism by which the serine and cysteine proteases achieve amide 
cleavage is illustrated.
1.1 The Serine Proteases
Chymotrypsin is a digestive serine protease which is involved in the hydrolysis of 
proteins in the small intestine.111 The enzyme selectively cleaves amide links on 
the carboxyl side of aromatic and other large hydrophobic side chains. This 
preference is caused by the the presence of a large hydrophobic pocket in the 
tertiary structure of the enzyme which, once filled by suitable side chains, places 
the following amide link close to specific active residues. As with others of this 
class the enzyme employs an unusually reactive serine side chain to initiate 
peptide link cleavage. A closer analysis of the tertiary structure of the enzyme 
indicates how this hydroxyl group, normally unreactive under physiological 
conditions, is activated.
6The specific folding of the enzyme results in three residues, distant from each 
other on the protein chain, being sited within close spatial proximity to each other 
(figure 1.1-1).
?C - / V  5+ 8 '
Asp 102^ 0 -----------------------H - I ^  ^ -------------------  H - ° v
Ser 95
His 57
(figure 1.1-1)
The three side chains of aspartate, histidine and serine occupy positions 102, 57 
and 95 respectively in the linear amino acid sequence of the enzyme. However, 
as indicated, the close arrangement of the side chains in space allows a 
complex sequence of hydrogen bonding to occur. The net result of this 
interaction is a partial deprotonation of the serine hydroxyl oxygen thus imparting 
an increase in nucleophilicity. The following sequence of events can now occur:
Stage 1: The peptide substrate is aligned close to the active serine side chain 
(figure 1.1-2).
?
H
Asp 102 o  ---------------------- H - N    H --O n
6 + §
VSer 95
His 57
(figure 1.1-2)
Stage 2: Nucleophilic attack by the active serine on the amide carbonyl results 
in the formation of a tetrahedral intermediate (figure 1.1-3). This intermediate is 
stabilised by hydrogen bonding from amide NH groups in the enzyme main 
chain.
7O R s V
II N —C — R'^■Cv — ^  u /  T
Asp 102 o ............... H—N N - H  H o
Ser 95
His 57
(figure 1.1-3)
Stage 3: The proton held by the histidine side chain is donated to the nitrogen 
atom of the intermediate facilitating its collapse (figure 1.1-4). Release of the 
product amine can now occur. The product acid remains bound to the serine 
residue by an ester linkage.
O R v c u  ,R '
II nn _H  c
Asp 102 o .................H - N  N ......... H o \_Ser 95
His 57
(figure 1.1-4)
Stage 4: With the product amine now replaced by water, the process of 
activation can be repeated with this molecule (figure 1.1-5).
o IJ .R 'y
Asp ]02 O ................... H  H o
' Ser 95V
His 57
(figure 1.1-5)
Stage 5: A second tetrahedral intermediate results from the attack of water on 
the acyl-enzyme species (figure 1.1-6). This intermediate is stabilised in a 
similar manner to that formed in stage 2.
H s  < f
Asp ,0 2 ^  O  -.............................................................. 0  £  R '
His 57
(figure 1.1-6)
Ser 95
Stage 6: Donation of the proton from the histidine side chain to the tetrahedral 
intermediate facilitates the collapse of this species thus giving the carboxylic acid 
product and returning the serine residue to its original state (figure 1.1-7).
Asp 102 0 h —:
His 57
(figure 1.1-7)
From this illustration, the catalytic behaviour of the enzyme in this case can be 
readily appreciated and, as such, the three key residues involved in the cycle are 
often referred to as the catalytic triad of chymotrypsin.
Other members of the serine protease family share this arrangement of residues 
in the active site. Where each member differs however, is in the selection of 
substrates.[2][3] While with chymotrypsin the large hydrophobic pocket selects 
aromatic and similar bulky non-polar side chains, the selectivity of trypsin is 
different due to a slight modification in this region. A serine residue at the base 
of the pocket is absent and in its place exists aspartate. Thus trypsin is found to 
cleave peptide links which follow an arginine or lysine residue due to the 
favourable electrostatic interaction these species form. In the case of elastase 
the hydrophobic pocket is partially blocked by the replacement of two glycine 
residues with valine and threonine. This enzyme is therefore found to select 
substrates containing small non-polar side chains such as the methyl group of 
alanine.
Other enzymes of this class include thrombin, an enzyme involved in blood 
clotting and acetylcholinesterase which plays a key role in nerve function.
91.2 The Cysteine Protease
Cysteine proteases (or thiol proteases) utilise a thiol-imidazolyl catalytic system, 
analogous to that employed by the serine proteases (figure 1.2-1).[41 In this 
case the unusually reactive serine residue is replaced by a similarly activated 
cysteine. A family of cysteine proteases similar in structure to each other can be 
found in plants including papain, from the papaya fruit, and fiacin from figs.[5]
J L  s + 5 -
Asn 175 i f - ---------------------H — N  N ------------------H ~ ‘
H ^ = 4  Cyszs
His 159
The papain  catalytic triad 
(figure 1.2-1)
Most mammalian tissues contain only three major cysteine proteases, 
cathepsins B, H, and L. As these proteases are involved in protein turnover they 
are generally located within the lysosomes of cells.161 Sub-cellular lysosomes are 
responsible for the breakdown of cellular protein and thus play a key role in the 
maintenance and renewal (turnover) of this material.
1.3 Cysteine Proteases and Disease States
Extralysosomal cysteine proteases are believed to have a causitive role in a 
number of disease states. During the sequence of steps resulting in the spread 
of cancer from one tissue to another (metastasis), the release and extracellular 
activity of cysteine proteases has been noted.171 Cathepsin B has also been 
found to be present in elevated amounts in cell variants of high metastatic 
potential. Thus the inhibition of such enzymes may result in the limitation or 
elimination of this process with obvious therapeutic advantages. Similarly, non- 
lysosomal cysteine proteases have been implicated as being involved in 
extracellular collagen degradation in conditions such as arthritis suggesting a 
further possible application of selective inhibitors.181
10
In the realm of parasitic diseases the role of cysteine proteases has been the 
subject of much research.161 The proteases of parasites are crucially involved in 
many aspects of host-parasite interaction in addition to their general role in 
protein turnover. Cysteine proteases have been detected in most groups of 
parasitic protozoa (unicellular eukaryotes which are unable to derive energy from 
photosynthesis or inorganic chemicals and therefore require to feed on plants or 
animals). Indeed many species contain relatively large numbers of distinct 
enzymes unlike mammalian tissues. These enzymes tend to have high activity 
in at least one stage in the life cycle of the parasite, often a stage which takes 
place within the mammalian host. Since parasite cysteine proteases have been 
noted as being different from their mammalian cousins (for example many 
appear to be larger and/or have a higher stability to alkaline conditions), the 
opportunity for selective inhibition of either general life processes or specific 
host-parasite interactions may exist. Unfortunately, for the majority of these 
enzymes, little is known about substrate specificity.
1.4 Cysteine Proteases and Parasitic Diseases
In order to fully appreciate the crucial role played by parasite cysteine protease 
enzymes, in addition to standard protein turn-over, one must first discuss typical 
parasite life cycles and their resulting impact on the human host. From this, a 
measure of the importance of research in this area can also be gauged.
Malaria1911101
Approximately 250 million people are affected by this disease at any one time 
and between 2 and 4 million of these die each year as a result. This disease is 
caused by sporozoans (non-motile, amoeba-like, spore forming parasites) of the 
genus Plasmodium which are transmitted by the female Anopheles mosquito. 
When the Anopheles mosquito takes a blood meal from from a human it injects 
saliva in order to inhibit clot formation. It is from this saliva that the Plasmodium 
cells of the sporozoite stage enter the host where they are carried by the blood
11
stream to the liver (figure 1.4-1). In this organ the sporozoites grow for between 
5 and 15 days after which they divide producing a large number of cells known 
as merozoites. These are released from the liver and penetrate red blood 
corpuscles (erythrocytes) within which they divide rapidly. This process causes 
enlargement and eventual rupture of the corpuscle resulting in the release of the 
fresh merozoites which enter further corpuscles continuing the process. 
Eventually some merozoites develop into gametocytes which have the potential 
to become either male or female sex cells (gametes). These cells will not 
mature as gametes while they remain within the human host but must pass, 
during a blood meal, back into a female Anopheles mosquito. Within the gut of 
such a mosquito these cells complete their development and reproduce sexually. 
The product of this process divides to ultimately produce new sporozoites which 
migrate to the salivary glands of the mosquito and are then ready to infect further 
human hosts.
M O SQ U ITO  HU M A N
G row th and division
Injection by 
m osquito
w ithin  liver
▼
Sporozoites form  
w ith in  m osquito
4
m osquito
M ultip lication 
w ith in  red  b lood 
corpuscles
G am etocy t
fo rm ation
(figure 1.4-1)
Cysteine protease enzymes are believed to be involved in the invasion of red 
blood corpuscles by merozoites and the earlier maturation of these within the
12
liver.[11] [61 Work on the species Plasmodium falciparum has also suggested that 
the parasite cysteine proteases are responsible for the digestion of the host 
corpuscle haemoglobin.[12] The breakdown of host haemoglobin is essential in 
order to provide the developing parasite with amino acids for protein 
synthesis.1131 Indeed it has been shown that inhibition of cysteine protease 
enzymes prevents intraerthyrocytic development and causes the enlargement of 
parasite food vacuoles (analogous organelle to mammalian lysosomes).[11]
Trypanosoma and Leishmania
These parasitic protozoa belong to the phylum zoomastigina.[14] The distinctive 
feature of the zoomastigotes is that they achieve motility by the use of one or 
more long flagella. Thousands of species of zoomastigotes exist, many of which 
are parasitic.
Trypanosoma cruzi affects 11-12 million people in Central and South America.1151 
The vector for this disease are bugs belonging to the Reduviidae family. As with 
malaria the vector species becomes infected by feeding on mammalian blood 
containing the organism. Multiplication occurs within the insect host with the 
infective species passed out in the insect faeces. The human host becomes 
infected if these faeces come into contact with the insect bite or other wounds or 
the conjunctiva of the eye. The parasites then enter a variety of tissues 
particularly macrophages (mobile cells of the immune system which engulf and 
digest invading bacteria, fungi, other microorganisms and general cellular 
debris), muscle and nerve cells where they multiply and develop. The life cycle 
of the parasite continues upon ingestion by the insect vector during a blood 
meal. In the most serious cases of Chagas disease, as caused by this parasite, 
cardiac failure or loss of alimentary canal nervous control can result.
The cystein protease cruzain (also known as cruzipain) has been shown to be 
responsible for the major proteolytic activity of this organism. Cysteine protease 
enzymes may also play a role in the penetration of the host cell.[161
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The African variants Trypanosoma brucei gambiense and Trypanosoma brucei 
rhodesiense are responsible for the disease commonly known as sleeping 
sickness.[15] The vector in this case being the tsetse fly of the Glossinidae 
family. The closely related Trypanosoma brucei brucei, which similarly affects 
horses, camels and cattle, is often used as a model system for the study of 
these species. At least four cysteine protease enzymes are believed to be 
present in Trypanosoma brucei brucei.[6]
Stages in the life cycle of the Central American Leishmania mexicana 
(transmitted by the sand fly Lutzomyia) take place within the macrophages of a 
human host. Cysteine proteases, of which at least seven are present, are 
probably required for the survival of the parasite within these cells of the immune 
system.'151161
1.5 Protease Enzyme Inhibition
The parasite cysteine protease enzymes are a major target for the development 
of specific inhibitors in order to combat the widespread diseases discussed 
above. The apparent differences between these enzymes and their mammalian 
counterparts suggests that effective inhibition may be possible with minimal side 
effects.
To inhibit an enzyme the potential inhibitor must bind in such a way that the 
active site is either blocked or altered in structure. In effect the active site or its 
associated catalytic machinery must no longer exist in a functional form. The 
inhibitor molecule may bind directly to the active site of the enzyme, possibly by 
mimicking the general structure of the true substrate. If the interaction between 
this material and the enzyme is weak, and the binding therefore reversible, the 
degree of inhibition will depend on the concentrations of both inhibitor and 
substrate. This is inevitable as both materials will, in effect, be in competition for 
the same site.
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An alternative to this is the binding of the inhibitor to a region remote from the 
active site. Such a material relies on the gross conformational change inflicted 
on the enzyme by its attachment to disrupt the active site arrangement. In such 
a system the inhibitor molecule need not compete for the active site with the 
substrate.
For irreversible inhibition the enzyme-inhibitor interaction must be extremely tight 
or permanent. Once again the binding of the inhibitor may be competitive or 
non-competitive. In both cases the net result will be the same; complete and 
permanent inactivation of the enzyme. With competitive inhibitors however, this 
may take some time in the presence of the true substrate.
From the small selection of serine protease enzymes discussed earlier it can be 
clearly seen that the variation of one or more residues in the region of the active 
site can change substrate selectivity markedly. It may therefore be possible to
specific enzyme. In theory this inhibition could take place in the presence of 
other protease enzymes without seriously affecting their performance. Another 
important feature giving scope for inhibition is the formation of a covalent bond 
between the enzyme and the substrate during the catalytic cycle. This cycle can 
be descibed by the following simple diagram (figure 1.6-1).
1.6 Concepts Inferred from the Serine Protease Model
design substrate-like inhibitors which have the ability to reduce the activity of one
Enzym e + Substrate Enzym e/substrate com plex
Product
V
Enzym e Enzym e-product 2
Product 2
(figure 1.6-1)
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If the covalent bond formed between the enzyme and product 2 can be made 
permanent not only will the substrate site be blocked but the catalytic machinery 
will also be effectively destroyed (figure 1.6-2).
Enzyme + Inhibitor  Enzym e/inhibitor com plex
Product 1 
«■ — Enzym e-product 2
(figure 1.6-2)
1.7 Cysteine Protease Inhibition
As very little is known about the exact structure of most of the cysteine 
proteases a selective non-competitive inhibitor may be difficult to develop. The 
scope for active site directed inhibition is, however, significant. With proteases 
the opportunity exists in using pseudo-peptides as competitive inhibitors. These 
peptide-like species could be fine tuned to mimic the exact amino acid sequence 
found in the preferred substrate. As the activity of each protease varies with 
each substrate sequence, a degree of selectivity may then be possible.
The desire also exists for inhibition to be irreversible. This could be satisfied by 
the formation of a covalent link from the inhibitor to the active site cysteine. The 
agent or group chosen to effect the formation of this link should ideally possess 
the following qualities:
1. Only the active site cysteine should be attacked. The thiol groups of 
other biological molecules should be unaffected. The inhibitor must not react 
with non-activated cysteine residues which may be found in other enzymes, 
proteins and free cysteine.
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2. The activated hydroxyl group of the serine proteases must be left 
unharmed by the attention of the molecule. As indicated earlier, the serine 
proteases are a numerous and diverse family which play a variety of vital roles in 
the biochemistry of organisms. This becomes even more important when the 
same pseudo-peptide may perfectly mimic a serine protease substrate.
Thus, with the information so far available, the ideal inhibitor would appear to be 
a peptide consisting of residues which would normally be part of the natural 
substrate of the parasite cysteine protease. These residues would preferrably 
also reject or limit the attentions of host cysteine proteases such as the 
cathepsin family. The peptide would also contain a reactive group which, once 
directed to the heart of the enzyme, would be able to irreversibly modify the 
activated cysteine residue. This group would however, have no effect on the 
serine protease catalytic triad.
;
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Chapter 2: Aldehyde based Inhibitors of Cysteine Proteases
The history and development of a selection of protease inhibitors will now be 
discussed in order to expand and illustrate the basic concepts discussed in the 
previous chapter. Such a study will also allow the indication of which inhibitors 
show the greatest potential for development into anti-parasite drugs.
A number of peptide derivatives possessing reversible activity against serine and 
cysteine proteases have been isolated from a range of Streptomyces}^ [18]
Leupeptin
Isolated from the culture filtrates of over eleven species of streptomyces, the 
leupeptin group of compounds were observed to have an inhibiting effect on 
trypsin, plasmin and papain. The parent form of leupeptin is illustrated in figure
(figure 2.1-1)
The analogues of these compounds where leucine is replaced by isoleucine or 
valine, also possess similar activity.
Antipain
Isolated from Streptomyces michigaensis, Actinomyces violasceus, 
Streptomyces mauvecolor and Streptomyces yokosukaensis, antipain (figure
2.1-2) shows inhibiting action on papain, trypsin and cathepsin B.
2.1 Natural Aldehyde Based Inhibitors
2 . 1- 1.
Where R= CH3 or CH3CH2
R C O N tL X O N H . X O N tR  X H O
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HOOCL ^NHCONH^ XO N H ^ XO N H ^ ^CHO
NH
0,^ N H 2
NH
O ^ ^ N H 2
(figure 2.1-2)
Chymostatin
Isolated from Streptomyces hygroscopicus and Streptomyces lavendulae, this 
compound (figure 2.1-3) has shown activity against the serine protease 
chymotrypsin.
HOOCX ^NHCONHv^^CONH^ ^CONH^ ^CHO
■ r
H2N NH
(figure 2.1-3)
Elastatinal
This compound (figure 2.1-4) was isolated from Streptomyces griseoruber, and 
found to inhibit pancreatic elastase.
H O O C v ^ N H C O N H ^ ^ C O N H ^ ^ C O N H ^ ^ C H O
i c o n h 2
H2N NH
(figure 2.1-4)
Much information can be obtained from a comparative analysis of the 
structure/activity relationship for these compounds. The peptide nature of this 
selection of compounds is readily apparent but a closer look reveals another key 
feature. In each case the terminal residue, adjacent to the aldehyde, is identical 
to that normally recognised by the enzyme as part of the natural substrate (see
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section 1.1). Indeed, the aldehyde is located at the position normally occupied 
by the peptide link selected for cleavage. One can therefore suggest that this 
group plays an active role in the inhibition mechanism. This postulate is backed 
up by the fact that the corresponding acid, alcohol and dibutyl acetal of leupeptini
do not show such pronounced activity.1181
Aldehydes structurally related to the acyl portion of natural substrates have been 
synthesised and shown to be potent inhibitors of papain.[19] The necessity of 
both aldehyde and peptide portions for effective inhibition can be illustrated with 
reference to the compounds shown in figure 2.1-5.
O
Benzyloxycarbonylam ino acetaldehyde
(figure 2.1-5)
These three materials show reversible inhibiting activity against papain. The 
strength of this inhibition was observed to be greatest for acetyl-(L)- 
phenylalanylamino acetaldehyde and weakest for benzoylamino acetaldehyde. 
The presence of a longer peptide-like portion therefore increases the 
effectiveness of the inhibition in some way. Indeed acetaldehyde and 
propionaldehyde are relatively ineffective in comparison to these three 
compounds. Thus it can be postulated that initial selection by the enzyme takes 
place by recognition of the substrate mimicking portion.
O
Benzoylam ino acetaldehyde
0
Ar-A cetyl-(L )-phenylalanylam ino acetaldehyde
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Considering the aldehyde group, it was shown that the corresponding nitrile, 
carboxylic acid, amide and methyl ester of benzoylamino acetaldehyde are much 
less tightly held. From this result it can also be postulated that some form of 
strong but non-permanent enzyme-aldehyde interaction takes place causing 
greater reversible inhibition.
Further experimental results add weight to these theories. The observed 
enzyme/inhibitor binding ratio (approximately 1:1) is as expected for competitive, 
substrate-like recognition. Papain has also been shown to be reversibly 
protected from the action of A/-ethylmaleimide, a known active site thiol modifier, 
in the presence of these peptidyl aldehydes indicating their active site directed 
nature.
While at this stage of discussion we can conclude that the peptidyl aldehydes 
are reversible and competitive inhibitors, the actual role of the aldehyde is still 
unclear. There are two possible explanations for the increased binding power 
conferred by this group.
1. In aqueous solution the aldehyde function will exist mainly as the hydrate 
(figure 2.1-6).
HO OH 
(figure 2.1-6)
This hydrate closely resembles the tetrahedral intermediate formed during 
peptide hydrolysis. The significant hydrogen bonding employed by the enzyme 
to stabilise this intermediate may therefore be responsible for the tighter binding 
of the hydrated aldehyde inhibitor.
2. The enzyme itself may attack the aldehyde, as it would a peptide link 
carbonyl, forming a hemiacetal (serine proteases) or hemithioacetal (cysteine
O
1  + h 2o
R ^ H
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proteases). The inhibitor would therefore be covalently bound to the enzyme for 
the lifetime of the tetrahedral adduct. Once again the hydrogen bonding abilities 
of the enzyme may be utilised to stabilise this normally labile structure. This 
inhibitor-enzyme complex however, must not be permanent if the reversible 
nature of the inhibition is to be maintained.
2.2 NMR Spectroscopic Studies on Papain Inhibition
The true role of the aldehyde in papain inhibition was uncovered using a 13C 
enriched inhibitor and NMR spectroscopy.[20]
[1-13C] A/-Acetyl-(L)-phenylalanylglycinal (figure 2.2-1) was prepared from [1-13C] 
glycine.
CH3CONH. X O N H
where * indicates enrichment position 
(figure 2.2-1)
The 13C NMR spectrum of this material in water, in the absence of enzyme, 
shows two main sets of signals. The stronger of these occurs at 88.2 ppm and 
corresponds to the hydrate of the aldehyde. Ninety-five percent of the material 
was observed to exist in this form in aqueous solution. Smaller signals for the 
unhydrated aldehyde were also present at 200.9 ppm.
On the addition of excess papain both sets of signals were found to disappear 
and be replaced by a new set at 74.9 ppm. Addition of a three-fold excess of 
inhibitor to this solution resulted in enhancement of the new set and 
reappearance of the hydrate signals. These new signals were postulated as
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being due to the presence of a hemithioacetal which was confirmed by the 
synthesis of model compounds.
Further evidence for the reversible participation of the thiol in the inhibition 
mechanism was obtained by the addition of 2,2’-dipyridyl disulfide at pH 4.1.
This active site thiol modifying reagent caused the disappearance of the 
hemithioacetal signal resulting in the corresponding increase in hydrate peak 
intensity.
This combined evidence confirms that free papain and the hemithioacetal 
containing inhibited complex are in equilibrium in an aqueous solution of peptidyl 
aldehyde (i.e. reversible competitive inhibition via hemithioacetal formation).
Closer examination of the hemithioacetal peak revealed that it was actually 
composed of two broad signals. Incubation of the complex with 2,2’-dipyridyl 
disulfide at pH 7 preferentially removed the downfield peak and caused the 
corresponding increase in hydrate signals. This can be explained as follows: 
The binding of the inhibitor to the enzyme via a hemithioacetal (figure 2.2-2) will 
result in the formation of a new chiral centre. As both enzyme and inhibitor are 
chiral and enantiomerically pure, binding will result in diastereomer formation.
It is conceivable that one of these diastereomers will be significantly more stable 
than the other. The less stable form can therefore be induced to collapse, 
leaving the thiol group free for the attentions of 2,2’-dipyridyl disulfide, under less 
acidic conditions. The more stable configuration is likely to be that which best 
fits the available hydrogen bonding framework used to stabilise the substrate 
hydrolysis intermediate. Which configuration is more stable, however, is still 
unclear.
O Enz— S OH HO S— Enz
+ Enz— SH +
(figure 2.2-2)
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2.3 Fluorescence Studies on Peptidyl Aldehyde Inhibitors
A fluorescence study on a series of mansyl (6-[A/-methylanilino]-2-naphthalene 
sulfonyl) protected peptidyl aldehydes (figure 2.3-1) highlighted a further, 
potentially useful, feature regarding inhibitor structured211
For all three structures (n = 0, 1 and 2) the observed intensity of fluorescence 
from the mansyl group was found to increase on the binding of the inhibitor to 
the enzyme. The extent of this increase was found to be dependent on the 
glycine chain length with n = 0 showing the greatest change. Chain length 
however had little influence on binding ability as all three were shown to be 
equally effective inhibitors.
The increase in fluorescence was assigned to energy transfer from a papain 
tryptophan residue to the mansyl group. The strength of this transfer would 
obviously diminish as the distance between the two groups increased. It was 
therefore proposed that the mansyl group protruded further into the solvent 
(water) as the chain length of the inhibitor increased. The important point to be 
taken from this study is that bulky AMerminus protecting groups may be used 
without adversely affecting the inhibitor binding. In the three case studied here 
the large mansyl group had little influence on the inhibiting ability of the 
compounds, even when close to the active site (n = 0). If indeed the AMerminus
•S02-(NHCH2C0) — NHs^^CONH.
m ansyl-(G ly)n-(L)-Phe-glycinal n = 0 , 1, 2 
(figure 2.3-1)
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protrudes into the solvent as suggested here then protecting group selection will 
not be limited by enzyme steric restrictions.
2.4 Limitation of Aldehyde Based Inhibitors
A possible problem with aldehyde based inhibitors was reported by Sutherland 
and Greenbaum in 1983.[22] Leupeptin, in adequate concentrations in vivo, was 
shown to be a potent stimulator of cathepsin B activity in striated muscle, heart, 
liver and kidney tissues of the mouse. The mechanism of this action was 
unclear but what the result did illustrate was that leupeptin, or its metabolites, 
has complex effects on cells beyond that of an antiprotease. The in vivo 
application of these materials may, as a result, be limited.
The lack of selectivity for cysteine proteases exhibited by members of this group 
presents further limitations for in vivo use. The reversible nature of the inhibition 
mechanism may exacerbate this problem as relatively large and repeated doses 
may be required in order to achieve a sufficient effect.
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Chapter 3: E-64. a Natural Irreversible Inhibitor
In 1978 a compound of the formula was reported as being isolated
from a solid culture of the fungus Aspergillus japonicus (TPR-64) and named E- 
64.[23] Initial structural assignments were made on the basis of infra-red 
spectroscopy and chemical reactivity. Degradation studies in conjunction with 
proton NMR and a range of partial syntheses later confirmed the structure as 
being that shown in figure 3-1.1241
HOOC.
NH
Af-[W-(L-3- rrarcs-carboxyoxiran-2-carbonyl)-L-leucyl]-agm atine 
(or L-/raH£-epoxysuccinyl leucylamido[4 -guanido]butane)
(figure 3-1)
Two years later, E-64 was reported to bind to an equimolar quantity of active 
cysteine residues in isolated cathepsin B (under physiological conditions) but not 
simple unactivated thiols.[25] Further work in this area showed that E-64 inhibited 
cathepsins B, L and papain irreversibly. The selectivity for such cysteine 
proteases, while better than that achieved with aldehyde based inhibitors, was 
found not to be absolute with the serine proteases trypsin and thrombin affected 
in a similar manner.[26]
3.1 Investigations into the Mode of Action of E-64
The site of inhibition was confirmed as being the same as that used by peptidyl 
aldehydes by the protection of cathepsin B and papain with the reversible 
competative inhibitor leupeptin.[27] One can therefore assume that E-64 is 
initially selected by the enzyme on the basis of its substrate mimicking peptide
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chain. The resemblance of the E-64 structure to the peptide (L)-leucine-(L)- 
arginine (figure 3.1-1) is readily apparent.
:0 0 H
NH
NH
(L)-leucine-(L)-arginine 
(figure 3.1-1)
If the site of binding is the same as that for the natural substrate, one would 
expect some degree of selectivity with respect to the structure of the peptide 
portion of the inhibitor. Indeed, the rate of E-64 induced inhibition on a series of 
closely related proteases was found to vary. Similarly the analogue Ep-475 
(figure 3.1-2), where only the peptide portion has been varied, was shown to 
inhibit cathepsins B and L faster than the parent compound.1271
HOOC,
NH
E p -475
(L-fratt.s,-epoxysuccmylleucylamido [3 -methyl] butane)
(figure 3.1-2)
Considering the mechanism of inhibition, the initial isolators of E-64 found that 
destruction of the epoxide, by the use of hydrochloric acid, resulted in the 
complete loss of irreversible inhibition activity.1281 It can therefore be postulated 
that after initial recognition of the peptide fragment by the enzyme, irreversible 
inhibition takes place by covalent binding of the epoxide to the active site. By 
comparison with the aldehyde inhibitor mechanism, it appears plausible that the 
epoxide binding position is the active site cysteine.
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By 1988 direct observation of such an alkylated cysteine had not yet been 
reported. In this year Yake, Guillaume and Rich reported the results of 13C NMR 
spectroscopic studies on enriched Ep-475 (figure 3.1-3).[29]
HOOG
NH.
NH
Ep-475 where * indicates enrichm ent site
(figure 3.1-3)
Non-enzymic thiols at high pH were shown, by 13C NMR spectroscopy in water, 
to attack both epoxide carbons giving two products in a 4:1 ratio. The chemical 
shifts of the 13C (C-2) enrichment following this reaction are indicated in figure
3.1-4.
HOOC... * ,,H
H ^ V So C O N H -R
benzyl m ercaptan/N aO H  
pH  10
HOOC H
C6H5CH2— S
H  C O N H -R
4:1
H  C O N H - R
S— CH2C6H5
HOOC H
chem ical shift * ~73  ppm  chem ical shift * ~53  ppm
C -3 A T TA C K  C -2  A T T A C K
(figure 3.1-4)
With papain, buffered at pH 6.8, the only 13C enriched signal observed was 
located at 76.5 ppm. No new signal in the 50 ppm area was apparent. Thus the
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activated cysteine of papain attacks the epoxide at C-3 exclusively, resulting in 
irreversible inhibition by covalent bond formation (figure 3.1-5).
HOOC,
^ / vT^CONH—r
H —B
Enz— S
HOOC H
H C O N H -R
OH
Enz
(figure 3.1-5)
3.2 Limitations of Epoxide Based Inhibitors
The irreversible activity of these compounds represents a significant 
improvement over aldehyde based inhibitors. However, the selectivity for 
cysteine proteases, though better than that achieved with previous compounds, 
is not absolute. A further problem yet to be overcome is the rate at which these 
compounds are eliminated from the body. This was illustrated by tracer studies 
on tritium labelled E-64 in rats.[26] On initial administration the material was 
observed to diffuse rapidly from the injection site. This process was, as 
expected, accompanied by a rapid rise in blood radioactivity. An equally rapid 
fall in blood radioactivity was then noted and assigned as being due to the 
uptake of E-64 by the internal organs. The liver and kidneys were identified as 
being the main recipients of the radioactivity suggesting that metabolism and 
excretion are early fates for the injected material. Indeed, within 24 hours, 
74.9% of the administered dose of radioactivity was found to be excreted in the 
urine.
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Chapter 4: Halomethyl Ketone Based Inhibitors
In 1962 Schoellmann and Shaw reported the use of an amino acid derivative 
(figure 4-1) as a labelling agent for the active centre of chymotrypsin.[30] 
Designed to mimic a known substrate of this enzyme, A/-tosyl-(L)-phenylalanyl 
bromomethyl ketone was observed to cause the irreversible loss of enzymic 
activity.
Ar-tosy l-(L )-phenylalan ine m ethyl ester 
(Substrate fo r hyd ro ly sis  b y  chym otrypsin)
Ar-tosy l-(L )-phenylalanyl brom om ethyl ketone 
[L-( 1 -tosy lam ido-2-phenyl)ethyl brom om ethyl ketone]
(figure 4-1)
The active site directed nature of the material, due to its substrate similarity, was 
confirmed by the protection of the enzyme with hydrocinnamic acid, a known 
reversible and competitive inhibitor of chymotrypsin. These results triggered 
research into a range of halomethyl ketones that would prove to be powerful 
tools for the study of the biological function of proteases both in vitro and in vivo.
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4.1 The Chloromethyl Ketones
Initially investigated as more stable variants of the bromine containing 
compounds, chloromethyl ketones were found to exert a similar biological action. 
For example A/-tosyl-(L)-phenylalanyl chloromethyl ketone (figure 4.1-1) was 
observed to completely inactivate chymotrypsin in a specific and stoichiometric 
manner.[31] Irreversible inhibition in this manner suggested that the compound 
was binding to one specific residue in the enzyme active site. In order to verify 
this, the enzyme-inhibitor complex was digested and the resulting short chain 
peptides separated allowing the isolation of a decapeptide bearing a modified 
histidine residue. This peptide fragment was shown to be non-artefactual by 
comparison of the amino acid sequence with the known primary structure of 
chymotrypsin. The histidine residue was therefore implicated as being the active 
site alkylation target of the chloromethyl ketone.
In the same manner, trypsin inactivated with A/-tosyl-(L)-lysyl chloromethyl 
ketone (figure 4.1-2) yielded an octapeptide fragment bearing a modified 
histidine residue.1321
CH2Ph
Af-tosyl-(L)-phenylalanyl chloromethyl ketone 
(figure 4.1-1)
O
(CH2)4N H 2
iV-tosyl-(L)-lysyl chloromethyl ketone 
(figure 4.1-2)
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In this case a derivative of the modified residue was also isolated and shown to 
be of the structure shown in figure 4.1-3 (note that the generation of the alcohol 
function is an artefact of the technique used to allow isolation).1331
COO'
Inhibitor-histidine derivative 
(stereochemistry not specified)
(figure 4.1-3)
Notice how in both cases above the inhibitors are derived from the amino acids 
normally selected as part of the natural substrate. Indeed, chloromethyl ketones 
unrelated to the natural substrate for a particular serine protease tend to react 
only very slowly or not at all with that enzyme.[34] [35] Thus the same substrate- 
mimic selection observed with the aldehyde and epoxide bearing compounds is 
also found with these competitive, irreversible inhibitors. The inhibitor must 
therefore bind to the enzyme active site in such a fashion as to place the 
alkylating group close to the histidine residue of the catalytic triad.
4.2 NMR Spectroscopic Studies on Chloromethyl Ketone Induced Inhibition
In 1983 Malthouse, Mackenzie, Boyd and Scott reported NMR spectroscopic 
evidence to suggest that the binding between the chloromethyl ketone and the 
enzyme is more complex than the accepted single bond to histidine.1361
For this study A/-benzyloxycarbonyl-(L)-lysyl chloromethyl ketone, 13C enriched 
at the ketone carbonyl, was used to inhibit trypsin. The carbon spectrum of the 
pure compound in DMSO consisted of a single large peak at 200.6 ppm. In
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water however, hydrate formation was significant and two peaks were observed;
204.7 ppm (ketone) and 95.4 ppm (hydrate).
Addition of the enzyme to the aqueous solution of the inhibitor at pH 3.2 resulted 
in no change to the enriched signals and no loss of enzyme activity. At pH 6.9 
however, both enriched peaks disappeared and were replaced by a single new 
peak at 98.0 ppm while enzyme activity was significantly reduced. By 
sequentially adding excess inhibitor and enzyme to this solution it was possible 
to show that the new peak was indeed due to some form of stoichiometric 
enzyme-inhibitor interaction. As gel filtration and the addition of a competitive 
inhibitor (benzamidine) were unable to remove the 98.0 ppm signal, it was 
concluded that covalent binding between the labelled inhibitor carbonyl and 
enzyme active site had taken place.
A tetrahedral state formed from attack of the active site serine residue on the 
carbonyl was proposed as being responsible for the 98.0 ppm peak. Further 
evidence for this was obtained from the alkali induced denaturation of the 
enzyme which resulted in new hydrate and ketone signals at 95.1 ppm and
205.5 ppm respectively. These occur as the inhibitor in the denatured enzyme 
remains attached only to histidine. The residues of the catalytic triad are no 
longer in close proximity therefore the tetrahedral enzyme-inhibitor complex 
cannot reform and the inhibitor carbonyl is left free for the attention of water.
The results observed in this study bear a significant degree of similarity to those 
found with aldehyde based inhibitors as discussed earlier. Thus it can be 
postulated that, in the absence of the chlorine moiety, these compounds would 
cause reversible inhibition in a similar manner to the aldehyde based inhibitors.
The binding of chloromethyl ketones to serine proteases can now be 
represented by the following diagram (figure 4.2-1, stereochemistry not 
specified).
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A
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?
R—C
H
HO—Seri95 
NHis57
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(figure 4.2-1)
18Using heavy water (H2 O) as an NMR solvent it was shown that a hemiketal 
was indeed formed between the enzyme and the inhibitor.[37] In a dilute heavy 
water solution, as the ketone is in equilibrium with the hydrate one would expect 
both oxygen atoms of the hydrate to be 180  enriched. With a hemiketal 
however, one of the two oxygen atoms will always originate from the serine 
hydroxyl group and therefore always be 160. The effect of substituting 180  for 
160  directly bonded to 13C is to shift the NMR signal of this species slightly 
upfield (e.g. 0.05 ppm movement for the inhibitor ketone carbonyl).[38] This shift 
is quantifiable from model systems and is additive (i.e. replacing two 160  with 
two 180  doubles the magnitude of the 13C shift). When bound to trypsin it is 
possible to show that only one solvent derived oxygen is present. Thus the 
inhibition is not due to the simple binding of the hydrate in conjunction with 
histidine alkylation.
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4.3 X-Ray Crystallographic Studies on Inhibited Serine Proteases
The presence of more than one bond between A/-benzyloxycarbonyl-(L)-lysyl 
chloromethyl ketone and trypsin, as suggested by the NMR spectroscopic data, 
was confirmed by X-ray studies.1371 Continuous electron density was found 
between the inhibitor ketone carbonyl carbon and serine 195 in which the 
carbonyl carbon to serine oxygen distance was roughly that expected for a 
carbon-oxygen bond of standard length. The geometry around this carbon was 
also virtually identical to that expected for a purely tetrahedral species. The 
expected stabilisation of the tetrahedral state was also clearly seen with two 
relatively long hydrogen bonds from the amide protons of glycine 193 and serine 
195 to the carbonyl oxygen.
These results however, represent only the solid state of the enzyme-inhibitor 
complex. In solution this may not be the case. Solid state NMR spectroscopy 
was therefore used to find the 13C chemical shift of the enriched carbonyl carbon 
of the bound inhibitor. This signal was observed at 98.0 ppm, identical to that 
found in solution for the postulated tetrahedral adduct.
The inhibitor therefore clearly binds to the trypsin catalytic triad via two covalent 
bonds with the normally labile tetrahedral state thus produced, stabilised by 
hydrogen bonding from the enzyme main chain. A further interesting feature 
noted was that no accurate electron density could be obtained for the benzyl 
group of the inhibitor A/-protection. This indicates that the group is not held in 
any specific geometry by the enzyme. As suggested earlier, variation of this 
bulky protecting group should therefore have little effect on the binding ability of 
the molecule.
In the same year the crystal structure of proteinase K, a serine protease isolated 
from the fungus Tritirachium album, with a bound chloromethyl ketone was 
reported.1391 In this case the inhibitor [A/-CBZ-(L)-Ala-(L)-AlaCH2CI] was again 
found to bind to both the histidine and serine residues of the catalytic triad
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(figure 4.3-1). Extensive hydrogen bonding between the enzyme main chain 
and the rest of the inhibitor molecule was also observed resulting in a triple anti­
parallel pleated sheet structure.
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(figure 4.3-1)
An important point which should be noted from this study is how the longer 
inhibitor chain participates in the binding to the enzyme. What is not evident 
from this structure however, are the substrate/inhibitor side chain selection sites. 
It is these peptide and side chain interactions that are considered to represent 
the initial complexation between enzyme and inhibitor.
4.4 Kinetic Studies on Chloromethyl Ketone Induced Inhibition
The peptidyl chloromethyl ketone (D)-Phe-(L)-Pro-(L)-ArgCH2CI inhibits the 
serine protease thrombin and has been shown to prevent intravascular 
coagulation in rabbits.1401 A study of the kinetics of this inhibition indicated that 
there was indeed a reversible complex rapidly formed prior to the slower
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irreversible binding. Four years after this, Stein and Trainor reported the 
formation and accumulation of two complexes within this reversible step for the 
inhibition of human leukocyte elastase with a peptidyl chloromethyl ketone.[41] 
The dissociation constant ( K j)  of the enzyme-inhibitor reversible complex (figure 
4.4-1) was also shown to be ten times lower than those of substrates and other 
reversible inhibitors lacking the chloromethyl ketone end group.
E + I _  EI K i = M L
[EI]
(figure 4.4-1)
Thus kinetic evidence suggests that the peptide to enzyme complexation is 
indeed followed by a further reversible interaction prior to irreversible alkylation. 
Further kinetic evidence for the formation of a hemiketal intermediate after initial 
complexation was provided by McMurray and Dyke from their study on trypsin 
inhibition by a-substituted peptidyl ketones.[42] In this series of experiments the 
stength of binding of (L)-Lys-(L)-Ala-(DL)-LysCH2X was noted as X was varied 
(X = H, CH2COOCH3, COCH3, OCOCH3 and F, racemisation of the modified 
lysine was due to the method employed for the attachment of the end group and 
will be discussed in chapter 10.1) It was found that the binding strength for the 
reversible stage increased as the electron withdrawing power of X increased. 
This effect would be expected if nucleophilic attack at the adjacent carbonyl was 
involved in the binding mechanism. The reversible binding constant for the 
corresponding chloride was also shown to fit the relationship calculated from 
these experiments.
By combining the results from the X-ray, NMR spectroscopic and kinetic studies 
discussed here, it can be confidently stated that the mechanism of inhibition 
proceeds as indicated in figure 4.4-2.
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4.5 Chloromethyl Ketones With Cysteine Proteases
As one would expect, peptidyl chloromethyl ketones were observed to have a 
similar effect on cysteine proteases. The initial selection of the inhibitor by the 
enzyme follows the same basic substrate-mimic requirements as found with 
serine proteases. For example, A/-benzyloxycarbonyl-(L)-phenylalanyl 
chloromethyl ketone was shown to have a second order rate constant for the 
inhibition of papain 150 times greater than the tosyl protected variant.[43] This 
effect is presumably due to the greater peptide-like character of the former 
protecting group.
The inactivation of papain with chloromethyl ketones, however, was shown to 
result in no drop in the amount of histidine residues observable by amino acid 
analysis.C44] Only the quantity of cysteine showed any significant change and 
was therefore identified as being the target residue for alkylation.1451 The rate of 
alkylation was also shown to increase rapidly with increasing pH. For example 
the rate of alkylation of papain by A/-Tos-(L)-PheCH2CI increased 34 fold in the 
pH range 6.5 to 9.[441 Thus the anionic form of the active centre thiol must be the 
species involved in the displacement of the inhibitor chlorine.
4.6 Limitations of Chloromethyl Ketones
As has been shown here, chloromethyl ketones have been widely used in the 
investigation of serine protease mechanisms. The a-choro ketone arrangement
38
makes these compounds strong alkylating agents and any desired selectivity for 
cysteine proteases must be sought from the amino acid sequence of the 
inhibitor. With such a great variety of serine proteases present in organisms this 
selectivity may be difficult to achieve.
The alkylating power of chloromethyl ketones also leads to further problems. 
These highly electrophilic species are vulnerable to the attentions of non­
activated thiols.[46] 171 Indiscriminate alkylation would therefore be expected in 
vivo thus limiting the therapeutic use of this group of compounds.
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Chapter 5: Diazomethyl Ketones
Interest in diazomethyl ketones was initiated in 1973 with the isolation of a 
natural antibiotic, named (L)-azaserine (figure 5-1), from broths of 
Streptomyces.[A7]
This compound was observed to cause inactivation of an amido transferase 
enzyme. The biological role of enzymes of this type is to catalyse the 
transference of the side chain nitrogen of (L)-glutamine (figure 5-3) to other 
substrates thus forming a new carbon-nitrogen bond. In order to do this the 
enzyme utilises an optimally placed cysteine side chain to attack the y-amide of 
glutamine and effect hydrolysis.
(L)-Azaserine was observed to compete with glutamine for the active site of the 
enzyme and cause irreversible inhibition. Digestion of a sample of enzyme 
inactivated with 14C labelled (L)-azaserine indicated that cysteine was indeed the 
target for alkylation. It was then proposed that alkylation occurs by protonation 
of the diazomethyl group followed by nucleophilic attack expelling molecular 
nitrogen (figure 5-2).
O
HOOC.
ftH 2
(L)-azaserine 
(figure 5-1)
Amido transferase w ith (L)-azaserine 
(figure 5-2)
The structural similarity of (L)-azaserine to the natural substrate (L)-glutamine is 
clearly evident (figure 5-3). The possibility may therefore exist for inhibition of 
cysteine proteases by the use of a substrate related short chain peptide bearing 
a diazomethyl ketone end group.
O
HOOC 1  -\  +
n h 2
(L)-azaserine
(figure 5-3)
5.1 Diazomethyl Ketones with Protease Enzymes
In 1977 it was reported that A/-CBZ-(L)-PheCHN2 and A/-CBZ-(L)-Phe-(L)- 
PheCHN2 could be used to inactivate papain in a competitive, irreversible and 
stoichiometric manner.1431 This inactivation took place at the active centre thiol 
and was observed to decrease in rate rapidly as the pH was increased above 
6.5. Thus the protonated form of the active site cysteine is involved in the 
mechanism as suggested above. This is in contrast with chloromethyl ketone 
inhibitors where the anionic thiolate is required and rate increases sharply with 
increasing pH.
O
H O O C
'N H 2
i t h2
(L)-glutam ine
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The participation of the “extended binding site” in substrate/inhibitor selection 
was also well illustrated by this case where the action of A/-CBZ-(L)-Phe-(L)- 
PheCHN2 was shown to be 200 times more rapid than A/-CBZ-(L)-PheCHN2.[48] 
In a more extensive study with cathepsin B this substrate-mimic theory was 
backed up as inhibitors bearing unnatural D amino acids were found to be poor 
inhibitors.1491 Interestingly enough, tri-peptides were also shown to be of no 
greater effectiveness than related dipeptides.
A feature of great importance noted during these studies was the retention of 
chymotrypsin activity in the presence of A/-CBZ-(L)-PheCHN2.[49] Under 
conditions which would give rapid and total inactivation of cathepsin B, 
chymotrypsin was unaffected. The characteristic 277 nm absorbance of the 
diazomethyl ketone group in aqueous solution was however, observed to slowly 
diminish in the presence of this serine protease at pH 7. Similarly, when pre­
incubated with chymotrypsin, A/-CBZ-(L)-Phe-(L)-AlaCHN2 was observed to lose 
its papain inactivating ability. This catalytic destruction of the diazomethyl 
ketone was not observed with chymotrypsin previously inactivated with a 
chloromethyl ketone, implying the participation of the active site. This process 
alone cannot account for the relative immunity of the serine protease however, 
due to its slow rate. For example, 25% decomposition of diazomethyl ketones 
has been observed in 3 hours under conditions where complete cysteine 
protease inactivation is measured in minutes.
Kinetic studies showed that with papain, cathepsin B and chymotrypsin an initial 
competitive, reversible inhibition complex is formed with peptidyl diazomethyl 
ketones. The complexed inhibitor molecule would then, in theory, pick up a 
proton to form the unstable diazonium ion. Only in the case of papain and 
cathepsin B does alkylation rapidly follow, chymotrypsin remains unharmed. In 
the active site of cysteine proteases the diazomethyl ketone end group must 
therefore be held in close proximity to the reactive cysteine anion. With serine 
proteases the inhibitor must not be so ideally oriented or the activity of the 
nucleophilic species (histidine) must be lower. Considering the highly reactive
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nature of the protonated diazomethyl ketone the former explanation seems more 
plausible.
In order to test the serine protease immunity further, Green and Shaw 
synthesised a series of diazomethyl ketones based on amino acid sequences 
normally present in serine protease substrates.[50] Indeed resistance was found 
to be general. Some discrimination between cysteine proteases was also 
achieved as reagents not satisfying a particular specificity either did not inhibit or 
did so only very slowly. For example, considering the cathepsins B, L and H, N- 
CBZ-(L)-Phe-(L)-AlaCHN2 reacted 2000 times faster with L than B but 1000 
times faster with B than H.[51]
In most cases the diazomethyl ketones were observed to be less reactive 
towards the enzyme than the corresponding chloromethyl ketone.t46] This would 
be expected if initial hemithioketal formation at the active site were still 
important. The low carbonyl infra-red absorption frequency of diazomethyl 
ketones (typically 1615-1645 cm'1) indicates the presence of conjugation with 
the group. Thus the carbonyl would be slightly inactivated towards nucleophilic 
attack. For chloromethyl ketones (carbonyl infra-red absorption frequency 
typically 1725-1745 cm'1) one would expect the carbonyl to be activated towards 
nucleophilic attack due to the inductive effect of chlorine.
While this decrease in rate of inhibition is significant, the increase in specificity of 
these compounds for cysteine proteases more than compensates. Furthermore 
the reagents were observed not to alkylate non-activated thiols. For example; 
diazomethyl ketones were shown to be stable to high concentrations of 
dithiothreitol [(R,R)-1,4-dimercapto-2,3-butane diol] while chloromethyl ketones 
were rapidly destroyed.[46] Similarly, no reaction was observed with the cysteine 
residue of glutathione (y-(L)-Glu-(L)-Cys-Gly).[50] Glyceraldehyde-3-phosphate 
dehydrogenase, a non-protease enzyme possessing an active site thiol, was 
also unable to induce any reaction further highlighting the essential nature of 
accurate complex formation.[50]
5.2 Limitations of Diazomethyl Ketones
The specificity of action of these species suggests that widespread application in 
living systems would be possible. Unfortunately the instability of diazomethyl 
ketones under acidic conditions prevents their in vivo use. This is well illustrated 
by the decomposition catalysed by serine proteases. Thus, in any environment 
where there are loosely held protons, modification of the inhibitor molecule 
would be expected and further interaction with the biological system a distinct 
possibility. This has indeed been shown to be the case with diazomethyl 
ketones having drastic effects on protein synthesis and also possessing 
mutagenic properties.1521181
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Chapter 6: Peptidyl Fluoromethyl Ketones
A logical step in the attempt to moderate the reactivity of chloromethyl ketones 
would be to replace chlorine with fluorine. This would give an inhibitor with a 
stronger halogen-carbon bond and result in the formation of a poorer leaving 
group during alkylation. In addition to this the inductive effect of fluorine should 
also result in a stronger hemithioacetal complex.*421
6.1 Inhibition by Fluoromethyl Ketones
First synthesised in 1985 by Rasnick, the dipeptide fluoromethyl ketone A/-CBZ- 
(L)-Phe-(DL)-AlaCH2F was observed to be 30 times more potent in the inhibition 
of cathepsin B than the corresponding (L)-(L)-diazomethyl ketone (note once 
again that the racemisation of the alanine stereocentre was due to the early 
technique used for the introduction of the fluoromethyl ketone end group as will 
be discussed in chapter 10.1).[46] This increased potency was assigned to the 
tighter reversible binding of fluoromethyl ketones to the enzyme. By the theory 
discussed in chapter 5.1 this could have been predicted from the observed infra­
red absorption frequency for the carbonyl of fluoromethyl ketones (typically 1750 
cm'1). One would therefore expect the initial reversible binding displayed by a 
fluoromethyl ketones to also be stronger than that of the corresponding 
chloromethyl ketone.
Fluoromethyl ketones are, however, less reactive than chloromethyl ketones.
For example, as also noted with diazomethyl ketones, fluoromethyl ketones are 
unaffected by non-activated thiols such as dithiothreitoI.[46] In more detail, 
chlorinated inhibitors were shown to be as much as 500 times more active in the 
alkylation of glutathione at 37°C and pH 7.4.[531
Considering the reactivity towards protease enzymes, the work of Rauber, 
Angliker, Walker and Shaw suggests much scope for selective inhibition.1[54] The 
rate of inhibition of chymotrypsin by A/-CBZ-(L)-PheCH2F was found to be 1/40th
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of that noted for the corresponding chloromethyl ketone. The site of alkylation 
by the fluorinated inhibitor on this serine protease however, remained the same 
with the modification of the active centre histidine being cofirmed by amino acid 
analysis and radiolabelling experiments.
With the cysteine protease cathepsin B, the difference between chlorinated and 
fluorinated inhibitor activity was found to be much less pronounced. Typically 
the fluoromethyl ketones were observed to be about 35-40% as effective as the 
chlorinated forms. In this case the lower rate of alkylation displayed by the 
fluorinated inhibitors (usually around one quarter that of the chloromethyl 
ketones) was partially offset by tighter reversible binding to the enzyme.
It is considered that the mechanism of cysteine protease inactivation by 
fluoromethyl ketones involves two main stages as the formation of an 
intermediate complex has once again been noted prior to irreversible 
alkylation.[54][55] The first of these stages is therefore the formation of the 
reversible hemithioketal. Collapse of this complex then results in a 1,2-shift of 
the cysteine residue with a nucleophilic displacement of fluorine (figure 6 .1-1). 
Such a mechanism is also believed to take place during chloromethyl ketone 
induced inhibition (see section 4.5).
This mechanism is in contrast with that involving the histidine side chain as used 
by the serine proteases (see section 4.2). Thus it appears that the vital 
difference between serine and cysteine protease action has been uncovered. It 
is also apparent that this difference can be exploited by appropriate selection of 
the inhibitor end group.
1,2-shift 
(figure 6.1-1)
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To summarise, it is now possible to distinguish between serine and cysteine 
proteases by the mechanism of alkylation with halomethyl ketone bearing 
inhibitors. It has also been found by experiment that the rate of irreversible 
inhibition caused by fluoromethyl ketones compared with chloromethyl ketones 
is far less depressed with cysteine proteases than with serine proteases. The 
extent of this difference is around one order of magnitude making the in vivo 
inhibition of cysteine proteases, with a minimum of side effects, a real possibility.
6.2 Fluoromethyl Ketones in Biological Systems \
The ability of A/-CBZ-(L)-Phe-(DL)-AlaCH2F to curtail the development of acute 
rheumatoid arthritis in a rat model, by the inhibition of cathepsin B, has been 
investigated. The LD50 value of this compound (360 mg/kg mice) was found to 
be 3000 times greater than the effective dose for in vitro inhibition and 500 times 
greater than the oral dose for a similar effect in vivo.[7]
Thus the fluoromethyl ketones are effective and reasonably selective cysteine 
protease inhibitors in mammalian systems. One would therefore hope for a 
similar effect on parasitic organisms.
In 1990 Ashall, Angliker and Shaw reported a significant result on the application 
of the fluoromethyl ketone A/-CBZ-(L)-Ala-(L)-PheCH2F to intact 
trypanosomes.1561 The compound was observed to have a lethal effect that was 
limited to the infectious phase of the parasitic growth cycle. The use of a 
radiolabelled derivative also indicated that this effect corresponded to the 
labelling of a protein which was therefore deduced as being an essential 
protease. Taking this concept one step further, the administration of small 
doses (1-2 mg per day) of a dipeptide fluoromethyl ketone has been shown to be 
sufficient to protect mice from a lethal infection of Trypanosoma cruziP6]
The isolation and crystallisation of the main cysteine protease (cruzain) of 
Trypanosoma cruzi has been discussed in a review by McKerrow, McGrath and
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Engel.[16] X-Ray analysis of this enzyme after inhibition by A/-CBZ-(L)-Phe-(L)- 
AlaCH2F confirmed that the site of attachment of the irreversible inhibitor was 
indeed the active site cysteine. Also, as illustrated earlier, the A/-terminus 
protecting group of such compounds was observed to make no contact with the 
protein and in fact protrudes from the active site. Derivatisation of this group 
should therefore have little effect on the binding properties of the inhibitor.
Plasmodium falciparum trophozoite cysteine protease (TCP) has been 
implicated as being involved in the degradation of host haemoglobin by 
intraerythrocytic malaria parasites. By the use of a panel of peptidyl fluoromethyl 
ketones, it was possible to show that the effectiveness of inhibiting this enzyme 
correlated with the effectiveness at blocking haemoglobin degradation and killing 
cultured parasites.1121 In this system A/-CBZ-(L)-Phe-(DL)-ArgCH2F proved to be 
the most potent. In picomolar concentrations this compound proved capable of 
inhibiting TCP while at nanomolar concentrations the blocking of haemoglobin 
degradation and death of the parasite resulted. Micromolar concentrations were 
also shown to be non toxic to cultured mammalian cells.
The fine tuning of these compounds for antiparasite action in the presence of 
mammalian cysteine proteases, by informed choice of amino acid sequence, is 
also a distinct possibility. It has been reported that cathepsin L is 10 times more 
susceptible to an inhibitor containing the A/-CBZ-(L)-Phe-(L)-Ala sequence than 
A/-CBZ-(L)-Leu-(L)-Tyr.[11] On the other hand, fluoromethyl ketones bearing the 
former sequence are 50 times more effective at inhibiting the intraerythrocytic 
development of Plasmodium falciparum.
6.3 The Unsuitability of Peptidyl Fluoromethyl Ketones as Drugs
It appears feasible that A/-protected peptides, bearing a suitable amino acid 
sequence and the fluoromethyl ketone end group, can be developed which 
selectively disrupt the biochemical processes of parasites. It is also possible 
that this effect can be achieved with only a limited effect on the host organism.
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However, one serious problem remains: protease inhibitors derived from 
peptides are themselves vulnerable to the actions of proteolytic enzymes.
These enzymes may be the proteases of the host or indeed those of the parasite 
itself. As a result, not only will the rapid destruction of the inhibitor be observed, 
but an increase in side effects will be observed due to the presence of 
fluorinated amino acid derivatives. This is illustrated in figure 6.3-1 for the 
chymotrypsin catalysed cleavage of A/-BOC-(L)-Phe-(L)-AlaCH2F.
.NH
BOCNH
chym otrypsin 
o f  host
v
OH +
( :
o 6h3
(figure 6.3-1)
In order to prevent this it may be possible to replace the vulnerable amide link 
with a non-hydrolysable alternative. Such a linkage, while being immune to the 
attentions of proteolytic enzymes, must mimic the appearance of the amide in 
order to allow the compound to perform its designated role.
CH2Ph
BOCNH'
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Chapter 7: The Concept of the (E)-Ethene Isostere
X-Ray studies of peptides and proteins indicate that the peptide link is in fact 
rigid and planar.[57] There is no free rotation around the amide bond joining the 
two amino acid residues. This is due to the significant double bond character of 
this linkage (around 50%) resulting from amide-iminol tautomerism (figure 7-1).
Amide-Iminol Tautomerism 
(figure 7-1)
As a result of this double bond character the observed C-N bond length lies 
between that expected for single and double bonds.[58] [59] Furthermore the bond 
angles around nitrogen have values close to those expected for a purely trigonal 
system (figure 7-2).
125 '
110 '114 ' 114 '
1.32 1.52
M ain Chain B ond Lengths (Angstrom s Selected Bond Angles
(figure 7-2)
Note however that the single bonds between the components of the amide link 
and the a-carbons of the joined amino acids, are of standard length. A 
significant amount of conformational freedom therefore exists on either side of 
this rigid link.
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An important result of the partial double bond nature of the amide link is that only 
two conformations are generally observed (figure 7-3).
O O
R i \  J k  —
N  R2 -------------------- N  R 2
I I
H Ri
trans cis
(w here R i and R 2 represent the continuation o f  the peptide chain
(figure 7-3)
In most systems the amide link is found to adopt the more thermodynamically 
stable trans geometry.
Considering these factors as a whole, it is clear to see the viability of using the 
fra/is-ethene group as a structural replacement for the amide function (figure 7-
4 )  [58] [59]
109.5109.5
1.54
M ain Chain B ond Lengths (Angstrom s Selected Bond Angles
(figure 7-4)
Such a group is isosteric with the amide linkage and also possesses the desired 
rigidity and geometry while being immune from enzymic hyd rolys is.[60]
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Chapter 8: The History and Development of (E)-Ethene Isostere Synthesis
Early attempts at (E)-ethene incorporation into biologically active molecules were 
focused on the synthesis of more stable forms of the enkephalins (figure 8-1). 
These naturally occuring peptides and their analogues display agonist activity at 
opiate receptors.
(L )-Tyr-G ly-G ly-(L )-Phe-(L )-M et (L)-Tyr-G ly-G ly-(L )-Phe-(L )-Leu
M ethionine enkephalin Leucine enkephalin
(figure 8-1)
However, these compounds have a very short half life in vivo presumably due to . 
enzymic hydrolysis.1611 In theory, the replacement of one or more amide links 
may increase the resilience of the compound. An added bonus of amide bond 
replacement would also be an increase in lipophilicity thus facilitating passage 
through the blood/brain barrier.
8.1 The Cox Approach
The synthetic approach adopted by Cox and colleages was basically composed 
of a series of functional group manipulations and a-alkylations of frar7s-hex-3- 
enedioic acid.[62] Esterification of the diacid produced a mixture of mono and 
diester (figure 8 .1-1), both of which were utilised to produce a range of isosteres.
h o oc^ ^ / COOCH3
h3cooc^ ^ COOCH3
dioxan
methanol
(figure 8.1-1)
The acid group of the monoesterified material was converted into the tert- 
butoxycarbonyl protected amine via a modified Curtius reaction (figure 8.1-2).[63]
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1. diphenylphosphoryl azide 
Et3N toluene
hooc^ ^ COOCH3 ------------   m uo^NH^ ^ - COOCH3
2. 'BuOH
(figure 8.1-2)
Treating this compound with lithium diisopropylamide followed by benzyl 
bromide produced the protected, racemic Gly-Phe (E)-ethene isostere (figure 
8.1-3a). Similarly, replacing benzyl bromide with acetaldehyde allowed the 
isolation of the Gly-Thr variant (figure 8.1-3b).
,COOCH3
'BuO O C N H  ^  r  /BuOOCNH
CH2Ph C H (O H )CH 3
protected Gly-Phe isostere protected Gly-Thr isostere
(a) (figure 8.1-3) (b)
It is worthy of note that with these alkylations the py-unsatu rated products, and 
not their structural isomers containing an ap-unsaturation, were isolated when 
the reaction temperature was maintained below -50°C.
Using the same monoester starting material, a similar route was employed to 
effect a-alkylation to what would become the A/-terminus. In this case the 
methoxyethoxymethyl (MEM) ester was employed to induce regioselective a- 
alkylation, presumably due to internal lithium chelation (figure 8.1-4).
MEM-Cl
Et3N
HOOC^ ^ ^ COOCH3 ^  MEMOOC^ ^ - ' COOC" 3
LDA
benzyl bromide 
CH2Ph THF
tetramethylurea
MEMOOC'
(figure 8.1-4)
Selective removal of the MEM ester, using titanium tetrachloride, followed by the 
modified Curtius procedure gave the protected, racemic Phe-Gly isostere. With
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a little additional protecting group manipulation the same synthetic route was 
extended to allow preparation of the tyrosine-glycine analogue. In this case 
para-terf-butoxybenzyl bromide was used in the alkylation step.
Carrying out dialkylation on the diester from figure 8.1-1 with benzyl bromide 
resulted in the production of the 2,5-dialkylated compound (figure 8.1-5a).
Partial ester hydrolysis, using iodotrimethylsilane, on this compound followed by 
the modified Curtius procedure gave the protected Phe-Phe isostere (figure 8.1- 
5b) as two pairs of enantiomers.
dialkylation product protected Phe-Phe isostere
(a) (figure 8.1-5) (b)
Obviosly the routes described here bear no consideration to stereochemistry. 
They do, however, allow the rapid synthesis of a wide range of isostere 
analogues.
8.2 Biological Activity of Isostere Containing Compounds
The Gly-Gly and racemic Tyr-Gly isosteres were separately incorporated into 
varients of the enkephalin analogue (L)-Tyr-Gly-Gly-(L)-Phe-(L)-Pro-NH2.[64] In 
the case of the Gly-Gly isostere, the resulting pseudopeptide exhibited just 0.1% 
of the activity of the parent pentapeptide. Better results were achieved with the 
Tyr-Gly isostere where elaboration of this material gave a pseudopeptide which 
showed up to three times the activity of the parent compound on the tissues 
tested despite the inclusion of a racemic centre.
Using solid phase techniques, the Phe-Gly and Phe-Phe isosteres were 
elaborated into mimics of the peptide pyroGlu-(L)-Phe-(L)-Phe-Gly-(L)-Leu-(L)-
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Met-NH2. The use of pyroglutamic acid (figure 8.2-1) as an A/-terminus blocking 
group in this peptide is also worthy of note.
Th ese derivatives possessed 24% and 100% activity respectively when 
compared to the parent peptide, ft is also worthy of note that for the Phe-Phe 
isostere containing compound (displaying 100% activity of the parent peptide) 
the corresponding saturated analogues exhibited much lower activity (0.35% for 
the SS/RR enantiomeric mixture and 40% for SR/RS).
Thus, it is apparent that the Gly-Gly amide link of enkepalin analogues has some 
important biological role. This bond may, for example, induce a specific 
conformation on the rest of the molecule by intramolecular hydrogen bonding or 
may be instrumental in binding to the receptor. The Tyr-Gly amide bond, on the 
other hand, appears non-essential but the maintenance of amide geometry 
enhances activity. The results obtained from this study however, remain 
ambiguous due to the use of peptides bearing mimics of the non-natural (D)- 
amino acids.
The initial step in the breakdown of the enkephalins was identified as enzymic 
hydrolysis of the Tyr-Gly amide link.[61] The product of this hydrolysis appeared 
to be far more resilient than the parent compound but without the biological 
activity. It was therefore considered that replacement of just the Tyr-Gly bond 
would result in a longer active lifetime in vivo. The initial target of Sammes and 
co-workers was therefore the Tyr-Gly isostere of leucine enkephalin [(L)-Tyr-Gly-
O nh  COOH
pyroglutamic acid 
(figure 8.2-1)
8.3 The Sammes Approach
Gly-(L)-Phe-(L)-Leu].t5811591
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In this synthesis the stereochemistry at the A/-terminus (tyrosine mimic) was 
defined by the use of natural (L)-tyrosine as a starting material. The synthesis 
then centred on the application of Wittig methodology. A stabilised ylide, 
synthesised from prop-2-yn-1-ol, was condensed with the aldehyde obtained 
from diisobutylaluminium hydride reduction of 0,A/-protected (L)-tyrosine methyl 
ester (figure 8.3-1 ).[65]
O
m uO O C N H
H
m uO O CN H
W ittig
• SiM e3
— +
W ittig reagent M e3Si— C==C— C H -P P h 3
(figure 8.3-1)
Hydroboration of the frans-enyne thus produced followed by oxidation yielded 
the desired (5y-unsaturated acid. This compound was coupled with the short 
peptide Gly-(L)-Phe-(L)-Leu-OMe then deprotected to give the leucine- 
enkephalin analogue with totally defined stereochemistry (figure 8.3-2).
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/BuOOCNH.
1. dicyclohexylborane
2. alkaline hydrogen peroxide
dicyclohexylcarbodiimide 
mediated coupling
-Gly-(L)-Phe-(L)-Leu
leucine enkephalin containing the Tyr-Gly isostere
(figure 8.3-2)
This compound was observed to have an activity virtually identical to the natural 
pentapeptide. It was also noted that the isostere containing material remained 
effective on prolonged incubation under conditions which would induce the rapid 
proteolysis of the parent peptide.
Thus, once again we can conclude that the Tyr-Gly amide link is non-essential in 
this system and functions merely as a steric spacer. The trans disposition is, 
however, vital as the fully reduced hydrocarbon analogue showed negligible 
opiate receptor binding. Attempts to synthesise the corresponding c/'s-Py- 
unsaturated variant for comparative testing proved fruitless due to low stability. 
With this compound rearrangement to the more stable frans-ap-unsaturated 
isomer was noted during an attempted ester hydrolysis.
Following the early success, attempts were made to expand the methodology to 
allow the introduction of a second substituent by direct alkylation.1661 The target 
chosen for study was Melanocyte Stimulating Hormone Release Inhibiting 
Factor. (MIF) This peptide (figure 8.3-3a) is rapidly inactivated in biological 
systems by enzymic hydrolysis of the Pro-Leu amide link.
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NB
NH2
(
NH
COOH
M IF (L)-Pro-(L )-L eu-G ly-N H 2
(a) (figure 8.3-3)
Pro-Gly isostere
Firstly, using a sequence similar to that previously described, the A/-protected 
Pro-Gly isostere (figure 8.3-3b) was synthesised from (L)-proline.
The work of Rathke and Sullivan indicated that lithium enolates of a (3- 
unsaturated esters react by alkylation at the a  position giving py-unsaturated 
products.1671 it was therefore suggested that a-alkylation of the Pro-Gly isostere 
methyl ester would occur without the double bond moving into conjugation. As 
expected, treating this compound with lithium diisopropylamide and isobutyl 
iodide (for the Pro-Leu isostere) or benzyl bromide (for the Pro-Phe isostere) 
resulted in a-alkylation in reasonable yield.
Unfortunately the diastereomers produced could not be separated by standard 
chromatographic methods. A degradative procedure was therefore employed to 
investigate the stereochemistry of this alkylation and results showed that while 
the stereochemical integrity of proline was retained, no chiral induction had 
occurred at the site of alkylation. Similar results were observed in the attempted 
synthesis of the (D)-Ala-(D)-Ala isostere.
Therefore by the use of chiral amino acids as starting materials, the Sammes 
method allows the stereochemistry at only one position to be defined. The chiral 
nature of the starting material is not sufficient to induce further stereoselectivity 
during alkylation.
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A very similar route was employed by Johnson in order to incorporate Leu-Gly 
(E)-ethene isosteres into substrate-like renin inhibitors.1[68] In this case, where 
the chirality of the leucine mimic was defined by the choice of (L)-leucine as a 
starting material, the isosteres were shown to have an inhibitory activity very 
similar to the parent peptides. It was therefore proposed that the amide link 
replaced held a trans conformation while bound to the active site of the enzyme.
8.4 Thompson Methodology
A more direct approach to (E)-ethene isosteres was reported by Thompson and 
co-workers.1691 This route involved the application of the Trost alkylation to allylic 
acetates.
The desired allylic acetates were produced in good yield by the reaction of the 
corresponding amino aldehyde with vinylzinc chloride followed by acetylation of 
the resulting alcohol (figure 8.4-1). The diastereoselectivity for the threo product 
in such systems (typically 8:1 threo:erythro) is worthy of note.
O 1. CH 2=CHZnCl
(BuOOCNH. J L  ™ __ ► /BuOOCNH
h
: 2. Ac 20, Et 3N, DMAP
A R
(figure 8.4-1)
Palladium catalysed coupling (Trost alkylation) of these compounds was then 
carried out with acetylated diethyl tartronate and the resulting 1,3-diesters further 
reacted in order to yield the Xxx-Gly isosteres (figure 8.4-2) . [701
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OAc
/BuOOCNH muOOCNH COOEt
R EtOOC-CH(OAc)-COOEt 
NaH, cat. Pd(PPh3)4, THF
R AcO COOEt
1.UBH4, DME
2. N aI04
COOH
R
(figure 8.4-2)
This method therefore provides a more rapid route to chiral dipeptide ethene 
isosteres but is limited to the incorporation of a glycine mimic at the carboxyl 
terminus. The achievement of the trans double bond geometry (typically 99:1 
trans:cis) in this case can be explained by the participation of the BOC group in 
the allylic acetate/palladium complex. It is thought that, due to the involvement 
of this group, the complex holds a chair-like conformation. In the more stable of 
these, of which an example is shown in figure 8.4-3, nucleophilic attack on the 
complex would result in the observed trans product.
tBu—O
c
where X=PdL+
-► trans  product
Nu
(figure 8.4-3)
8.5 The Hanson Synthesis
The reaction between vinylzinc chloride and protected amino aldehydes in the 
Thompson method illustrated selectivity for the formation of the threo product. 
Earlier work by Hanson et al showed that this selectivity was not as pronounced
with vinylmagnesium bromide (figure 8.5-1 ).[711 It was also shown that the 
proportion of threo product obtained could be increased by carrying out the 
reaction at a higher temperature.
CH2=CHMgBr
THF
OH OH
muOOCNH
H
muOOCNH ^  +
CH2Ph CH2Ph CH2Ph
threo:erythro
56:44 at -78°C 
70:30 at 25°C
(figure 8.5-1)
It was suggested that, once again, the A/-terminus plays a role in the reaction 
mechanism. Complexation of magnesium bromide between the aldehyde 
oxygen and carbamate nitrogen enforces a conformation which favours the 
formation of the threo product (figure 8.5-2). At higher temperatures it was 
assumed that a greater proportion of the carbamate groups would be 
deprotonated, thus allowing the formation of this complex and giving higher 
threo selectivity.
The mixture of diastereomers produced by this reaction was separated by HPLC 
and individually elaborated as illustrated in figure 8.5-3 for the minor 
diastereomer.
CH2Ph
H
preferred direction 
of nucleophile 
approach
(figure 8.5-2)
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9 H Ac20/pyridine
OAc
/BuOOCNH
CH2Ph CH2Ph
1. 0 3, MeOH
2. dimethylsulphide
H
9 H OAc
COOH
1. Ph3P=CHCOOEt, THF
2. NaOH, H 20 , MeOH
^BuOOCNH
CHO
CH2Ph CH2P h
(figure 8.5-3)
A route very similar to this was employed by Shue and co-workers to synthesise
allylic alcohols, produced by the reaction of vinylmagnesium bromide on the 
amino aldehyde, was used directly without separation. Acetylation, followed by 
an analogous process of olefin cleavage, produced an aldehyde which was 
condensed with an alternative Wittig reagent (figure 8.5-4).
Careful methanolysis of the acetyl protecting group, followed by mild bromination 
yielded the corresponding allylic bromide. Treating this material with zinc metal 
in acetic acid effected a double bond shift giving the protected (E)-ethene 
isostere as a pair of diastereomers (figure 8.5-5). Separation of these 
diastereomers at this stage, or as the free acids produced on mild 
hydrogenation, was found not to be possible.
a range of dipeptide isosteres.1721 [73] In this case the mixture of diastereomeric
'BuOOCNH
1. Ac20/pyridine
2. NM0/NaI04/0s04(cat.)
3. Ph3P=CH(R')COOCH2Ph
'BuOOCNH
COOCH2Ph
R R
(figure 8.5-4)
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teuOOCNH
OAc R'
1. NajCOs, MeOH
2. PPhj, CBr4, THF Br R'
COOCH2Ph muOOCNH COOCH2Ph
R R
Zn/HOAc
1,4-cyclohexadiene, ^
K Pd/C, MeOH K
(figure 8.5-5)
A number of isosteres were synthesised bearing various side chains (R and R’). 
As can be seen however, the problem of undefined stereochemistry at R’ still 
exists. Since difficulty was experienced in the separation of these 
diastereomers, a further stereoselective stage needs to be incorporated into the 
synthesis.
The stereochemical problem inherent in this route was finally overcome by the 
application of methodology developed by Ibuka, Fujii, Yamamoto and 
colleagues.1741 The enantiomerically pure y-hydroxy-ap-unsatu rated carboxylic 
acid, produced by the Hanson route, was esterified and converted into the y- 
mesyloxy variant. Treating this material with MeCu(CN)Li.BF3(LiBr), produced 
by the sequential addition of MeLi/LiBr (Et20) and BF3.Et20  to a THF slurry of 
CuCN, resulted in alkylation with clean 1,3-chirality transfer (figure 8.5-6).
9 S0 2CH3
t B u O o m u ^ ^ X ^ ^
CH2Ph
c h 3
COOMe
/BuOOCNH
COOMe
CH2Ph
MeCu(CN)Li.BF 3(LiBr), THF
(figure 8.5-6)
The observed olefinic product was found to be exclusively of the (E) geometry. 
The level of diastereoselectivity for the desired product, achieved in this
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alkylation, was also extremely high. In this case reaction yields were of the 
order of 98% with a diastereoselectivity greater than 99:1.
While the controlling factors in this reaction remain unclear, an explanation for 
the observed (E) product has been postulated.
Conformer A (figure 8.5-7), which would lead to the (Z) product, is destabilised 
by the steric interaction between the bulky R group (CH2Ph in this case) and the 
olefinic hydrogen. Conformer B is therefore more favourable with nucleophilic 
attack resulting in the observed (E) product geometry. Thus displacement of the 
mesylate leaving group only takes place when it and the attacking nucleophile 
are in a mutually antiperiplanar disposition. The reaction can therefore be 
described as proceeding by an anti-S^fi! mechanism.
OMs OMs
.COOMe
Conform er A
MeOOC.
Conform er Battack o f  nucleophile 
on bottom  face ^
(figure 8.5-7)
8.6 The Hopkins Organosulfur Route
Stereocontrol at both chiral centres and trans double bond geometry was also 
achieved by Hopkins and colleagues by a convergent route incorporating the 
Julia Olefin Synthesis (figure 8.6-1 J.175117611771
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R — CH2- S 0 2- A r R. ^S 0 2Ar>
OHC— R' HO
Julia Olefin Synthesis 
(figure 8.6-1)
In the previously described synthetic routes, chiral amino aldehydes were used 
in order to define the stereochemistry at the AMerminal side chain in the product 
peptide mimic. Unfortunately, in this application, the coupling of these 
compounds with sulfones provided only traces of the desired olefinic product. 
Better results were however achieved with the sulfone as the amino acid derived 
species (figure 8.6-2).
In general, the aldehydes required for coupling to these sulfones were 
synthesised from 4-methylpent-3-enoic acid.N Evans’ method for asymmetric 
alkylation was employed in this sequence to introduce the R’ groups with defined 
chirality (figure 8.6-3). These reactions will be discussed in more detail in later 
chapters.
ABuOOCNH
COOH
R
v
'BuO O C N H . y v
S0 2Ar +
A
OTHP
(figure 8.6-2)
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COOH
CH
OHC
R'
J L  OTHP
(figure 8.6-3)
Thus the synthesis of dipeptide isosteres with fully defined chirality is possible. 
However, the application of such methodology to peptidyl cysteine protease 
inhibitors has not yet been reported.
66
Chapter 9: Aims and Objectives
Literature synthetic routes to dipeptide (E)-ethene isosteres with fully defined 
stereochemistry are available as illustrated above. Such a stereoselective 
synthesis may be essential as the adequate separation of dipeptide isosteres 
may be difficult to achieve (see section 8.5). In order to prove the concept of the 
isostere with regard to anti-parasitic activity, it was decided to synthesise a 
series of such compounds, with defined chirality, bearing the fluoromethyl 
ketone end group.
The compounds produced in the first round of synthetic work would be tested for 
activity against an initial battery of parasitic species. From the results of this 
study, clues as to the ideal selection of side chains for effective inhibition of each 
species would hopefully be obtained. Promising compounds could then be 
employed in more extensive testing incuding investigations into the comparative 
in vivo stability of active isosteres and the corresponding amides.
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Results and Discussion 
Chapter 10: Fluoromethyl Ketone End Group Investigations
Classically, the fluoromethyl ketone end group has been formed by the direct 
conversion of A/-protected amino acids or peptides. Methodology therefore 
exists for the synthesis of this group from carboxylic acids and its application to 
completed (E)-ethene isosteres should be possible. Prior complete formation of 
isosteres may be essential as in the viable routes to these compounds selected 
for further study, generation of the carboxylic acid terminus occurs late in the 
synthetic sequence. It was therefore considered wise to test the potential end 
group elaboration method as it would eventually be employed in the closing 
stages of non-trivial syntheses.
10.1 Literature Fluoromethyl Ketone Syntheses
Traditional methodology for the formation of A/-protected peptidyl halomethyl 
ketones involved reacting the corresponding diazomethyl ketone with hydrogen 
halides.[78] While being effective for chloromethyl and bromomethyl ketone 
formation, the route fails for the insertion of fluorine (figure 10.1-1). Upon 
treatment of A/-CBZ-(L)-PheCHN2 with hydrofluoric acid, a cyclised product is 
produced. This intramolecular cyclisation reaction dominates in this situation 
due to the lower nucleophilicity of fluoride. This factor also explains the isolation 
of hydroxymethyl ketones rather than the fluorinated product during attempted 
halogen exchange (note that in the failed fluorination cases reported in the 
literature, product stereochemistry was not considered and is therefore assumed 
to be unaffected by the reagents). In contrast, iodomethyl ketones are readily 
prepared from chloromethyl ketones by halogen exchange using sodium iodide 
in acetone.
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-nh^ J LP—NR. P—NIL /CHN2  *“
R X  = Cl or Br R
P = protecting group
PhCH2CK. .N H  A .  ^
Y  1 chn2 • -------
O CH2Ph
HN 0
0
PhCH20 > ^ N H ><Y \ ^ ' I  AgF  ^ PhC^Ov^/NH^ ^O U
I  ^ IT O  I'
0  CH2Ph 2U 0  CH2Ph
(figure 10.1-1)
This problem of C-F bond formation was indirectly overcome by the use of a 
modified Dakin-West reaction (figure 10.1-2).1791 In this reaction the entire 
carboxyl group of the amino acid is replaced thus forming a new C-C bond.
PhCH2O ^ N H ^ X OH  „  PhCH2O ^ N H  J l ^ / F
O CH3 fluoroacetic anhydride, O CH3
Et3N, DMAP(cat-), benzene
(figure 10.1-2)
The synthetic utility of this reaction is limited as racemisation is inherent, yields 
are generally poor and purification is tedious due to the large number of by­
products formed. Despite this, much early work has been carried out on 
fluoromethyl ketones formed by this method (see sections 4.4, 6.1 and
0  2 ) [46][80][81]
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The direct, racemisation free conversion of peptidyl diazomethyl ketones to 
fluoromethyl ketones was achieved by Shaw and colleagues using HF/pyridine, 
the problem of the competing cyclisation reaction being solved in this case by 
the use of the A/-phthaloyl protecting group (figure 10.1-3).1541 It was this 
synthetic sequence that was selected for further study with the aim of being 
incorporated into the synthesis of A/-protected dipeptide isostere fluoromethyl 
ketones. However, scope for improvement of this method existed as the yields 
reported for the fluorination step were both low and variable. For example, from 
A/-phthaloyl-(L)-phenylalanyl diazomethyl ketone (R = PhCH2) a 33% yield was 
reported while with A/-phthaloyl-(L)-alanyl diazomethyl ketone (R=CH3) only 5% 
of the fluorinated product was obtained.
1 . EtsN, isobutyl 
chloroformate, 
THF
2 . CH2N 2 in ether
o o
52% HF/pyridine
o
o
(figure 10.1-3)
10.2 Experimental Investigations into the Shaw Route
A/-Phthaloyl protected amino acids were formed according to the method of 
Nefkens, Tesser and Nivard.[82] (L)-Phenylalanine, (L)-alanine and glycine were 
protected in consistently good yield (>70%) and high purity (figure 10.2-1).
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h 2n .a
R
O
OH
N-ethoxycarbonyl
phthalimide,
Na2C0 3 , water OH
O
R = CH2Ph, CH3 or H
(figure 10.2-1)
Treatment of these compounds with triethylamine and isobutyl chloroformate, in 
dry THF at -20°C, resulted in the formation of the corresponding mixed 
carbonate (figure 10.2-2). In such a system, the carbonyl originating from the 
carboxylic acid is activated towards nucleophilic attack. The carbonate carbonyl 
is less receptive in comparison, due to the presence of flanking oxygen atoms. 
Thus, on the addition of diazomethane, formation of a diazomethyl ketone 
occurs accompanied by fragmentation of the mixed carbonate.
The ethereal solution of diazomethane required for this step was prepared by 
alkali induced decomposition of Diazald® (A/-methyl-A/-nitroso-p- 
toluenesulfonamide) using the procedure defined by Hudlicky (figure 10.2-3).[83] 
Quantities of diazomethane between 0.06 and 0.3 moles were produced and 
reacted without any problems as the standard precautions for the safe handling 
of this material were observed throughout its generation, storage and use.
Et3N, isobutyl 
chloroformate PhthNPhthN
R R
CH2N 2 (ether solution)
u
o
PhthN
R
(figure 10.2-2)
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diethylene glycol 
monoethyl ether, 
diethyl ether
K 0 H ,H 20
CH2N2 + /w ra-to luenesu lfonate
(figure 10.2-3)
The ethereal diazomethane solution was prepared regularly and, preferably, 
used while fresh. In this situation the 90% Diazald® to diazomethane 
conversion, as achieved by Hudlicky, could be assumed. Storage at under 5°C 
for short periods of time (2-3 weeks) was found to be possible as long as the 
possible reduction in concentration, by decomposition, was accounted for by the 
use of a greater volume. Obviously some degree of inaccuracy results from 
these estimations but the intended use of at least a three to one molar ratio of 
diazomethane to carboxylic acid, in diazomethyl ketone synthesis, should 
partially allow for this. By taking this factor into account, variable product yields 
due to diazomethane concentration inaccuracy and decomposition were not 
observed. A method for the determination of diazomethane solution 
concentration, by the back titration of excess benzoic acid in dry THF, was in 
fact tested but considered to be superfluous and impractical for regular use.[84]
Thus, the addition of a three fold excess of diazomethane to the mixed 
carbonate of A/-phthaloyl-(L)-phenylalanine allowed the reliable production of the 
desired diazomethyl ketone, with purity being attained by a simple 
recrystallisation process. Similarly, application of the procedure to A/-phthaloyl- 
(L)-alanine gave the diazomethyl ketone containing product as a yellow oil. 
Solidification and recrystallisation of this compound was not achieved by the 
original authors but was found to be possible here by storage of the material at 
0°C. During this reaction, for simplicity and to test the resilience of the method, 
far greater than required quantities of reagents were used. No significant ill 
effects were noted but racemisation was however, unchecked for. N- 
Phthaloylglycyl diazomethyl ketone, not discussed by the authors of the original 
method, was also synthesised in crystalline form.
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10.3 Characteristic Spectroscopic Details of Diazomethyl Ketohes
As a significant amount of later work concentrated on the formation of more 
complex diazomethyl ketones, the spectroscopic details of these simple model 
compounds are worthy of discussion.
The most striking feature of the infra-red spectra of these compounds is an 
extremely strong and sharp peak in the normally clear area around 2100 cm-1. 
This absorption is due to the C=N=N grouping of the diazomethyl ketone and as 
a result can be used to identify the presence of such compounds in mixtures or 
crude products.
The single hydrogen of the diazomethyl ketone group appears as a broad signal, 
typically between 5 and 5.5 ppm, in the 1H NMR spectrum of these compounds 
in deuteriochloroform. Since such a peak can be easily mistaken for a 
carbamate NH or partially obscured by components of olefinic signals, its 
diagnostic use can be limited with A/-protected peptides and (£)-ethene 
isosteres. Better results can be achieved when the spectrum is run in d6-DMSO. 
In this solvent the diazomethyl ketone hydrogen can be observed as a sharp 
peak in the much clearer region around 6.5 ppm.
A common feature observed in the mass spectrum of diazomethyl ketones is the 
early loss of N2. The parent molecular ion, if seen at all, is usually found at very 
low intensity. The product of this nitrogen loss is often the highest molecular ion 
peak of significance observed.
10.4 Attempted Direct Fluorination by Shaw’s Procedure
Attempted conversion of A/-phthaloylphenylalanyl diazomethane to the 
corresponding fluoromethane, using HF/pyridine, gave what appeared to be two 
distinct products (Rf 0.61 and 0.43, 2:1 chloroform:ethyl acetate). These were 
separated by dry flash chromatography using a 2:1 chloroform:ethyl acetate
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solvent system as suggested by Shaw et al. The later eluted material showed 
no 19F signal and was considered to be hydroxymethyl ketone (figure 10.4-1) 
formed as a by-product. This was later confirmed by the deliberate synthesis of 
this material.
Avoiding the production of such a material would be difficult due to the highly 
hygroscopic nature of HF/pyridine. This problem is further compounded by the 
unsuitability of standard glassware for the handling of this reagent.
The earlier material to be eluted was identified by 1H NMR spectroscopy (in d6- 
DMSO) as being partly, but not exclusively, starting material. A clean 19F NMR 
signal coupled to two identical species was observed for this sample (-232.7 
ppm, 46.1 Hz) suggesting the presence of some of the desired product. 
Subtraction of the diazomethyl ketone 1H NMR spectrum from that of the fluorine 
containing product suggested that the CH2-F connection was indeed present as 
a coupling of approximately 46 Hz was observed for a plausible CH2-X signal. 
Isolation of this small amount of material was not attempted but it could be 
clearly seen, however, that product yields by this route were unacceptably low.
In an attempt to reduce the amount of unreacted starting material recovered and 
limit moisture uptake by the reagent, slightly stronger conditions involving less 
reagent manipulation were investigated (note that the use of 52% HF/pyridine 
required the addition of pyridine to the commercially available 70% reagent). 
Once again the major fluorine-free by-product observed in the previous reaction 
was isolated. A small sample of the partially purified reaction product was
CH2JPh
iV -Phthaloylphenylalanyl hydroxym ethyl ketone
(figure 10.4-1)
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observed to contain an 19F NMR signal at the desired chemical shift. This signal 
was, however, dwarfed by a variety of additional peaks suggesting that 
uncontrolled fluorination had taken place.
Under the same conditions, the reaction was attempted with a milder reagent.
No desired fluorination was observed from the reaction in neat triethylamine 
trishydrofluoride, the major product in this case being the unreacted starting 
material.
Direct conversion of diazomethyl ketones to fluoromethyl ketones with 
HF/pyridine, though possible, was considered to be highly inefficient from these 
results. The unreliability of this method was also illustrated by the varying yields 
obtained by Shaw. For our purposes the possibility of obtaining a mere 5% 
yield, as suggested by Shaw for A/-phthaloyl-(L)-alanyl fluoromethyl ketone, is • 
totally unacceptable. It was therefore decided to investigate the use of 
bromomethyl ketones as intermediates.
10.5 Studies Concerning Bromomethyl Ketone Synthesis
The rather vague procedure described by Pattabiraman and Lawson, using 
lithium bromide in acetic acid, was tested as a potentially mild route to 
bromomethyl ketones.[85] The physical characteristics of this mixture made 
crude product manipulation and isolation difficult but, after some degree of 
experimentation, conditions were developed where at least partial reaction of N- 
phthaloylphenylalanyl diazomethyl ketone could be observed. With this reagent, 
and with 45% aqueous HBr, several by-products were also formed. The most 
significant of these was identified by 13C NMR spectroscopy as being the a- 
acetate (figure 10.5-1).
75
OAc
(figure 10.5-1)
1H NMR spectroscopy was found to be extremely useful in assessing the 
number and approximate relative quantities of products resulting from these 
reactions. This could be gauged by analysing the appearance of the a-CH 
signal in the relatively clear 5 to 5.5 ppm (CDCI3) region.
The search for an improved method by which hydrobromic acid could be utilised 
free from moisture and alternative nucleophiles, uncovered the synthesis of 
triphenylphosphonium bromide.1861 Easily prepared from triphenylphosphine and 
aqueous hydrobromic acid, this crystalline material can be thermally 
decomposed to release hydrogen bromide gas.
Solid triphenylphosphonium bromide, prepared and purified by this very simple 
method, was dissolved in dry xylene and brought to reflux. The gaseous 
hydrogen bromide thus produced was carried in a stream of dry nitrogen through 
a dichloromethane solution of A/-phthaloylphenylalanyl diazomethyl ketone. 
Immediate reaction of this material was noted by the evolution of further gas 
(nitrogen) and the loss of the characteristic yellow diazomethyl ketone solution 
colouration. As a result, excellent yields (around 90%) of the corresponding 
bromomethyl ketone (figure 10.5-2) were obtained following product purification 
by a simple recrystallisation. The purified product compound was found to be 
strongly optically active suggesting that racemisation had not taken place. 
Repeating this process with A/-phthaloylalanyl and A/-phthaloylglycyl diazomethyl 
ketones also achieved the desired conversion.
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P h th N ^ /H ^  HBrgas^ PhthN  ^ ^Br
| C H N 2  dichloromethane
R &
(figure 10.5-2)
With A/-phthaloyl protected materials, the HBr gas method is far superior to the 
other bromination procedures investigated here. It is also considered that the 
practical yield attainable could be brought close to 100% with further work.
10.6 Fluoromethyl Ketones by Halogen Exchange
Using HF/pyridine and yellow mercuric oxide, Olah reported a 6 8 % yield in the 
halogen exchange reaction of a-bromoacetophenone (figure 10 .6-1 ).[87]
o
HF/pyridine, HgO 
55°C, 15 hours
(figure 10.6-1)
An attempt to apply this methodology to /\/-phthaloyl-(L)-phenylalanyl 
bromomethyl ketone however, resulted in gross decomposition of the starting 
material. Studies involving this method were not continued as a concurrently run 
experiment with an alternative fluorinating agent showed greater signs of 
promise.
It has been reported that fluoroacetone can be formed by the reaction of 
bromoacetone in triethylamine trishydrofluoride at 110-115°C.[88] The effects of 
this reagent on A/-phthaloylphenylalanyl bromomethane were therefore 
investigated. One of the potential advantages of the use of triethylamine 
trishydrofluoride, as opposed to standard HF reagents, is that regular glass 
apparatus may be employed without problems. The handling characteristics of 
this reagent are also far superior. '
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Initial experiments using approximately three molar equivalents of this reagent in 
a chloroform solution showed that some fluoromethyl ketone was formed when 
the reaction mixture was heated to 80°C. During further studies the course of 
the reaction was carefully followed by thin layer chromatography allowing the 
successful production of the desired fluoromethyl ketone to be achieved. This 
compound was purified by precipitation from dichloromethane by the addition of 
hexane, giving a 78% yield. Repeating the procedure with A/-phthaloylalanyl and 
A/-phthaloylglycyl bromomethyl ketones also achieved success. It is predicted 
that, with further experimentation, the yields obtainable by this method could be 
significantly improved.
Had the triethylamine trishydrofluoride route proved not to be successful, it was 
intended that the next attempted halogen exchange would be carried out using 
potassium fluoride and 18-crown-6 as described by Liotta and Harris.1891 It was 
later discovered that this method has been used on racemic N- 
phthaloylphenylalanyl bromomethyl ketone by Kolb et al, giving a 45% product 
yield (figure 10.6-2).[90] [91] Note however that this yield is inferior to that 
obtained here with the developed Et3N.3HF route.
KF/18-crown-6, 
acetonitrile, 
30 hour reflux
CH2PhCH2Ph
(figure 10.6-2)
10.7 Features Requiring Further Investigation
Recent developments in the field of cysteine protease inhibitors, which will be 
discussed in due course, caused the premature termination of studies in the 
direction of fluoromethyl ketone synthesis. Unfortunately, at this stage of the
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investigation, several important questions remain unanswered and methods 
untested.
Application of the Developed Route to A/-BOC Protected Compounds
The use of HBr gas in the developed route suggests that the diazomethyl to 
bromomethyl ketone conversion may cause problems with fe/f-butoxycarbonyl 
protected compounds. In order to assess this problem A/-BOC-(L)-phenylalanyl 
diazomethyl ketone was synthesised. As expected, treatment of this compound 
with HBr gas caused the destruction of the protecting group. It is unknown if 
moderation of the conditions employed, by the use of low temperatures for 
example, would allow the successful reaction of the diazomethyl ketone group in 
the presence of a A/-BOC protection.
A variation of the HBr/acetic acid method was employed by Zimmerman, Bissell 
and Smith to allow the formation of bromomethyl ketones in the presence of tert- 
butoxycarbonyl or benzyloxycarbonyl protecting groups.[92] In this case the 
HBr/acetic acid was significantly diluted with dichloromethane prior to its use on 
a solution of the starting material. A product yield of 75% was claimed for this 
methodology.
An analogous moderation process was employed by Kolb et al where a 94% 
yield of A/-phthaloylphenylalanyl bromomethyl ketone was obtained using 47% 
aqueous HBr in THF.[90]I91] The use of these procedures should therefore 
overcome the side-product formation problems experienced in more 
concentrated systems (see section 10.5).
Scope and Limitations of the Triethylamine Trishydrofluoride Halogen Exchange
The factors governing this reaction have not been fully investigated. For 
example, the reaction times required (typically greater than 25 hours) for 
complete halogen exchange were considered to be excessive. The effects of
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increased reagent concentration on this have not been investigated. Similarly 
the use of HgO, as employed by Olah in the HF/pyridine induced exchange, may 
also reduce the necessary reaction time or temperature. Such moderation may 
be essential to allow the selective reaction of A/-BOC or A/-CBZ protected 
materials. The stability of such groups with triethylamine trishydrofluoride has 
not been tested.
Possible Racemisation of A/-Phthaloylphenylalanyl Fluoromethyl Ketone
The optical rotation of the synthesised A/-phthaloylphenylalanyl fluoromethyl 
ketone was observed to be small. As no reference standard existed for this 
compound it could not be established to what extent, if at all, racemisation had 
occurred. It was intended that a sample of fluoromethyl ketone would be 
prepared, from the optically active bromomethyl ketone, by the Kolb KF/crown 
ether procedure for comparative purposes.
Racemisation by the KF/crown ether procedure however, may also be possible 
as Kolb reported a competing elimination reaction in a cyclic system (figure 10.7- 
1).I90] In this situation the fluoride ion is clearly acting as a base.
Cl
c h 3
KF/18-crown-6
CH3CN
c h 3
+
O
'CH3
(figure 10.7-1)
A literature value exists for the optical rotation of A/-CBZ-(L)-phenylalanyl 
fluoromethyl ketone.[54] Changing the protecting group, by the method employed 
by Shaw (figure 10.7-2), could therefore be considered if stereochemical 
ambiguity with the fluorinated material still existed.
4
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O
1. NaBH4, 
propan- 1 -ol/water
2. AcOH
3. 2MNaOH
H
h 2n
R
O
CBZ— N H
R
C1O 3 ,
pridine
dichloromethane
1. N aH C 03, 
water
2 . benzyl 
chloroformate, 
toluene
H
CBZ—N H
R
Protecting Group Exchange 
(figure 10.7-2)
10.8 Recent Advances in the Field of Cysteine Protease Inhibitors
Work on the fluoromethyl ketone end group was halted at this stage as 
alternative leaving groups have recently been developed and used in preference 
to fluorine.[92] [93]
A vast range of aryloxymethyl and arylacyloxymethyl ketones have been 
synthesised and shown to possess activity against cysteine proteases.t94] The 
theoretical basis of this study originates from the fact that the electronegativity of 
oxygen most closely approaches that of fluorine, particularly when the former 
atom is bonded to an aromatic ring. Typical leaving groups tested include those 
bearing further electron withdrawing substituents on the aromatic ring such as 
those shown in figure 10 .8-1.
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F
4-nitrophenoxym ethyl pentafluorophenoxym ethyl
ketone end group ketone end group
(figure 10.8-1)
The main advantage of the use of such end groups appears to be that the 
activity of the resulting compound can be modified by alteration of the aromatic 
substitution pattern. Thus, a large degree of reactivity fine tuning is now 
possible as the selection of electron withdrawing leaving groups is no longer 
limited to halogens.
Leaving groups derived from aspirin, p-acetaminophenol and similar anti­
inflammatories have also been suggested (figure 10.8-2). The release of such 
compounds directly at the site of anti-parasite drug action would obviously be of 
benefit.
R
NHCOCH3
R
methyl salicylate releasing end group p -ace tam inopheno l releasing end group
(figure 10.8-2)
It may be possible that investigations concerning alternative leaving groups were 
initiated in order to minimise the toxic effects of drug metabolites. Since the 
incorporation of isosteres into peptidyl fluoromethyl ketones is not yet common 
practice, undesirable side-effects would be expected during the use of such 
compounds as amide link hydrolysis is still possible. This process would result 
in the production of unprotected amino acids bearing the fluoromethyl ketone 
end group. It may be possible that the metabolic products of compounds
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bearing the alternative end groups are less toxic or are metabolised further due 
to their additional functionality.
The activity of such compounds also indicates the absence of steric constraints 
in this area of the active site or the protrusion of the leaving group from the 
enzyme.
More recently, work has been carried out on end groups unrelated to a -  
substituted methyl ketones. Peptidyl vinyl sulfones have been synthesised 
which show activity against cysteine proteases but not serine proteases or 
unactivated thiols.1951 In these compounds the sulfone is thought to hydrogen 
bond to the enzyme active site thus compensating for the absence of the 
carbonyl group and its associated interaction with the enzyme (figure 10.8-3).
H -bonding
- H-bonding
attack o f  cysteine thio
(figure 10.8-3)
The application of the Fehrentz and Castro procedure has been specified in 
order to produce the chiral amino aldehydes from which these compounds can 
be formed.[96] Thus the application of this methodology, which will be described 
in section 11 .1 , to completed isosteres may be informative.
End group technology is advancing rapidly and as the pool of potential groups 
continues to grow, it seemed wise to concentrate on proving the concept of the 
isostere. Such testing can be carried out using any active end group on a 
battery of parasites. If (E)-ethene isosteres are shown to possess activity, the 
more complicated process of synthesising the compound of highest, and most 
specific, activity can begin.
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It was therefore decided to test the completed isosteres initially bearing the 
diazomethyl ketone end group. The most promising of these, indicated by the 
first round of biological tests, could then be taken further by incorporating the 
latest end-group technology.
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Chapter 11: Initial Studies Concerning (E)-ethene Isostere Synthesis
Much biological work has been carried out on the fluoromethyl ketone of the 
dipeptide A/-BOC-(L)-Phe-(L)-Ala. Because of this and the possible absence of 
complications arising from side chain functionality, it was decided that the (£)- 
ethene isostere of this compound would be a suitable first synthetic target.
An initial, rapid study was carried out concerning the possibility of using the 
Hanson route to hydroxyethylidene compounds followed by the 1,3 chirality 
transfer reaction as developed by Fujii, Ibuka and Yamamoto.1711 [74] (figure 11-1) 
One of the main attractions of this route is the prospect of stereocontrol at both 
chiral centres and exclusive synthesis of the trans double bond (see section 
8.5).
OH
^BuOOCNH a .
 ^  ^ y ^ ^ ^ C O O M e
H anson t H 2Ph
m ethodology
Fujii, Ibuka and 
Yam am oto m ethodology
muOOCNH.
COOMe
C H 2P h
(figure 11-1)
As the insertion of the carboxyl terminus side chain occurs in the final stages of 
the synthesis, extensive variation at this position may be possible without the 
need to alter reaction conditions or purification procedures for the majority of the 
route. Another feature worthy of mention is the use of A/-protected chiral amino 
aldehydes derived from the corresponding amino acids as starting materials. A
muOOCNH^^CHO
CH2Ph
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wide variety of such A/-protected amino acids are commercially available and 
inexpensive.
The addition of vinyl magnesium bromide to A/-BOC protected phenylalaninal, as 
described in the Hanson procedure, results in the production of a pair of 
diastereomeric vinyl alcohols (figure 11-2). For the synthesis of (E)-ethene 
isosteres bearing the same chirality as the natural dipeptide, the elaboration of 
the minor erythro diastereomer would be required. Hanson et al specify the use 
of HPLC to effect the separation of these diastereomers and, in their situation, 
both were isolated and used in further studies.
O CH2=CHMgBr OH 9H
'B u O O C N H ^J l^  TH? » f B u O O C N H ^ A ^ *  + ® u O O C N H ^ /k ^ s
CH2Ph iH 2Ph CH2Ph
threo.erythro
56:44 at -78°C 
70:30 at 25°C
(figure 11-2)
As preparative HPLC was unavailable, it was decided to undertake a rapid test 
synthesis of this diastereomeric mixture to investigate if efficient separation 
could be achieved by standard silica gel column chromatography.
11.1 Synthetic Test of the Hanson Route
A sample of A/-BOC protected (L)-phenylalaninal was produced from /V-BOC-(L)- 
phenylalanine by the method of Fehrentz and Castro (figure 11.1 -1).[96]
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ABuOOCNH^ XOOH
1. Et3N, BOP
2 . HN(CH3)(OCH3),
Et3N  
 ►
^BuOOCNH
121 11CH2Ph CH2C12
LiAlH4, Et20
'B uO O C N H ^ X H O
CH2Ph
(figure 11.1-1)
This method was chosen as it was claimed by the original authors that, in 
general, the crude aldehyde products contained minimal impurities thus avoiding 
the need for further purification. Such a result would be beneficial as column 
chromatography of optically active a-amino aldehydes often leads to 
decomposition or racemisation.
The 1H NMR spectrum of the crude amino aldehyde compared well to that 
quoted by Fehrentz and Castro. This material was therefore used directly 
without further purification or analysis.
As expected, the reaction of vinyl magnesium bromide with A/-BOC protected 
phenylalaninol produced two main compounds with close retention factors on 
thin layer chromatography (typical Rf difference 0.05, eluent 1:4 ethyl 
acetate:hexane). Purification was attempted by dry flash, positive pressure and 
gravity column chromatography but efficient separation of the two diastereomers 
could not be achieved.
This route therefore no longer represents an efficient option for the synthesis of 
the (L)-Phe-(L)-Ala isostere. The efficient synthesis of isosteres mimicking 
peptides bearing the unnatural (D)-amino acid at the C-terminus may however, 
still be possible by this route. In this situation vinylmagnesium bromide would be
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replaced with vinylzinc chloride as this reagent was shown by Thompson to 
increase the proportion of the major (threo) isomer formed (see section 8.4).[69] 
The methodology combination required for synthesis of the A/-B0 C-(L)-Phe7(D)- 
Ala isostere methyl ester is outlined in figure 11.1-2.
'BuOOCNH
H
R Thompsonmethodology
(involving
CH2=CHZnCl)
'BuOOCNH
Ac
R
Hanson
methodology
9H3
/B u O O C N H ^ ^ ^ A , 
CH2Ph
H
COOMe 'BuOOCNH
Fujii, Ibuka and
Yamamoto
methodology
'COOMe
CH2Ph
(figure 11.1-2)
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Chapter 12: The Formation of Precursors for an Alternative Strategy
The Hopkins approach to the synthesis of (£)-ethene isosteres involved the 
formation of the olefin by the coupling of a sulfone with an aldehyde (figure 12- 
1).[75] The synthetic routes employed here to obtain these precursors will be 
discussed separately and in turn.
^BuOOCNTL
COOH
R
\ fv
^BuOOCNH,
R
R'
S 0 2Ar + OTHP
OHC'
(figure 12-1)
12.1 Formation of the Sulfone Synthon
Initial studies on the synthesis of sulfones were carried out using A/-BOC 
protected (L)-phenylalanine as a starting material. The carboxyl group of this 
compound was activated by the formation of a mixed carbonate then reduced to 
the corresponding alcohol by the action of sodium borohydride (figure 12 .1-1).
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O O
'B u O O C M T  X O O H 'BuOOCNH
CH2Ph ethyl chloroformate 
Et3N, THF
CH2Ph
NaBH4, H 20
m uO O C N H
OH
CH2Ph
(figure 12.1-1)
A significant quantity of white solid, later identified as triethylamine 
hydrochloride, was removed from the mixed carbonate solution by filtration 
before addition of the solution to a sodium borohydride/water slurry. The use of 
water as a co-solvent is apparently essential in this situation as sodium 
borohydride is poorly soluble in THF alone and thus would give rise to low
Prior activation of the carboxylic acid, as a mixed carbonate, allows the reduction 
to proceed very smoothly under mild conditions. However, extreme care was 
found to be necessary during the course of the reaction as the breakdown of this 
activated system resulted in the generation of significant quantities of carbon 
dioxide and heat. The crude product alcohol, identifiable by the loss of the 
carboxylic acid infra-red absorbance (1714 cm'1, KBr disc), was shown as being 
virtually pure by 1H NMR spectroscopy. Absolute purity was easily attained by a 
simple recrystallisation from ethyl acetate/hexane.
Conversion of the A/-BOC-(L)-phenylalaninol to the corresponding mesylate was 
carried out in order to increase the susceptibility of the alcohol function to 
displacement by SN2 attack.[98] This was carried out using methanesulfonyl 
chloride and triethylamine in dichloromethane (figure 12.1-2 ).
yields.1971
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m uO O C N H
CH3S0 2 C1
Et3N ^BuOOCNH
OSO2CH 3
CH2Ph
OH
DCM
CH2Ph
(figure 12.1-2)
Product yields in excess of 95%, following recrystallisation, were regularly 
obtained for this reaction. Mesylates were generally used within three days of 
synthesis and during this time the compounds were stored at 0°C under a 
nitrogen atmosphere in order to minimise decomposition.
The mechanism of this reaction is worthy of discussion. Direct nucleophilic 
displacement, by the attack of the alcohol on sulfur, was ruled out by Crossland 
and Servis as the nucleophilicity of the alcohol appeared unimportant to the 
progression of the reaction. This was illustrated by the successful mesylation of 
2,2,2-trifluoroethanol and 1,1,1,3,3,3-hexafluoro-2-propanol. Indeed, King and 
Lee showed that the kinetics of the reaction were independent of alcohol 
concentration with the observed reaction rate being first order with respect to 
both the sulfonyl chloride and tertiary amine.I99]
Model studies carried out by this group showed that the reaction was most likely 
to proceed by an E2 mechanism where the base-induced elimination of 
hydrogen chloride leads to the formation of a sulfene (figure 12.1-3). This highly 
reactive intermediate then reacts rapidly with the available alcohol thus forming 
the product mesylate.
(figure 12.1-3)
The next stage in the synthetic route involved the displacement of the mesylate 
by thiophenol. In order to effect this, the thiol was added to a previously
C H 3SO 2CI + E t3N *  C H 2= S 0 2 +  E t3N H + C
slow and concerted
C H 2= S 0 2 +  R-O H -  R -O SO 2C H 3
fast
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CHoPh
prepared solution of sodium methoxide. In this base, one would expect virtually 
complete formation of the thiolate anion due to the lower basicity of this species. 
Sn2 attack of the thiolate anion with concurrent displacement of the mesyloxy 
group was found to be effective and efficient under the conditions described 
(figure 12.1-4).[75] Dilute sodium hydroxide solution was then added to the 
reaction mixture prior to work-up. Maintaining the basic nature of this mixture 
would prevent the inclusion of methanesulfonic acid into the product solution 
during extraction. The quantity of excess thiophenol similarly incorporated may 
also be limited.
teuO O C N H  ^  m uO O C N H'V ^ O S 0 2CH3  _
Ah2P1i PhSNa, THF, MeOH
(figure 12.1-4)
Recrystallisation was found to be sufficient to remove the small number of by­
products, observed by thin layer chromatography, from the product thioether. 
Excess thiophenol was indeed identified as being the major contaminant.
mefa-Chloroperoxybenzoic acid oxidation of the thioether, to give the desired 
sulfone (figure 12.1-5), initially gave some product purification problems.t75] 
These were eventually identified as being due to the incomplete removal of 
mefa-chlorobenzoic acid by extraction into sodium hydroxide. This by-product 
was also found to persist as a major contaminant during recrystallisation of the 
crude sulfone from methanol. Slow recrystallisation in several crops from hot 1:1 
ethyl acetate:hexane, although appearing visually to give a less pure product, 
was found to be more effective at keeping the by-product within the mother 
liquor. However, careful monitoring of the extensive nature and relative integral 
of the 1H NMR aromatic region was still essential for each crop to ensure the 
absence of this impurity. Typical yields of pure sulfone around 90% were 
achieved by this method.
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ffiuOOCNH
CH2Ph
mcpba muOOCNH.
S02Ph
CH2CI2 CH2Ph
(figure 12.1-5)
12.2 Advantages of the Employed Route for Sulfone Generation
An obvious advantage of the route employed for sulfone synthesis is the 
absence of the necessity for chromatographic purification. In each step a 
recrystallisation process was sufficient to obtain material of high purity. Indeed, 
in many cases the high yielding reactions furnished crude products of sufficient 
quality to be used directly in the following stage. Obviously this ease of 
crystallisation may not be generally extended to sequences involving amino 
acids other than phenylalanine but the high yields experienced and the ability to 
continue with crude products should minimise problems.
The above reactions were carried out a number of times with similar success in 
each case. Variation of the scale of the process, typically from 100 mg to 30 g, 
did not prove to be in any way detrimental to the course of the reaction.
Using the reaction procedure described above, A/-BOC protected (L)-valine and 
(L)-leucine were reduced to the corresponding alcohols in crude yields greater 
than 80% (figure 12.3.1). In both cases the crude products were viscous oils 
but, after storage under vacuum for several days, purity was indicated by 1H 
NMR spectroscopy and microanalysis.
12.3 Sulfones From Alternative Starting Materials
93
'BuOOCNH^^COOH
f t
1 . ethyl chloroformate 
Et3N, THF
'BuO OCNH
2. NaBH4, H20
R  = CH (CH 3) 2 or C H 2CH(CH 3) 2 
(figure 12.3-1)
Note that in the case of A/-BOC-(L)-leucine, the monohydrate was used as a 
starting material. The quantity of ethyl chloroformate employed was therefore 
doubled in order to give comparable results to the A/-BOC-(L)-valine reaction.
Conversion of A/-BOC-(L)-valinol and A/-BOC-(L)-leucinol to the corresponding 
mesylates proceded smoothly. After some degree of experimentation, 
crystallisation conditions were developed for both these products. As expected, 
isolated yields for this stage were found to be good (97% and 87% respectively). 
The slightly lower yield for the mesylate derived from A/-BOC-(L)-leucinol may be 
explained by the greater reluctance of this material to crystallise.
Displacement of the valine derived mesylate with thiophenol gave rise to a solid 
product which was partially purified by precipitation from 1:9 
dichloromethane:hexane. The resulting material was considered to be of 
sufficient purity for further reaction but for full analysis a small quantity was 
passed though a short column of silica giving a clean solid. In the case of the 
leucine derived sulfide, as crystallisation could not be achieved, the whole 
product oil was purified by chromatography in a similar manner.
The non-polar impurity present in both these compounds was identified by mass 
spectrometry, 13C and 1H NMR spectroscopy as being diphenyl disulfide. It was 
presumed that this material exists as a contaminant in the reagent thiophenol. 
Alternatively, this material may have been formed if addition of the thiol to the 
reaction mixture had taken place before the complete formation of sodium 
methoxide by the reaction of sodium with methanol.
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Following the oxidation of both sulfides to sulfones, extensive extraction of the 
crude product solutions was carried out using aqueous sodium hydroxide for the 
following reason. Since crystallisation of these materials was expected to be 
difficult, it was considered that prior removal of as much by-product meta- 
chlorobenzoic acid as possible would be essential. Crystallisation of the pure 
sulfones (figure 12.3-2) was then achieved after some degree of 
experimentation.
muOOCNH.
s o 2Ph
'BuOOCNH.
'S02Ph
(figure 12.3-2)
Thus, to summarise, sulfones derived from A/-BOC protected (L)-phenylalanine, 
(L)-valine and (L)-leucine have been successfully synthesised by a highly 
efficient and convenient route. These compounds were also observed to be 
optically active with rotations comparable to literature values.1751 Melting points, 
optical rotations and overall yields for the four step conversion are indicated in 
the following table.
/V-BOC-(L)- 
Amino Acid
Sulfone Yield Melting Point (lit.l'0J) Optical Rotation (lit. l'0J)
Phenylalanine 38% 204-206°C (215-216°C) -25.95 (-32.7)
Valine 56% 108-110°C (103-105°C) +9.2 (+11.02)
Leucine 27% 95-97°C (95-98°C) -9.65 (-9.87)
12.4 Synthesis of the Aldehyde Component
The coupling synthon required in order to mimic the carboxy terminus amino 
acid of a dipeptide can be defined as a chiral three carbon aldehyde bearing a 
protected p-alcohol and an appropriate a-side chain (figure 12.4-1).
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COOH OHC> OP
R R
R = desired amino acid side chain 
P = protecting group
(figure 12.4-1)
Fortunately, for R = CH3 (synthon required for an alanine mimic) a commercially 
available precursor exists bearing the desired stereochemistry. This compound, 
methyl 3-hydroxy-2(S)-methylpropionate, was therefore purchased and the 
alcohol function quantitatively protected as a tetrahydropyranyl ether (figure 
12.4-2).'751
Attempts were then made to reduce the methyl ester to the desired aldehyde 
using diisobutylaluminium hydride as described by Hopkins.[75] Initial reactions 
illustrated that a virtually clean sample of crude aldehyde could be obtained 
using DIBAL-H (1.0 M solution in hexane) in dry dichloromethane. Severe 
problems were then experienced with the reproducibility of these results as 
further reactions produced, at best, only traces of the desired product. A 
number of experiments were carried out with meticulously dried and purified 
starting material and solvents, without any improvement in yield, before the 
problem was finally identified as being due to the lability of the reagent to 
decomposition.
After first use, the reagent was found to become inactive very rapidly despite 
being stored in a sealed (Aldrich Sure-Seal® system), nitogen filled vessel at 
less than 5°C. Thus, once purchased, DIBAL-H was used as rapidly as possible 
as the fresh reagent gave excellent yields of the desired product.
R dihydropyran 
pyridinium /7-toluenesulfonate R
D C M
(figure 12.4-2)
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1H NMR spectroscopy was found to be extremely useful for the estimation of the 
success and extent of this reaction. Apart from the obvious loss of the methyl 
ester and appearance of aldehyde signals, the chemical shift of the a-methyl 
peaks were also highly characteristic of the compound in question. These 
signals could be used to gauge the amount of product, starting material and 
other a-methyl bearing impurities, such as the corresponding carboxylic acid, in 
crude mixtures. The diastereomeric nature of THP protected chiral compounds 
was also indicated by these peaks.
The problem of rapid reagent decomposition was compounded by the instability 
of the product aldehyde. Indeed, a sample of this material was observed to give 
almost complete carboxylic acid by air oxidation when stored at room . 
temperature for approximately one week. During initial experiments on the 
aldehyde-sulfone coupling, the severe problems experienced (which will be 
discussed in section 13.2) were at first considered to be due to aldehyde 
impurity or decomposition. Thus, during further studies, the aldehyde was 
synthesised regularly on a small scale immediately prior to its use. This material 
was also carefully purified by distillation.
Once the true source of the coupling problem had been identified, the aldehyde 
was used without purification as the small amount of contaminants present were 
observed not to interfere with the reaction. Storage of the aldehyde in a sealed, 
nitrogen flushed vessel at 0°C was found to be effective at minimising 
decomposition.
12.5 Alternative Aldehydes
The route defined by Hopkins et a l [75] for the synthesis of alternative aldehydes
(figure 12.5-1) utilised Evans’ alkylation for the introduction of defined chirality. 
[100]
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c h 3 C6H5
1. LD A, THF 
 ►
2. RBr
CH3 C6H5
LiA lH4, THF
dihydropyran
pyridinium p-toluenesulphonate 
DCM
1 .0 3, DCM/MeOH  
2. (CH3)2S
▼
R
(figure 12.5-1)
A study concerning the synthesis of frans-4-methylpent-3-enoic acid, required as 
a starting material for this route, was initiated (figure 12.5-2). A Knoevenagel 
condensation with decarboxylative dehydration was investigated in order to 
synthesise the 2,3-unsaturated carboxylic acid.l101] Treating this compound with 
base would result in a double bond migration giving the 3,4-unsaturated product.
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r H 0  + CH2(C 02H )2
pyridine
cat. piperidine
1 .K 0 H ,H 20
2 . acidification
,COOH
(figure 12.5-2)
It is presumed that the trisubstituted olefin was employed by Hopkins as this 
would be less susceptible to the reverse double bond migration and y-alkylation 
taking place during the attempted a-alkylation. The products of both a- and y- 
alkylation are illustrated in figure 12.5-3.
deprotonation 
 ►
alkylation
(figure 12.5-3)
A simple test methylation of commercially available frans-3-pentenoic acid 
indicated that the synthesis of frans-4-methyl-pent-3-enoic acid may be
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superfluous. In this case the a-methyl-py-unsaturated acid was shown by 1H 
NMR spectroscopy to be the main product formed on alkylation (figure 12.5-4).
This result is in complete agreement with the findings of Rathke and Sullivan 
who stated that the a-carbon of the intermediate delocalised anion, formed in 
such systems, is kinetically the most reactive.1102111031 This also suggests that, if 
the delocalised anion is indeed formed, one would expect identical results in the 
alkylations of both ap- and py-unsaturated 4-methylpentenoic acid
Unfortunately, studies in this area were not taken further due to time constraints.
A simple route to an aldehyde precursor for a glycine mimic was devised using 
c/s-3-hexenol as a starting material (figure 12.6-1). The alcohol function was 
protected as a THP ether as before and attempts were made at cleaving the 
double bond by ozonolysis. Initial reactions using several variations of the 
ozonolysis procedure employed by Hopkins (dichloromethane/methanol mixed 
solvent, dimethylsulfide quench) yielded only traces of the desired aldehyde. It 
was suggested by 1H NMR spectroscopy that the main product was in fact the 
methyl ester of THP protected p-hydroxypropanoic acid, possibly formed as a 
result of methanol attack on the intermediate ozonide. The reaction was 
therefore attempted in pure dichloromethane where reasonable quantities of the 
desired aldehyde were observed by 1H NMR spectroscopy following a 
triethylamine quench. This crude product was used in subsequent reactions 
after only partial purification as the main residual impurity was identified as being 
triethylamine. Full purification was however, possible by short path distillation 
giving an estimated 28% yield.
COOH 1. LDA, THF
2. M el
3.HCI(aq)
(figure 12.5-4)
12.6 Aldehyde Precursor to a Glycine Mimic
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dihydropyran 
 ►
pyridinium
/ 7-toluenesulphonate
DCM
i . o 3, d c m
2. Et3N
OHC>
0  O 
(figure 12.6-1)
This route is therefore a suitable alternative to that preferred by Kozikowski and 
Stein (figure 12.6-2) which utilised 3-hydroxypropionitrile as an inexpensive 
starting material.11041
dihydropyran 
 ►
/>-toluenesu!phonic acid
1. DIBAL-H, diethyl ether
2 . citric acid, water
OHC>
O' 'O'
(figure 12.6-2)
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Chapter 13: The Coupling Reaction and Isostere Generation
The procedure commonly referred to as Julia Olefin Synthesis was emplo/ed by 
Hopkins to effect the sulfone to aldehyde coupling and double bond formation.[75] 
[77] Studies carried out by this group showed that the starting A/-BOC protected 
amino sulfone must be reacted with two equivalents of base before the coupling 
is attempted. This is essential as deprotonation of the carbamate nitrogen would 
be expected in addition to sulfone a-anion formation. Furthermore, the 
generation of such a dianion is required in order to prevent a p-elimination 
reaction from taking place. One would predict the decomposition of A/-phfrialoyl 
protected amino sulfones during attempted coupling (figure 13-1). The presence 
of a A/-BOC or A/-CBZ protection is therefore essential for successful coupling.
(3-eliminationO
S02Ph
^-elimination suDoressed
(figure 13-1)
13.1 Literature Methodology
Hopkins defined methodology for the coupling of a sufone produced from 0,/V- 
protected (L)-tyrosine, and the (L)-alanine mimic aldehyde synthon (figure 13.1- 
1).
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CH2C6H4(p-OCH2Ph) 0H C
/BuOOa^H-^ ^ ' S° 2Ph
(figure 13.1-1)
OTHP
Poor coupling yields were initially experienced by this group. Trapping of the 
product (3-hydroxysulfone by derivatisation of the hydroxyl group, in order to 
inhibit the reverse reaction, was attempted without any improvement in results. 
The problem was therefore considered by Hopkins to be due to the lack of 
progress of the forward reaction. After some degree of experimentation it was 
found that prior complexation of the aldehyde component with an aluminium ion 
allowed the effective generation of the coupled product.
13.2 Experimental Findings
Following the procedure prescribed by Hopkins, a sample of the sulfone derived 
from (L)-phenylalanine was taken up in dry THF to produce what appeared to be 
a milky white solution. A strong yellow colour was noted as being formed in this 
vessel during the addition of just over two equivalents of methyl lithium. In a 
separate vessel, two equivalents of aldehyde in THF were treated with 
diisobutylaluminium methoxide (formed by the addition of methanol to a 1.0 M 
solution of DIBAL-H in THF) then transferred dropwise via cannula to the sulfone 
solution. This method was expected to yield, after aqueous work-up, a crude 
mixture of p-hydroxysulfone diastereomers (figure 13.2-1).
d iisobu ty la lum in ium
m ethoxide PhSCh M
B O C N H -^ ^ \ O H C \^ —^ THF -nnvrw X  1  r ™ ,i SQzPh OTHP    B O C N H ^ ^ V ^ ^ /O T H P
CH2PI1 CH3 M eLi OH
THF
(figure 13.2-1)
However, initial attempts at the production of the coupled material resulted in the 
bulk recovery of unreacted starting sulfone. A further reaction was carried out 
where the crude product was used directly in a reductive elimination reaction. In
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this situation no noticeable quantity of olefinic product was observed thus 
indicating that the recovery of starting sulfone was not due to the reverse 
reaction occurring during the isolation process.
As previous problems were noted with DIBAL-H reactivity and aldehyde stability, 
these factors were initially blamed for the failure of the coupling reaction. The 
aldehyde/aluminium complex was also considered by Hopkins to be highly 
unstable, even at -78°C. Extensive experimentation was therefore carried out 
where the aldehyde was rigorously purified, aluminium complex formation 
techniques varied and fresh DIBAL-H (1.0 M solution in THF) employed. No 
improvement in results was noted for any of these experiments.
In situ formation of aldehyde, from the methyl ester, was attempted using DIBAL- 
H (1.0 M solution in THF) and DIBAL-H (1.0 M solution in hexane) with the direct 
transferrance of these crude reaction mixtures to the sulfone dianion solution. 
Again no improvement was noted.
It has been reported that the use of lithio derivatives of sulfones can give poor 
coupling results due to a-proton abstraction from highly enolisable aldehyde 
carbonyls.11051 In such situations, the use of ethylmagnesium bromide in place of 
methyl lithium gives improved yields. By the method of Lythgoe et al, the 
coupling was therefore attempted using this alternative base.[105] While mainly 
starting sulfone and p-elimination products were yielded by this method an 
interesting feature was also noted. At the higher temperatures employed in this 
procedure (0°C as opposed to -78) the reaction mixture of ethyl magnesium 
bromide and the starting sulfone in THF was observed to form a clear, colourless 
solution. To determine whether this was indicative of the decomposition of the 
sulfone, the solubility of this material at various temperatures was investigated.
It was found that, by the action of heat, a completely clear and colourless 
solution of the sulfone in THF could be achieved. It was also noted that, if this 
solution was sufficiently dilute, the previously noted colloidal nature would not 
return on cooling to -78°C.
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Thus it was postulated that the previous coupling reaction failures were not due 
to aldehyde problems, but instead caused by the poor performance of the 
sulfone as a fine suspension. The next stage was therefore to test this 
hypothesis by reacting the sulfone solution pre-warmed, at high dilution. 
Obviously reaction times would also have to be extended to compensate for the 
lower concentration.
Though the modification discussed here may appear simple, there is reason to 
believe that this problem was not defined or overcome by the Hopkins group as 
will be discussed in section 13.5.
13.3 Application of the Coupling Modification
On application, the coupling modification showed immediate signs of 
improvement. No permanent yellow colouration was formed in the sulfone 
solution until after one full equivalent of methyl lithium had been fully added. 
Addition of the second equivalent rapidly increased the intensity of the 
colouration suggesting that the dianion was responsible for the presence of this.
The 1H NMR spectrum of the crude product formed by completing the coupling 
process with this solution gave an indication of at least partial success as the N- 
BOC group for the starting sulfone was joined by a second similar peak 
approximately 0.03 ppm further upfield. No other worthwhile information could 
be obtained from this spectrum due to the highly diastereomeric nature of the p- 
hydroxysulfone and the presence of unreacted starting materials and their • 
decomposition products.
It was discovered that from the crude oily product mixture a quantity of clean 
white solid could be precipitated by the addition of ether. This material was 
identified as being the starting sulfone and, as the associated A/-BOC group was 
no longer evident in the 1H NMR spectrum of the material obtained by
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evaporation of the mother liquor, the quantity isolated was used to gauge the 
extent of the coupling reaction. A rough calculation suggested that 78% of the 
starting sulfone had either reacted or been modified in some way. It was 
decided that the best test of p-hydroxysulfone formation would be the reductive 
elimination of this material to form the desired olefin. As this process would 
result in the removal of undefined chirality at two centres* effective product 
purification should then also be possible.
13.4 Reductive Elimination of the p-Hydroxvsulfone
Reductive elimination of p-hydroxysulfones is thought to occur by initial electron 
transfer to the sulfone group which induces the expulsion of the 
benzenesulfinate anion or radical (figure 13.4-1 ).[106] [107] The intermediate 
carbanion thus formed is sufficiently long lived to seek the conformation bearing 
a minimum of steric interaction. Antf-periplanar elimination of this conformation 
would then result in the formation of the trans-o\ef\n.
?Phf 021
/ S - i f  -------    .  r ^ ^ r -
OH 0H
P-hydroxysulfone optimal conformation rra/w-product
(figure 13.4-1)
In systems where the premier carbons of R and R’ are further substituted, as in 
the case under consideration, the selectivity for the trans product is expected to 
be absolute.
Using the crude p-hydroxysulfone mixture, reductive elimination was 
successfully carried out with 2% sodium/mercury amalgam by the method of 
Trost (figure 13.4-2).11081 In this procedure, the addition of four equivalents of 
disodium hydrogen phosphate is specified in order to suppress the base induced 
retro-aldol decomposition reaction.
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The crude product obtained by following the Trost procedure was purified by 
chromatography to give the desired olefin in an overall yield of 64% for the two 
step process from the protected amino sulfone. Analysis by 13C NMR 
spectroscopy illustrated the diastereomeric nature of this material as pairs of 
signals (of similar intensity) were observed for carbon atoms close to the 
stereocentre of the THP protecting group. No other such double signals were 
observed. Any further diastereomeric nature, resulting from the racemisation of 
either aldehyde or sulfone, would hopefully have been evident at this stage.
The sulfone derived from A/-BOC-(L)-valine was individually coupled to both the 
alanine and glycine mimic precursor aldehydes (figure 13.5-1). In these cases 
the additional dilution and warming of the sulfone vessel was not required as the 
valine derived sulfone was found to be sufficiently soluble under the standard 
conditions. The precipitation of unreacted sulfone after coupling was also found 
not to be possible. The crude product mixtures were therefore used directly in 
the reductive elimination step.
Phso2
BOCNH -OTHP
Na/Hg
Na2HP04
MeOH
BOCNH
M e
OTHP
PhCH2 OH PhCH2
(figure 13.4-2)
■1JL5. The Coupling of Other Materials
BOCNI BOCNH, OTHP
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PhSOz
BOCNH
> ^^S 02P h OHC+ \^ ^ O T H P
BOCNH OTHP
(figure 13.5-1)
Reductive elimination of these materials still proceeded smoothly with column 
chromatography giving the Val-Ala and Val-Gly olefins in yields of 58% and 25% 
respectively (figure 13.5-2). The lower yield in the Val-Gly case is considered to 
be mainly due to the higher level of impurity present in the starting aldehyde as, 
with products bearing such a substitution pattern, high yields and an 
approximately 90% stereochemical preference for the trans olefin are still to be 
expected.1106111071
Phj°2  Me 
BOCNHs^  ^OTHP BOCNH OTHP
BOCNH OTHP
OH
B O C N H ^ ^ ^ ^ ^ ^ O T H P
(figure 13.5-2)
It is worthy of note that the yield experienced here for the two stage formation of 
the (L)-Phe-(L)-Ala olefin (64%) is far higher than that achieved by Hopkins for 
the (L)-Phe-(L)-Phe analogue (37%). While direct comparison between these 
two results cannot be made, the fact that Hopkins achieved a 65% yield using 
the sulfone derived from 0,A/-protected tyrosine, giving the (L)-Tyr[0-Bz]-(L)-Phe 
mimic, suggests that solvation problems of the phenylalanine derived sulfone 
were not overcome by this group. It is also worthy of note that none of the 
combinations described here were reported as being formed by Hopkins and co­
workers.
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Unfortunately, a lack of time prevented the coupling of the leucine derived 
sulfone.
13.6 Generation of the Carboxylic Acid
Removal of the THP protection and oxidation of the alcohol thus released was 
effected in one step by the use of Jones’ reagent in acetone.11091 [110] Purification 
of the resulting carboxylic acid was carried out by a sequence of extraction 
processes as outlined in figure 13.6-1.
ether 5% NaOH
crude reaction  m ixture ----------► ether extracts  ► basic extracts
10% HC1
ether extracts ■*-
evaporation
ether
acidified  aqueous m ateria
purified carboxylic acid 
(figure 13.6-1)
Initial attempts to purify the carboxylic acid of the A/-protected (L)-Phe-(L)-Ala 
mimic highlighted an unexpected problem. Retention of chromium by the 
carboxylic acid was thought to be resulting in extremely poor NMR spectra being 
obtained for the “purified” product. This problem was solved, after some 
experimentation, by significantly reducing the volume of the initial organic 
extracts by evaporation. Separation of a quantity of chromium (III) containing 
aqueous solution resulted which could then be easily removed thus preventing 
this material being carried into the aqueous stages of the purification process.
For ease of analysis, a small quantity of this oily material was partially esterified 
with diazomethane. Column chromatography of the product of this process 
allowed the isolation of a small amount of pure carboxylic acid in addition to the 
ester.
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Carboxylic acids of the Val-Ala and Val-Gly analogues were similarly produced 
with, in the case of the former material, further purification being effected by 
recrystallisation.
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Chapter 14: Diazomethyl Ketone Formation
Initial attempts at the conversion of the A/-BOC-(L)-Phe-(L)-Ala isostere 
carboxylic acid into the corresponding diazomethyl ketone met with failure (figure 
14-1). 1H NMR spectroscopy indicated that the standard method for this 
conversion had not yielded the desired compound.1543 Instead, the main product
(figure 14-1)
In order to prove that the observed product was not simply due to the failure of 
the intermediate mixed carbonate to react further, a similar reaction was carried 
out with phthaloyl protected alanine but without the addition of diazomethane. 
As expected, the results of this experiment showed that such simple mixed 
carbonate systems do not survive the aqueous work-up conditions employed.
It is known that diazomethyl ketones can undergo a Wolff rearrangement in the 
presence of an alcohol and a metal ion catalyst (figure 14.1-1).[1111[112] Such a 
process could possibly explain the observed bound isobutanol.
(figure 14.1-1)
This rearrangement seemed plausible as the presence of residual chromium (III) 
in the carboxylic acid was a distinct possibility (as outlined in section 13.6). In
of the reaction appeared to be a compound which contained some form of 
attached isobutanol.
Me 1 . isobutyl chloroformate, 
Et3N, THF, -20°C
Me
BOCNH
COOH BOCNH COCHN2
PhCH2 2 . CH2N 2 (ether solution) PhCH2-20°C to room
temperature
14.1 Theory 1: Wolff Rearrangement
O O
metal catalyst
R'OH
I l l
order to test this hypothesis, the reaction was carried out using commercial 3- 
pentenoic acid as a chromium free model compound. However, with this system 
similar results were experienced. This compound was therefore considered to 
be a suitable model material and used in further test reactions.
It has been reported that the Wolff rearrangement can be initiated by heat or 
light without the presence of a metal catalyst.1113111141 A series of experiments 
were therefore carried out, using the chromium free model compound, in the 
absence of light and also at a lower temperature than previously employed (- 
78°C as opposed to -20°C). In all these cases however, no improvement in 
results was noted. While it is known that increased conjugation can lower the 
temperature necessary to initiate the Wolff rearrangement, the conditions 
required are still far more harsh than those employed in the original diazomethyl 
ketone formation method.11151 Nevertheless, the modifications employed here to 
counter such a transformation were still considered to be a reasonable starting 
point to begin more general investigations into the cause of the reaction failure.
As it was considered possible that some form of transformation may be taking 
place during product isolation, direct derivatisation of the crude post-reaction 
material was attempted with both HBr/acetic acid and aqueous HCI. No 
derivatives of the diazomethyl ketone appeared to have been formed in these 
reactions.
Mass spectroscopic analysis of the common product of these reactions indicated 
that a Wolff rearrangement had not taken place. The results of this test 
indicated that the isobutyl ester of the starting acid had been formed (figure 
14.1-2) and no incorporation of an additional carbon atom from diazomethane 
had taken place. After this result, work began on an alternative avenue of 
investigation.
o 1 . isobutyl chloroformate, Et3N, THF
OH 2 . CH 2N 2 (ether solution) O
(figure 14.1-2)
14.2 Theory 2: Reagent Problems
Under standard conditions, the diazomethyl ketone generation reaction was 
attempted using fresh isobutyl chloroformate. No improvement in results was 
noted but an interesting feature was observed in a concurrently run reaction 
employing what appeared to be an old and impure sample of ethyl 
chloroformate. As with previous diazomethyl ketone formation failures, but not 
successes, a faint green/yellow colouration was evident in the reaction mixture 
before the addition of diazomethane. In the case of ethyl chloroformate this 
colouration was stronger and its evolution more rapid. It was therefore 
postulated that catalytic decomposition of the mixed carbonate was taking place, 
initiated by the attack of an impurity nucleophile.11161
The initiation stage in the catalytic decomposition of the mixed carbonate formed 
from isobutyl chloroformate is shown in figure 14.2-1. Note that once initiation 
has taken place, the process can be repeated by the generated isobutoxide. 
Such a chain reaction would also explain the isobutyl peaks observed in the 
product 1H NMR spectrum. Note also that in the ethyl chloroformate case, 
incorporation of an ethyl group into the product occurred as would be expected 
by this hypothesis.
X
(figure 14.2-1)
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Following this observation, reactions were attempted with a 5% molar equivalent 
of acetyl chloride either pre-mixed with the reagent or added to the reaction 
system prior to the reagent. In theory this compound may remove the initiating 
nucleophile without generating a similarly active species. A reaction was also 
attempted at high dilution where the propagation steps of the chain reaction may 
be more limited. In all these reactions the triethylamine employed (see figure 
14-1) was freshly dried, distilled and used promptly without being stored over 
further drying agents in order to eliminate the possibility of the contamination of 
this material. However, no change in the observed product was noted for any of 
these reactions with the isobutyl ester being the main compound yielded.
14.3 Theory 3: Problems Associated With the Extended Chain
In order to prove that the standard method for the formation of diazomethyl 
ketones from a-amino acids was applicable to compounds with a longer carbon 
chain, the outcome of the reaction with p-alanine was investigated. As 
expected, this compound was A/-phthaloyl protected and converted into the 
diazomethyl ketone (figure 14.3-1) by the method outlined in figure 14-1 with no 
significant problems.1541 [82]
It was decided that the next logical step in the investigation would be an 
attempted synthesis of the diazomethyl ketone using an alternative strategy for 
the activation of the carboxylic acid.
O
O
(figure 14.3-1)
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14.4 Alternative Activation of the Carboxylic Acid
Classically, diazomethyl ketones were synthesised from the corresponding acid 
chloride.11171 Indeed, such methodology has been successfully applied to N- 
phthaloyl protected amino acids.[118][112111191 The main drawback of using this 
route is the production of hydrochloric acid in the reaction of the acid chloride 
with diazomethane. Such a by-product may react with the product diazomethyl 
ketone giving the corresponding chloromethyl ketone which also possesses 
biological activity (as discussed in chapter 4).[901 The extent of chloromethyl 
ketone formation can be limited by the presence of a large excess of 
diazomethane. Despite this, careful product purification may still be required. A 
rapid test reaction with isobutyryl chloride indicated that this route could be used 
to produce samples of diazomethyl ketones (figure 14.4-1).
(figure 14.4-1)
Studies were therefore initiated with the aim of producing the acid chloride of 3- 
pentenoic acid.
In 1966 Lee reported the formation of acid chlorides by heating the carboxylic 
acid with triphenylphosphine in carbon tetrachloride (figure 14.4-2).111201 This 
conversion procedes with no generation of highly acidic by-products.
RCOOH + CC14 + (C6H5)3P -------- ► RCOC1 + (C6H5)3PO + HCC13
This reaction was attempted several times with 3-pentenoic acid but direct 
treatment of the product with diazomethane did not yield the desired diazomethyl 
ketone. Although infra-red analysis was hampered by the presence of by­
products, this technique was employed in a more detailed study which 
suggested that formation of the acid chloride had not taken place.
o excess
diazomethane
CHN2
(figure 14.4-2)
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On repeating this reaction with phthaloyl protected alanine, a small quantity of 
diazomethyl ketone was formed. The main product in this case was the methyl 
ester indicating incomplete formation of the acid chloride. Such simple 
identification of the complex by-products formed in the 3-pentenoic acid situation 
was however, not possible.
As stated earlier, reacting acid chlorides with diazomethane generates 
hydrochloric acid in addition to the diazomethyl ketone. Were this by-product not 
to be rapidly and efficiently removed from the system further reaction of the 
diazomethyl ketone would occur. In this situation formation of the chloromethyl 
ketone would be expected. In order to obtain a typical value for the 1H NMR 
chemical shift of a chloromethyl ketone group, a residual sample of 
phthaloylalanyl diazomethyl ketone was deliberately treated with hydrochloric 
acid. The generation of the chloromethyl ketone was confirmed by full analysis 
of the product with the 1H NMR chemical shift of the CH2CI group being 
observed at 4.20 ppm. No signal in this area was observed in the 3-pentenoic 
acid reactions indicating that such derivatisation of the diazomethyl ketone had 
not taken place. The problem was therefore considered to reside in the 
formation of the activated species.
The use of oxalyl chloride as a reagent for the formation of acid chlorides is 
generally limited by the accompanying generation of acidic by-products as 
shown in figure 14.5-1 .[121]
14.5 Further Acid Chloride Investigations
R C O O H  + (CO Cl) 2 (R C O O C O ) 2 +  2HC1
(R C O O C O ) 2 -  
(R C O )20  + (CO Cl) 2
(R C 0 )20  +  C 0 2 +  CO
 ► 2RCOC1 +  C 0 2 +  CO
(figure 14.5-1)
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As expected, carrying out this reaction by the standard method on A/-BOC 
protected (L)-phenylalanine resulted in starting material decomposition.
Attempts were then made to reduce the severity of the conditions by increasing 
dilution and reducing the reaction temperature to under 0°C. No improvement in 
results was noted for these modifications but the incorporation of triethylamine 
into the reaction mixture showed some signs of promise with reduced 
decomposition. The extent of the acid chloride formation was however, not 
investigated. At this stage, studies in this area were halted due to an important 
discovery which will be discussed in section 14.6.
In 1979 Venkataraman and Wagle reported the generation of acid chlorides in 
high yield by the use of cyanuric chloride (figure 14.5-2).[122]
+ E t3N H+ RCO O H  + E t3N
O COR
+ RCOC1 +  E t3
(figure 14.5-2)
In general, this mild reaction is carried out at room temperature in acetone with
0.5 molar equivalents of the reagent. An added bonus arises from the 
precipitation of the by-product 2,4-dichloro-6-hydroxy-1,3,5-triazine during the 
reaction thus reducing the need for purification.
This conversion was attempted with A/-BOC-phenylalanine and the product 
treated directly with diazomethane. The resulting crude mixture was shown, by
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comparative thin layer chromatography in several solvent systems, to contain 
the desired diazomethyl ketone. Partial purification by column chromatography 
followed by 1H NMR analysis in both CDCI3 and d6-DMSO allowed the presence 
of this compound to be confirmed. It was also indicated however, that 
purification would not be as straightforward as predicted.
The reaction was repeated with IR analysis in order to gauge the success of acid 
chloride formation. Unfortunately the spectra obtained from the crude reaction 
mixture were extremely complex and therefore ambiguous.
As with the oxalyl chloride method, studies in this area were terminated at this 
stage for reasons which will now be explained.
The search for further acid chloride formation methods revealed a problem which 
may be more generally applicable to the system under study. In the presence of 
a suitable base, the a-hydrogen of an acid chloride may be extracted allowing 
the formation of a ketene (figure 14.5-3).[1231 Note that this mechanism can be 
considered as analogous to that of methanesulfonyl chloride with triethylamine 
as described in section 12 .1 .
It is therefore postulated that in py-unsaturated systems triethylamine would be a 
sufficiently powerful base to promote this reaction. Indeed, diphenylketene has 
been isolated following the addition of triethylamine to diphenylacetyl chloride at 
0°C.[124] Were this reaction to occur during attempted py-unsaturated acid 
chloride formation, the observed products may be extremely complex but in the 
case of mixed carbonate activation, the corresponding ester would conceivably 
be formed as illustrated in figure 14.5-4.
R'/
C = C — o
(figure 14.5-3)
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0X,0
E t,N
triethylam m onium  
isobutoxide 
and C 0 2
1 . isobutanol or isobutoxide
2 . protonation
0
(figure 14.5-4)
The deliberate formation of ketenes in the presence of trapping species has 
been carried out.[123] Furthermore, pyridine has been reported as being a 
suitable catalyst for the acetylation of glucose with ketene.[125] Notice that in the
catalytic since it may be reformed in the final stage of the reaction. It is also 
possible that the deprotonation process may be continued by the generated 
isobutoxide.
The formation of such a ketene may also explain the colouration noted during 
unsuccessful mixed carbonate reactions (see section 14.2).
14.6 The Use of an Alternative Base in Mixed Carbonate Formation
Racemisation, by C-terminal a-hydrogen exchange, during the mixed carbonate 
method of peptide synthesis has been the subject of an extensive study.[1261 It 
was reported that, if racemisation were a problem it could be reduced to zero by 
the use of A/-methylmorpholine as a base and a 5% excess of isobutyl 
chloroformate. This modification was therefore incorporated into the standard 
method for diazomethyl ketone synthesis. However, carrying out the procedure 
with 3-pentenoic acid once again resulted in the formation of the isobutyl ester.
process illustrated in figure 14.5-4 the base employed can be considered as
According to Anderson et al interaction between the base (normally 
triethylamine) and chloroformate prior to coupling is essential for high yields.[126]
119
Despite this it was decided to investigate the use of sodium hydride in this 
reaction with the following reasoning. With this reagent, rapid neutralisation of 
the carboxylic acid would result in the generation of gaseous hydrogen which will 
not interfere with the further progress of the reaction. Such an assurance cannot 
be given with triethylamine as, despite the precipitation of the hydrochloride salt, 
the potential remains for the reformation of a small amount of the free base.
This catalytic quantity of base may initiate the decomposition of the mixed 
carbonate.
A reaction was therefore attempted with the slow addition of just under one 
equivalent of sodium hydride (suspended in THF) to a THF solution of A/-BOC- 
(L)-phenylalanine (figure 14.6-1). With this stoichiometry complete reaction of all 
hydride would be expected. Addition of isobutyl chloroformate and 
diazomethane followed in the usual manner and resulted in the formation of the 
desired diazomethyl ketone.
O
'B u < X  ^ N H  1. NaH (<1 equiv.), THF fl3uCL .N H
on  ► "c h n 2II : 2. isobutyl chloroformate || i
O CH2Ph 3 CH2N2 (ether solution) ^  CH2Ph
(figure 14.6-1)
The yield (27%) and product purity were, as expected, lower than those 
achieved by the standard route. At this stage it could not be deciphered if this 
was due to the lack of a base-chloroformate complex or lower than expected 
assay of sodium hydride.
Following the success of this reaction, the same conditions were employed with 
the aim of effecting a similar conversion on 3-pentenoic acid (figure 14.6-2). 
Analysis of the product by 1H NMR spectroscopy in both CDCI3 and d6-DMSO 
indicated the presence of the desired diazomethyl ketone end group. In order to 
simplify the procedure, the reaction was repeated where the effects of adding 
the solution of the acid to a hydride suspension were investigated. Results
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indicated that the combining of these two materials could be carried out in either 
order at -78°C without a detrimental effect on the course of the reaction.
After some product manipulation, samples of 3-butenyl diazomethyl ketone were 
isolated and characterised. The product yields obtained for this conversion 
were, as expected, not high (typically 15%).
This methodology was next tested on the A/-BOC-(L)-Phe-(L)-Ala isostere. 
Extensive thin-layer chromatographic anaysis of the product indicated that two 
main compounds were present. As the more polar of these was observed to be 
more active to UV irradiation it was presumed that this material would be the 
desired diazomethyl ketone. Repeating this chromatographic study with a 
mixture of the reaction product and a known sample of isostere methyl ester 
indicated that this compound may be the main by-product. 1H NMR analysis of 
the product mixture, in both CDCI3 and d6-DMSO, confirmed these findings with 
it being possible to show by integral comparison (NH, CHN2, OCH3) that a ratio 
of approximately 60% diazomethyl ketone to 40% methyl ester had been 
obtained. Unfortunately an insufficient quantity of this material remained for 
further purification to be attempted.
14.7 Potassium Trimethylsilanolate Method of Salt Formation
In 1984 Laganis and Chenard reported the use of potassium trimethylsilanolate 
as a reagent for the formation of carboxylate salts from the corresponding methyl 
esters.11271 This methodology was later employed by Padwa to give a 61% yield 
of a diazomethyl ketone (figure 14.7-1) by a route which can be considered as 
analagous to the sodium hydride method discussed in section 14.6.[128]
O 1. NaH (<1 equiv.), THF
2 . isobutyl chloroformate
3. CH2N 2 (ether solution)
(figure 14.6-2)
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O O
OCH3
1. potassium trimethylsilanolate
2. methyl chloroformate
3. CH 2N 2 (ether solution)
CHN2
(figure 14.7-1)
The potential use of the methyl esters o f isosteres as starting materials made 
this route highly attractive as these compounds are much more readily purified 
than carboxylic acids. With simplified isostere purification in mind, it was 
decided to investigate the use of this reagent on the methyl ester of 3-pentenoic 
acid.
Prior to the addition of the chloroformate, good cleavage of the methyl ester was 
indicated by 1H NMR spectroscopy after acidification of a small portion of 
reaction mixture. Continuing the reaction with isobutyl chloroformate resulted in 
the formation of the desired diazomethyl ketone (figure 14.7-2) as shown by IR 
and NMR spectroscopic analysis. The isolated material compared well with that 
obtained by the sodium hydride route. Once again however, product yield was . 
low but tolerable (23%).
Following this success, a quantity of the Phe-Ala isostere was esterified with 
diazomethane. An attempt was then made at converting this material into the 
corresponding diazomethyl ketone which resulted in the generation of at least 
six reaction products. After partial purification by column chromatography, 1H 
NMR spectroscopy was used to show that none of these compounds were the 
desired diazomethyl ketone. It is worthy to note that destruction of the olefin 
appeared to be a very important, and still unexplained, side reaction.
O O
1 . potassium trimethylsilanolate
2 . isobutyl chloroformate
3. CH2N 2  (ether solution)
(figure 14.7-2)
122
14.8 Isostere Diazomethyl Ketone and Methyl Ester Formation
With the failure of the potassium trimethylsilanolate test reaction it was decided 
to form the isostere diazomethyl ketones using the sodium hydride/isobutyl 
chloroformate methodology. It has been shown that in this reaction the main by­
product is the corresponding methyl ester which may also be used as a control 
material in comparative biological testing. Such a control material was required 
as it was expected that active diazomethyl ketones would cause some degree of 
parasite growth inhibition by reversibly blocking the substrate binding site of the 
protease enzyme. Such a process may still occur if the reactive diazomethyl 
ketone end group is not ideally placed for irreversible binding. The methyl ester 
on the other hand, lacking the active site modifying group, can exert an inhibitory 
effect only in the reversible manner. Thus, by comparing the results obtained for 
both compounds, the degree of growth inhibition due to irreversible activity can 
be deduced. By using the hydride methodology it may therefore be possible to 
produce both the potentially active compound and a relevant control material in 
a single reaction.
Application of the developed methodology to the three isosteres gave, as 
expected, low yields of diazomethyl ketones and reasonable yields of methyl 
esters as shown in figure 14.8-1. The poor yields of diazomethyl ketone are 
considered to be due mainly to the inherant difficulties in handling small 
quantities of sodium hydride accurately. As even a tiny excess of base may be 
sufficient to initiate catalytic decomposition of the activated isostere it was 
thought wise to err on the side of caution and tolerate such low yields.
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Backbone Structure X Y Yield (%)
I 1
Y
-CH2Ph CO
Xo
I 25
-CH(CH3)2 CO
X01 17
-CH(CH3)2 -H 5
IB O C N I T ^ T ^ O C H j
Y
-CH2Ph CO
Xo1 56
-CH(CH3)2 -ch 3 49
-CH(CH3)2 -H 52
(figure 14.8-1)
Compound purity was not absolute in the case of the Phe-Ala diazomethyl 
ketone. Repeated attempts at removing the tiny impurity remaining gave limited 
results and, as the quantity of material remaining was approaching the critical 
level necessary for biological evaluation, purification was therefore halted. A 
sample containing elevated levels of this impurity was also produced for use in 
biological testing in order to clarify results if required.
It is worthy to note at this stage that characterisation of these compounds 
indicated that the desired trans double bond was indeed present. Furthermore, 
no signs of diastereomer formation by racemisation of either chiral centre, were 
observed by 1H NMR spectroscopy. All six compounds also proved to be 
optically active.
Molecular mechanics calculations were carried out on the diazomethyl ketones 
of both the A/-BOC-(L)-Val-(L)-Ala dipeptide and (E)-ethene isostere. The results 
of this study (shown in appendix 1) confirmed that the (E)-ethene group is a 
reasonable structural replacement for the amide link in this compound. Note
however that this simple calculation does not take into account features such 
hydrogen bonding or solvation.
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Chapter 15: Anti-parasite Evaluation
The initial test battery of parasites employed in biological evaluation comprised 
three strains of Trichomonas, (T. foetus F2, T. vaginalis G3 and T. augusta) 
Leishmania mexicana (wild type and the genetic modifications N53, AN8m and 
AC10), Giardia lamblia and Giardia intestinalis.
Such a selection of parasites should allow a reasonable screening of 
compounds for activity. With Trichomonas vaginalis at least 11 distinct cysteine 
protease activities have been detected. Similarly Leishmania mexicana 
possesses at least seven cysteine proteases while two major such enzymes are 
found in Giardia Lamblia.[6] In the case of Leishmania mexicana, genetically 
modified strains where the genes coding for specific cysteine protease enzymes 
are disrupted, were also selected for initial testing. The absence of activity in 
only a selection but not all of these modified variants would confirm the action of 
the compound under investigation as a cysteine protease inhibitor.
It is also worthy to note that, in addition to the synthesised compounds, a sample 
of ZPA (A/-CBZ protected, amide linked (L)-Phe-(L)-Ala peptide bearing a 
diazomethyl ketone end group, figure 15-1) was obtained and used in testing.
,NH.
CBZNH
(figure 15-1)
Biological evaluation of the compounds was carried out in two ways:
1. Protease enzyme inhibition (SDS-PAGE)
In order to test for protease enzyme inhibition, the parasites were incubated in 
the presence of each compound and the cell extracts separated by gel
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electrophoresis. As the strongly coloured gel on which the extracts are 
separated is composed of an amide linked polymer, destruction of this material 
can be observed at positions occupied by protease enzymes. Thus a visual 
fingerprint of the protease activity of the cell can be obtained. Inhibition of such 
activity, by the presence of the test compound, would be indicated by the 
absence of one or more such zones of destruction. Obviously a control gel is 
run concurrently using cells incubated in the absence of the compound under 
evaluation.
2. In vitro parasite growth reduction
As protease activity is essential for parasite cellular function, one would expect 
an inhibition of the growth of such species in the presence of an active 
compound. Isolated parasites were therefore incubated in the presence of 
various concentrations of test compound. A control sample containing no such 
potential inhibitor was treated similarly. In each case the number of parasite 
cells in a specific volume of culture were counted visually after incubation. From 
this it is possible to gauge the minimum dose of each active compound required 
for 100% lethality.
15.1 Results of Biological Evaluation
The results of first and second round biological evaluation are shown in 
appendices 2 and 3 respectively.
Testing indicated that the A/-BOC-(L)-Phe-(L)-AlaCHN2 isostere is a highly 
capable inhibitor of the growth of Leishmania mexicana. Since the 
corresponding ester was shown to have no such effect it can be concluded this 
action is due to the presence of the diazomethyl ketone function. It is also 
interesting to note that the amide link containing A/-CBZ-Phe-AlaCHN2 did not 
exhibit this inhibiting ability. As the replacement of a A/-CBZ protection for a 
similar carbamate based group (A/-BOC) should have little effect on the action of
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the inhibitor (see section 6 .2 ), one can assume that the evolution of activity is 
due to the presence of the isostere. The lack of performance of the amide linked 
compound, which is known to be a potent inhibitor of isolated cysteine protease 
enzymes (see section 5.1), may be due to the hydrolysis of this group by the 
battery of proteases possessed by the organism. If this were indeed to be the 
case, the suitability of (E)-ethene as an isosteric replacement for the amide link 
would be implied. This result does not however, indicate what level of inhibitor 
activity towards the isolated target enzyme is retained following such a structural 
replacement. It also has not been proven that growth reduction was indeed 
achieved by cysteine protease inhibition. No major impact on the visual 
proteolytic fingerprint was observed and the genetic modifications of the parasite 
proved to be similarly susceptible to the attentions of the inhibitor.
It is therefore suggested that studies on the A/-BOC-(L)-Phe-(L)-AlaCHN2 
iscstere are continued. Initially, the activity of the molecule against isolated 
cysteine proteases must be evaluated and compared with that of the amide 
linked A/-CBZ-(L)-Phe-(L)-AlaCHN2. The Cathepsins B, H and L would be 
sutable enzymes for use in this study (see section 5.1).[51] Should this work 
prove to be fruitful, attempts must then be made at the conversion of the N- 
BOC-(L)-Phe-(L)-AlaCHN2 isostere to the corresponding fluoromethyl ketone or 
substituted phenoxymethyl ketone (see section 10.8), for further testing in intact 
bidogical systems. The methodology required to effect these conversions has, 
however, yet to be tested.
Prbr to further work on the isostere it is also considered wise that similar 
bidogical testing be carried out on the impurity noted as being present in the 
sanple of the A/-BOC-(L)-Phe-(L)-AlaCHN2 isostere (see section 14.8). It is 
worthy to note that this impurity was not observed as being present in the mixed 
sanple of ester and diazomethyl ketone produced during preliminary studies 
(see section 14.6). It is therefore suggested that a simple rapid test be carried 
ou on Leishmania mexicana using this early mixed material. A sufficient 
quantity of the mixture should be available for such a study and as the ester has
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now been shown to be inactive, clarification of the diazomethyl ketone test 
results should be possible.
Biological evaluation of the A/-BOC-(L)-Val-(L)-AlaCHN2 isostere indicated that a 
limited degree of growth inhibition could be achieved on the three species of 
Trichomonas employed. Such an activity was not noted for the corresponding 
ester. Later testing showed both diazomethyl ketone and ester to be slightly 
active on Leishmania mexicana. In this situation, however, adequate 
discrimination between the activity of these two materials was not achieved. 
Despite this slight activity neither compound had a noticeable impact on the 
visual proteolytic fingerprint of the parasites.
An unexpected result was obtained on the evaluation of the A/-BOC-(L)-Val-Gly 
isostere based pair of compounds. While the diazomethyl ketone had no 
noticeable effect on the proteolytic activity of the organisms tested, this was not 
the case with the “control” methyl ester. This compound reduced the activity of 
enzymes from T. foetus, T. vaginalis and T. augusta to some extent. In addition 
to this, the ester proved capable of completely halting the activity of at least one 
very powerful protease of wild type L. mexicana.
Parasite growth studies in the presence of the A/-BOC-(L)-Val-Gly isostere based 
compounds partially confirmed these findings. Relatively low concentrations of 
the ester proved to be extremely toxic on both wild type and genetically modified 
L. mexicana. A significant degree of toxicity was also noted on T. foetus, T. 
vaginalis and Giardia Intestinalis.
Since in many cases the corresponding diazomethyl ketones caused some 
reduction in growth without an obvious effect on the proteolytic fingerprint, it can 
be postulated that both compounds may show a more general toxicity. Such a 
toxicity may be explained by a reduction in selectivity due to the absence of a 
position 2 side chain. It is expected that this factor could be tested further on 
isolated enzyme systems.
Chapter 16: Conclusions
Protease enzymes can be selectively inhibited by A/-protected dipeptides bearing 
a modified carboxy terminus. The diazomethyl ketone and fluoromethyl ketone 
modifications of the carboxy terminus are known to be effective in this respect 
with the fluoromethyl ketone being more selective and efficacious. However, as 
little is known about individual protease enzymes, the most appropriate side 
chains for the dipeptides has not yet been defined.
In addition to this, the amide link of a dipeptide based inhibitor is itself vulnerable 
to the action of protease enzymes. The use of amide bond isosteres, which may 
alleviate this problem, has not yet been reported in this particular application. 
Studies on other biologically active peptides have shown however, that the (E)- 
ethene linkage can be used as a replacement for the amide group without 
causing a reduction in activity. The suitability of this group has also been 
suggested by crystallographic data and molecular mechanics calculations.
16.1 Synthesis of the Fluoromethyl Ketone End Group
The amino acids (L)-phenylalanine, (L)-alanine, glycine and p-alanine were N- 
phthaloyl protected and successfully converted into the corresponding 
diazomethyl ketones using literature procedures. The synthesis of the 
diazomethyl ketone derived from A/-BOC-(L)-phenylalanine was also shown to 
proceed efficiently by the same methodology. For these experiments the 
required diethyl ether solution of diazomethane was safely produced by the 
alkali induced decomposition of Diazald®.
As literature methodology for the direct formation of fluoromethyl ketones from 
diazomethyl ketones proved to be unreliable, the use of bromomethyl ketones as 
intermediates was investigated. Using dry hydrogen bromide gas, liberated from 
triphenylphosphonium bromide, bromomethyl ketones were successfully formed 
from the diazomethyl ketones derived from A/-phthaloyl protected (L)-
130
phenylalanine, (L)-alanine and glycine. High yields were recorded for these 
conversions and analysis of the (L)-phenylalanine derived product indicated that 
stereochemical integrity had been maintained.
While the application of this methodology to the A/-BOC protected material 
resulted in the destruction of this group, it is considered that optimisation of the 
reaction conditions would allow the selective generation of the desired 
bromomethyl ketone in the presence of such an amino terminus protection.
Reaction conditions were developed in order to allow the high yielding 
conversion of bromomethyl ketones into fluoromethyl ketones using 
triethylamine trishydrofluoride. Whether this process gives rise to a mainly 
racemic product has not been ascertained.
The techniques employed here for the synthesis of bromomethyl ketones and 
fluoromethyl ketones can, at this stage, be considered as complimentary to 
literature methodology. Studies in this area were not pursued as it has recently 
been reported that a variety of phenoxymethyl ketone based end groups have 
been developed and used in preference to fluoromethyl ketones.[94]
Methodology for the production of such end groups from diazomethyl ketones 
has been identified.
16.2 (EVEthene Isostere Synthesis - Route H
The initial route chosen for the synthesis of the A/-BOC-(L)-Phe-(L)-Ala (E)- 
ethene isostere required the use of A/-BOC-(L)-phenylalaninal as a starting 
material. This material was produced efficiently via the A/-methoxy-/V- 
methylcarboxamide. The addition of vinylmagnesium bromide to this aldehyde 
resulted in the generation of a pair of diastereomers of which the minor product 
was required for further elaboration. Effective separation of these diastereomers 
was not achieved.
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Since it has been reported that the replacement of vinylmagnesium bromide by 
vinylzinc chloride in the above reaction significantly increases the proportion of 
the major isomer formed, the use of this reagent may make viable the production 
of the /V-BOC-(L)-Phe-(D)-Ala (E)-ethene isostere and associated analogues.
16.3 (B-Ethene Isostere Synthesis - Route *2
The second route chosen for study utilised the Julia olefin synthesis as the key 
synthetic step. The two main groups of precursors required for this convergent 
isostere synthesis are shown in figure 16.3-1.
'BuOOCNH
COOH
R
> * v
R'
m uOOCNH
R
(figure 16,3-1)
The A/-protected p-amino sulfones required for this reaction were produced from 
A/-BOC-(L)-phenylalanine, A/-BOC-(L)-valine and A/-BOC-(L)-leucine by a four 
step sequence. This route was found to be extremely reliable with high yields of 
the desired product being obtained in both small and large scale studies. 
Purification of both intermediate and final products was found to be 
straightforward. Optical rotations comparable to literature values were obtained 
for the product sulfones.
The initial aldehyde (R’ = CH3) employed in the coupling reaction was produced 
from methyl 3-hydroxy-2(S)-methylpropionate using diisobutylaluminium hydride. 
It was found that the use of fresh reagent was essential for the successful 
generation of the desired aldehyde. Poor results were obtained using material
S 0 2Ar + oHcr .OTHP
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which had been stored for any length of time after first use. It was also found 
that oxidation of the product aldehyde could be limited by storage at 0 °C under 
a nitrogen atmosphere.
Studies on commercially available frans-3-pentenoic acid indicated that a- 
alkylation may be carried out without inducing a shift in the position of the 
unsaturation. From this result it can be concluded that 4-methyl-3-pentenoic 
acid, as employed in literature syntheses of alternative aldehydes (R’ *  CH3), 
would not be required.
For an aldehyde precursor to a position 2 glycine mimic (R’ = H), a route 
involving the ozonolysis of O-protected c/s-3-hexenol was devised. After some 
experimentation this approach proved to be successful and can be considered 
as complimentary to the literature methodology for the formation of this 
precursor.
16.4 Coupling and Isostere Generation
Initial problems with sulfone to aldehyde coupling were identified as being due to 
poor sulfone solubility. Thus the incorporation of suitable modifications was 
required to enable literature methodology to effect this reaction. Procedures 
were developed by which the extent of p-hydroxysulfone formation could be 
estimated and, in the case of the A/-BOC-(L)-phenylalanine derived material, 
recovery of the unreacted sulfone achieved. It is worthy to note that, for the 
successful reaction of the sulfone, the formation of a dianion by proton 
abstraction from the carbamate nitrogen in addition to abstraction a to the 
sulfone is essential to prevent an elimination reaction from taking place. Thus 
the selection of an appropriate base is essential. For example, while good yields 
of product were obtained by the use of methyl lithium, a method employing 
ethylmagnesium bromide resulted in the gross decomposition of the starting 
sulfone.
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Reductive elimination of the crude p-hydroxysulfones was shown to result in the 
formation of the desired trans olefins. It is recommended that the products 
obtained at this stage are thoroughly purified in order to remove any residual 
quantities of the many p-hydroxysulfone diastereomers.
Production of the C-terminus carboxyl group was effected by the use of Jones’ 
reagent. Initial purification of the product carboxylic acids was achieved by a 
sequence of extraction processes with a modification incorporated in order to 
limit chromium ion retention.
Thus the (E)-ethene isosteres of A/-BOC-(L)-Phe-(L)-Ala, A/-BOC-(L)-Val-(L:)-Ala 
and A/-BOC-(L)-Val-Gly were successfully synthesised bearing the desired 
chirality and double bond geometry.
1fL5 Diazomethyl Ketone Formation
The literature methodology, as tested earlier, for the formation of the 
diazomethyl ketone end group was found to fail with the synthesised isosteres. 
After much experimentation it was deduced that the observed product was 
formed by the further reaction of a transient ketene, generated by a-proton 
abstraction from the intermediate py-unsatu rated mixed carbonate. A technique 
was therefore developed by which the formation of this ketene could be 
prevented and thus the successful synthesis of the desired diazomethyl ketones 
achieved.
While the yields of diazomethyl ketones obtained by this route were not high, the 
main by-products were found to be the corresponding methyl esters which were 
also isolated and used as control materials in biological evaluation. A method of 
utilising the easily purified methyl ester, as opposed to the carboxylic acid, as a 
starting material in diazomethyl ketone synthesis was investigated but despite 
success being achieved with a model system, decomposition of the (E)-ethene 
isostere was found to occur.
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It is believed that the modified procedure for the successful generation of 
diazomethyl ketones from Py-unsatu rated carboxylic acids has not yet been 
reported in the literature. It is also believed that the three isostere diazomethyl 
ketones thus formed are novel compounds. While suitable literature 
methodology for the synthesis of (E)-ethene isostere carboxylic acids and methyl 
esters is available, the application of this to the specific compounds synthesised 
here (with the exception of the methyl ester of the A/-BOC-(L)-Phe-(L)-Ala 
isostere which was synthesised by Yamamoto and colleages[74]) has not been 
reported.
The diazomethyl ketones of the A/-BOC-(L)-Phe-(L)-Ala, A/-BOC-(L)-Val-(L)-Ala 
and A/-BOC-(L)-Val-Gly (E)-ethene isosteres, together with the corresponding 
methyl esters and the diazomethyl ketone of the amide linked dipeptide A/-CBZ- 
(L)-Phe-(L)-Ala, were screened for activity against a variety of parasitic species.
It is believed that the use of (E)-ethene isosteres in such an application has not 
been reported in the literature.
Results indicate that the diazomethyl ketone of A/-BOC-(L)-Phe-(L)-Ala 
possesses some form of growth inhibiting activity against Leishmania mexicana. 
This effect was not observed with either the isostere methyl ester or the 
diazomethyl ketone of the amide linked material. Similarly, the diazomethyl 
ketone of the A/-BOC-(L)-Val-(L)-Ala isostere caused a higher degree of growth 
inhibition than the corresponding methyl ester on several species of 
Trichomonas. Surprisingly however, the methyl ester of the A/-BOC-(L)-Val-Gly 
isostere proved to be a powerful anti-protease. Both this compound and the 
corresponding diazomethyl ketone showed the ability to inhibit parasite growth 
thus implying the more general toxicity of peptide mimic based inhibitors bearing 
no position 2 side chain.
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Thus it can be concluded that dipeptide isostere diazomethyl ketones show 
potential as selective parasite growth inhibitors. It is not clear however, if the 
observed effect is due to cysteine protease inhibition.
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Chapter 17: Avenues for Further Investigation
17.1 Further Work on Completed (E)-Ethene Isostere Diazomethyl Ketones
While the (E)-ethene dipeptide isostere diazomethyl ketones have shown some 
degree of selective anti-parasite activity, their exact mode of action remains 
open to question. Furthermore, as intact organisms were used in this study, a 
comparison with the protease inhibiting performance of amide link containing 
dipeptides cannot be made. It is therefore suggested that the synthesised (E)- 
ethene isostere diazomethyl ketones and methyl esters are tested on isolated 
cysteine protease enzymes. The results of this study may then be compared 
with published data for the amide linked variants. Cysteine proteases such as 
papain or the cathepsin family should be suitable for such a study as the activity 
of amide linked A/-CBZ-(L)-Phe-(L)-AlaCHN2 against these enzymes has been 
well documented (see section 5.1).
If the above study were to show the selective anti-protease activity of the 
synthesised diazomethyl ketones, one could then suggest the suitability of 
dipeptide (£)-ethene isosteres, albeit with a more suitable end group than that 
employed here (see section 10 .8 ), for use against disease states caused by 
irregularities in cysteine protease action (see section 1.3). Furthermore, the 
success of the (E)-ethene isostere of A/-BOC-(L)-Phe-(L)-AlaCHN2 against an 
isolated enzyme would imply that amide hydrolysis was responsible for the 
failure of amide linked A/-CBZ-(L)-Phe-(L)-AlaCHN2 in vivo (note the 
observations discussed in sections 2.3 and 6.2 concerning AMerminus 
protection).
Comparative work on isolated enzymes would also require the prior synthesis of 
amide link bearing diazomethyl ketones of the (L)-Val-(L)-Ala and (L)-Val-Gly 
structures. By the method discussed in section 10.2, the generation of 
diazomethyl ketones from the parent A/-protected dipeptide should be 
straightforward.
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Prior to commencing work on isolated enzymes it is advised that the small 
sample of the (E)-ethene isostere of A/-BOC-(L)-Phe-(L)-AlaCHN2 highly 
enriched in the unidentified impurity be tested for anti-parasite activity (see 
section 14.8). If this impurity, present in tiny amount in the original sample of 
diazomethyl ketone employed, is in fact responsible for the observed effect, a 
massive increase in activity would be expected for the enriched sample. Such a 
result is not anticipated; nevertheless testing must be carried out in order to 
clarify results.
A small quantity of mixed A/-BOC-(L)-Phe-(L)-Ala diazomethyl ketone and methyl 
ester was prepared during initial investigations into product generation (see 
section 14.6). As this sample of material was not observed to contain the 
unidentified impurity and as the ester has been shown to be inactive, biological 
evaluation of this mixture is now an additional option.
Since the result obtained for the isosteric A/-BOC-(L)-Val-Gly derived pair of 
compounds appears to be the opposite of that expected, it seems wise to repeat 
the study with fresh samples of both materials. Growth inhibition studies on a 
wider variety of organisms, particularly those known to contain few cysteine 
proteases, should be carried out in order to evaluate the general toxicity of the 
pair of isosteres. Such a study should indeed be carried out using all six 
synthesised compounds. Similarly, testing all compounds for inhibiting activity 
against isolated serine proteases, for which negative results are expected, would 
be worthwhile.
17.2 Further Work Concerning End Group Synthesis
Literature methodology for the preparation of phenoxymethyl ketones from the 
corresponding bromomethyl ketones has been uncovered (see section 10 .8 ). 
Indeed, this methodology may be applied to A/-BOC protected dipeptides where 
a yield of 85% can be expected. The bromomethyl ketones employed in this
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literature synthesis were generated from the corresponding diazomethyl ketones 
using 30% hydrogen bromide in acetic acid. Here the reaction was moderated 
by the use of low temperature and an additional solvent (dichloromethane).
While only mediocre yields (typically 40%) were claimed for this process the 
result suggests that, following further investigation into temperature and dilution 
effects, the method involving dry hydrogen bromide gas (section 10.5) may be 
applied successfully to such systems. It is also expected that the increased 
backbone length of dipeptide isosteres compared with protected amino acids, 
should reduce the likelihood of competing cyclisation reactions occurring during 
diazomethyl ketone manipulations.
Thus, it is suggested that the methods for the synthesis of bromomethyl ketones 
and phenoxymethyl ketones be tested and applied to the completed isostere 
diazomethyl ketones. Compounds formed during such a study may be tested in 
biological systems and the results compared with those obtained for the 
diazomethyl ketones.
Despite phenoxymethyl ketones replacing fluoromethyl ketones as the materials 
of choice for further study, the synthesis of the latter group may still be of 
interest. It is unknown if the methodology used in this study for the synthesis of 
fluoromethyl ketones (section 10.6) gave racemic products. It is therefore 
suggested that the fluoromethyl ketone generation be repeated in parallel with a 
study using KF/18-crown-6 in acetonitrile as an alternative. A small quantity of 
the target fluoromethyl ketone may be obtained by the reaction of the 
corresponding diazomethyl ketone with HF/pyrid.ine (see section 10.4) for use as 
a comparison. It has been reported that the chiral nature of the starting material 
is unaffected during conversion by the latter route.
17.3 Further Work Concerning Isostere Synthesis
The method employed here for the synthesis of (E)-ethene isosteres may be 
expanded to encompass a greater variety of side chains. Indeed, literature
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methodology which begins to address the problem of incorporating side chains 
bearing functional groups is available.1761
In the case of parasite enzyme inhibition, the synthesis of (E)-ethene isosteres 
bearing the non-natural (D)-configuration of the position 2 side chain would be of 
greater interest. For example, the effect of the (E)-ethene isostere of A/-BOC- 
(L)-Phe-(D)-AlaCHN2 on parasite growth should be investigated in comparison 
with the A/-BOC-(L)-Phe-(L)-AlaCHN2 isostere. It is anticipated that, if the 
material indeed inactivates an enzyme, the effect would be altered by the 
incorporation of an amino acid mimic of the non-natural configuration. The 
methodology discussed in sections 11 and 11.1 may be suitable for such a 
synthesis. Additional steps would be required, however, as the product isostere 
would be yielded as the methyl ester.
Fundamental results may be obtained by the synthesis and testing of peptide 
mimics containing an alternative amide group isostere. Improved results may be 
obtained, for example, by use of an isostere which is capable of some degree of 
hydrogen bonding (see section 4.3). The suitability of thioether based groups as 
amide link isosteres has been suggested by Spatola.[60] Furthermore, the 
possibility of oxidising such an isostere to generate sulfoxide and sulfone based 
mimics also exists. A proposed route for the synthesis of thioether based 
peptide mimics is outlined in figure 17.3-1. Note that the methodology required 
is, in many cases, similar to that tried and tested during this study.
'BuOOCNHLV ^ 0 S 0 2CH 3
6 H 2Ph
(synthesised as described in  section 12.1)
H S \ /COOCH3
CH3
Na, THF, MeOH
c h 3
*BuOOCNH>.
s  c o o c h 3
CH2Ph
potassium trimethyls ilanolate
fB uO O C N H ^^x
CH2Ph 
(figure 17.3-1)
XS '  COOH
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Experimental Preamble
Materials *
Solvents for chromatogrophic and general laboratory use were reagent grade or 
better (BDH General Purpose Reagent, Fischer Scientific Specified Laboratory 
Reagent, AnalaR Reagent or HPLC Grade).
Solvents and materials for use in reactions were dried in the following ways.
Tetrahydrofuran (THFV diethyl ether and xylene were dried by storage over 
sodium wire overnight followed by reflux over, and distillation from, sodium 
wire/benzophenone under a nitrogen atmosphere.
Dichloromethane (DCM1 and chloroform were dried by reflux over, and 
distillation from, diphosphorus pentoxide under a nitrogen atmosphere.
Ethanol and methanol were dried by reflux over, and distillation from, 
magnesium/iodine under a nitrogen atmosphere.
Acetone was dried by reflux over, and distillation from, activated 4A molecular 
sieves.
Carbon tetrachloride was dried by storage over dry calcium chloride.
Triethylamine and A/-methylmorpholine were dried prior to use by reflux over, 
and distillation from, potassium hydroxide under a nitrogen atmosphere. These 
materials were stored for short periods of time over potassium hydroxide. Note 
that in some cases direct use of the freshly distilled material, without the 
incorporation of additional potassium hydroxide, was preferred (see section 
14.2).
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Starting materials and reagents were purchased from the following suppliers.
Aldrich Chemical Company Ltd., Gillingham, Dorset.
Sigma Chemical Company Ltd., Gillingham, Dorset.
Fluka Chemicals Ltd., Gillingham, Dorset.
Avocado Research Chemicals Ltd., Heysham, Lancashire.
Lancaster Synthesis Ltd., Morecambe, Lancashire.
Thin layer chromatography was performed on Merck Silica Gel 60 F254 TLC 
plates with a 0.25 mm coating thickness. Dry flash chromatography (negative 
pressure) was performed on Fluka Silica Gel H (5 - 40 pm mesh) and positive 
pressure chromatography on Prolabo Sorbsil Silica Gel 60-H (40 - 60 pm mesh).
Equipment
Melting points were measured using a Gallenkamp 7/MF-370 melting block and 
are uncorrected.
Elemental analyses were performed on a Carlo Erba Strumentazione elemental 
analyser MOD 1106 with a Hewlett Packard 3394A integrator.
Optical rotations were measured using an Optical Activity Ltd. AA10 polarimeter 
operating at 589 nm.
Infra-red spectra were obtained using a Philips PU9800 Fourier transform 
spectrophotometer.
Mass spectrometry was carried out using electron impact conditions on an 
AEI/Kratos MS12 instrument for low resolution and an AEI/Kratos MS902S 
instrument for accurate mass investigations.
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Nuclear magnetic resonance spectra were obtained using either a Bruker 
AM200 or a Bruker WP200 instrument running at 200 MHz for hydrogen, 50 
MHz for carbon and 188 MHz for fluorine nuclei.
Spectroscopic and Analytical Data
Spectroscopic and analytical data are listed for each compound in the style 
prescribed by the Journal of the Chemical Society, Perkin Transactions.
Melting points (m.pU and boiling points (b.pt) are noted in degrees centigrade 
(°C) with a literature (lit.) value given where appropriate. In the case of vacuum 
distillation, the relevant pressure is given in millimetres of mercury (mmHg).
Chromatographic retention factors (Rfl are expressed as a fraction of the 
distance travelled by the solvent front.
Elemental analysis results are recorded for each element as a percentage.
Optical rotations ([a]E) are given in degrees (°) with the ambient temperature, in 
degrees centigrade (°C), noted as a superscript. Solution concentrations are 
given in milligrammes (mg) of sample per millilitre (ml) of the specified solvent.
Infra-red (IR) spectroscopic data is given with wavenumbers of maximum 
absorbance (vmax) expressed in reciprocal centimetres (cm’1). The abbreviations 
s, m and br are used for strong, medium and broad respectively.
Mass spectroscopic data is recorded as the mass to charge ratio (m/z) with M+ 
being the parent molecular ion. Fragments may be identified as the product 
resulting from the loss of a particular group from the parent ion. Relative signal 
intensities are given as a percentage of the largest observed peak.
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Nuclear magnetic resonance (NMRi spectroscopic data is given with chemical 
shifts (5) expressed in parts per million (ppm) with respect to tetramethylsilane 
(TMS) as an internal standard. The abbreviations s, d, t, q, quin and m are used 
for singlet, doublet, triplet, quartet, quintet arid multiplet respectively. 
Diastereotopic protons displaying geminal coupling are assigned the 
abbreviation ABq. Coupling constants (J) are recorded in hertz (Hz). When 
indicating the species responsible for each signal italics will be used in cases 
where ambiguity may still exist from the fragment given.
EXPERIMENTAL PART 1: A/-Phthaloyl Protection of Amino Acids 
N-Phthaloylglycine from glycine
H2Nv^ J l
o
OH OH
O
Materials
Glycine
Sodium carbonate decahydrate 
/V-Ethoxycarbonyl phthalimide 
Distilled water
0.50 g (6.67 mmol) 
1.93 g (6.75 mmol) 
1.50 g (6.85 mmol) 
15 ml
Method
In a 100 ml conical flask equipped with a magnetic stirring bar, glycine and 
sodium carbonate decahydrate were placed. Distilled water was added and the 
mixture stirred until total solution was achieved. A/-Ethoxycarbonyl phthalimide 
was added and stirring continued for 1 hour at room temperature. The small 
amount of undissolved material was then removed by filtration. The resulting 
clear filtrate was acidified slowly, with stirring, using concentrated hydrochloric 
acid (35% min.) giving a thick white precipitate. Heating this mixture to boiling 
gave a clear colourless solution which on slow cooling yielded long thin 
colourless needles. These needles were isolated by filtration and washed with 
distilled water. Analysis confirmed the identity of this material as A/- 
phthaloylglycine (0.98 g, 71.7% yield, m.pt. 193-197°C, lit. 193-196°C [129]).
Found: C, 58.61; H, 3.49; N, 6.84. C10H7N1O4 requires C, 58.53; H, 3.41; N, 
6.82%
vmax(KBr)/crn' 1 3063-2701 br (acid OH), 1775m (imide), 1725s (imide and acid 
C=0)
m/z 205 (M \ 1.3%), 160 (M - COOH, 100), 132 (4.8), 104 (21.7), 76 (27.5)
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m/z 205.0383 (M+, C10H7N 0 4 requires 205.03755)
5h(200MHz d6-DMSO) 4.34 (2H, s, CH2), 7.88-7.99 (4H, m, phth.) 
6c(50MHz d6-DMSO) 39.0 (t), 123.5 (d), 131.5 (s), 134.9 (d), 167.3 (s, phth 
C=0), 169.0 (s, COOH)
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Af-Phthaloyl-(L)-phenylalanine from (L)-phenylalanine
h 2n
CH2Ph
OH
CH2Ph
OH
O
Materials 
(L)-Phenylalanine 
Sodium carbonate decahydrate 
A/-Ethoxycarbonyl phthalimide 
Distilled water
2.00 g (12.1 mmol) 
3.48 g (12.2 mmol) 
2.64 g (12.1 mmol) 
60 ml
Method
In a 100 ml conical flask equipped with a magnetic stirring bar, (L)-phenylalanine 
and sodium carbonate decahydrate were suspended in distilled water. After 
stirring for 20 minutes at room temperature complete solution was almost 
achieved. A/-Ethoxycarbonyl phthalimide was added and stirring continued for a 
further 30 minutes. Filtration of this mixture gave a clear solution which was 
acidified slowly with concentrated (35% min.) hydrochloric acid. The resulting 
thick precipitate was found to be only partially soluble when the mixture was 
heated to boiling. After being allowed to cool the solid material was removed by 
vacuum filtration, crushed manually and washed with distilled water.
The resulting white solid was dried under vacuum after which the crystalline 
nature of the product could be more clearly observed. Analysis showed the 
crystalline solid to be A/-phthaloyl-(L)-phenylalanine (2.73 g, 77.1% yield, m.pt. 
177-184°C, lit. 178°C for racemate[82]).
Found: C, 67.62; H, 4.32; N, 4-75. C17H13N10 4 requires C, 69.15; H, 4.41; N, 
4.74%
Vmax(KBr)/cm'1 3272br (acid OH), 1773m (imide), 1750s (acid C=0), 1698s 
(imide C = 0 )
m/z 295 (M+, 5.5%), 250 (M - COOH), 77 (19.1), 91 (31.7), 76 (20.2)
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m/z 295.0821 (M+, C17H13N 0 4 requires 295.08441)
8h(200MHz CDCI3) 3.58 (2H, dd, J 7.5 and 9.2, CH2), 5.22 (1H, dd, J 7.5 and 
9.2, NCH), 6.82 (1H, brs, COOH), 7.16 (5H, m, Ph), 7.63-7.81 (4H, m, phth) 
8c(50MHz CDCI3) 34.3 (t, PhCH2), 53.0 (d, NCH), 123.5 (d), 126 (d), 128.6 (d), 
128.8 (d), 131.4 (s), 134.2 (d), 136.4 (s), 167.5 (s, phth C=0), 174.0 (s, COOH)
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A/-Phthaloyl-(L)-alanine from (L)-alanine
O
OH OH
O
Materials
(L)-Alanine
Sodium carbonate decahydrate 
A/-Ethoxycarbonyl phthalimide 
Distilled water
10.00 g (112.4 mmol)
32.05 g (112.1 mmol) 
24.63 g (112.5 mmol) 
250 ml
Method
Using the same basic procedure as that utilised for the production of N- 
phthaloyl-(L)-phenylalanine, A/-phthaloyl-(L)-alanine was obtained as fine white 
needles (18.52 g, 75.5% yield, m.pt. 143-146°C, lit. 145-147X I130]).
6.39%
vmax(KBr)/crn' 1 3264br (acid OH), 1777m (imide), 1757s (acid C=0), 1694s 
(imide C=0)
m/z 219 (M+, 2.1%), 174 (M - COOH, 100), 146 (1.7), 132 (1,4) 
m/z 219.0532 (M+, C^HgN 0 4 requires 219.05312)
8h(200MHz d6-DMSO) 1.57 (3H, d, J 7.3, CH3), 4.89 (1H, q, J 7.3, CH3), 2.82- 
7.95 (4H, m, phth)
8c(50MHz d6-DMSO) 14.9 (q), 47.0 (d, NCH), 123.3 (d), 131.3 (s), 134.8 (d),
167.2 (s, phth C=0), 171.1 (s, COOH)
Found: C, 60.31; H, 4.20; N, 6.34. C11H9N10 4 requires C, 60.27; H, 4.11; N,
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N-Phthaloyl-p-alanine from p-alanine
H 2N
o
OH
Materials
p-Alanine
Sodium carbonate decahydrate 
A/-Ethoxycarbonyl phthalimide 
Water (non distilled)
OH
2.00 g (22.5 mmol) 
6.50 g (22.7 mmol) 
4.93 g (22.5 mmol) 
40 ml
Method
Using the same basic procedure as that utilised to produce A/-phthaloylglycine, 
A/-phthaloyl-p-alanine was obtained as well formed white plates (3.22g, 6 6 .8 % 
yield, m.pt. 149-152°C, lit. 151.5°C|821).
Found: C, 60.23; H, 4.11; N, 6.40. C11H9N10 4 requires C, 60.27; H, 4.11; N, 
6.39%
Vm ax(K B r)/cm '1 3206br (acid OH), 1770m (imide), 1722s (acid C=0), 1702s 
(imide C=0)
m/z 219 (M+, 6.0%), 202 (M - OH, 1.7), 174 (M - COOH, 19.1), 160 (86.1), 146
(10.6), 132 (7.0), 104 (45.7), 76 (100)
m/z 219.0537 (M+, C^HgN 0 4 requires 219.05312)
5h(200MHz CDCI3) 2.80 (2H, t, J 7.3, CH2CO), 4.00 (2H, t, J 7.3, CH2N), 7.77- 
7.81 (4H, m, phth), 10.10 (1H, br s, COOH)
5c(50MHz CDCI3) 35.5 (t), 33.3 (t), 123.4 (d), 131.9 (s), 134.1 (d), 167.8 (s, phth 
C=0), 176.4 (s, COOH)
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H3C— /  V-SO2-N' ------ ► ch2n 2
EXPERIMENTAL PART 2: Diazomethylation of Protected Amino Acids Via
the Mixed Carbonate
Diazomethane from p-toluenesulfonylmethylnitrosamide (Diazald-)
CH3
>4 = 0
Materials
Potassium hydroxide 18.12 g (32.4 mmol)
Water 30 ml
Carbitol (diethylene glycol monoethyl ether) 105 ml
Diethyl ether 30 ml
Diazald® 63.18 g (29.5 mmol)
Diethyl ether 380 ml
Method
The synthesis of diazomethane was carried out using the Aldrich large scale 
Diazald® kit.11311 This kit consists of a 500 ml pressure equilibriated dropping 
funnel with a Teflon® stopper, a 500 ml two neck round bottom flask, a pressure 
equilibrated dry ice condenser and a 500 ml receiver vessel. The dry ice 
condenser is constructed such that the condensate is directed through a 
stopcock and U-tube before reaching the receiver vessel. All apparatus 
connections and joints are ground glass free. The kit is also equipped with 
Teflon® stopcocks.
The 500 ml two neck flask was equipped with a Teflon® coated magnetic stirring 
bar and charged with carbitol and diethyl ether. Potassium hydroxide was 
predissolved in water and added to this miixture and the vessel immersed in an 
oil bath. Diazald® was dissolved as far as possible in diethyl ether and placed in 
the dropping funnel. The receiver vessel was immersed in ice and the 
condenser pocket filled with acetone/dry ice. The oil bath was then heated to
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60°C, the magnetic stirring started and the introduction of the Diazald® initiated 
giving rise to yellow vapours. The rate of Diazald® solution addition was 
carefully controlled to ensure that all vapours produced were fully condensed. 
This condensate initially filled the U-tube, where it could be observed as a yellow 
solution, before slowly passing into the chilled receiver vessel. Complete 
addition of Diazald® was carried out over approximately 1.5 hours after which 30 
ml diethyl ether was added to the reaction vessel via the dropping funnel. The 
temperature of the oil bath was raised to 70°C and heating continued until the 
condensate in the U-tube appeared colourless. The receiver vessel was 
removed and its position replaced with an aqueous acetic acid bath. Aqueous 
acetic acid was also introduced slowly to the reaction vessel in order to 
neutralise any remaining potassium hydroxide and destroy residual 
diazomethane in the system.
A total of approximately 440 ml yellow diazomethane solution was obtained 
which, if complete conversion is assumed, contains 0.67 mmol/ml.
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M-Phthaloylglycyl diazomethyl ketone from A/-phthaloylglycine
N
OH
O
Materials
/V-Phthaloylglycine
THF
Triethylamine 
Isobutyl chloroformate 
Diazomethane (ether solution)
CH N 2
0.15 g (0.73 mmol) 
5 ml
0.3 ml (2.2 mmol) 
0.2 ml (1.5 mmol) 
c. 7.8 mmol
Method
The ground glass joints of a scratch free 100 ml three neck flask were thoroughly 
greased. This vessel was flame dried after being equipped with a nitrogen 
balloon, magnetic stirring bar (Teflon® coated) and septum caps. A solution of 
A/-phthaloylglycine in THF was added by syringe. After being cooled to -20°C 
triethylamine was added slowly. Isobutyl chloroformate was then added in a 
similar manner giving a white precipitate in the reaction mixture. This mixture 
was stirred for 20 minutes at -20°C after which the vessel was temporarily 
opened to admit the diazomethane solution under a nitrogen stream. The funnel 
used for this process was completely free of ground glass and surface 
imperfections. The resulting mixture was stirred for 1 hour at -20°C then allowed 
to warm to room temperature and stirred for a further hour. The reaction was 
quenched by addition of an equal volume of water and stirred vigorously for at 
least 1 hour before any manipulations were attempted.
The crude reaction mixture was transferred to a separatory funnel where the 
clear, strongly yellow, organic layer was separated from the clear, very mildly 
yellow, aqueous layer. The aqueous layer was extracted with ethyl acetate, the 
organic layers were combined and washed with saturated aqueous sodium
154
bicarbonate, dried with magnesium sulfate and filtered then evaporated under 
reduced pressure. The resulting yellow oily solid was recrystallised from ethyl 
acetate to give fine needles with a similar colouration (0.07 g, 42% yield, rn.pt 
177-179X, lit. 168°C l118], Rf 0.47 eluent 1:1 ethyl acetate:hexane).
Found: C, 57.61; H, 3.20; N, 18.17. Cu H7t iz0 3 requires C, 57.64; H, 3.05; N, 
18.34%
vmax(KBr)/crn"1 3075m (diazo CH), 2132s (diazo), 1775m (imide), 1736s (imide), 
1628s (diazo C=0)
m/z 201 (M - N2, 48.6%), 160 (M - COCHN2, 100), 146 (3.2), 132 (5.5), 104 
(40.5), 76 (59.3)
m/z 201.0413 (M - N2, CUH7H 0 3 requires 201.04256)
5h(200MHz d6-DMSO) 4.45 (2H, s CH2), 6.39 (1H, s, CHN2), 7.84-7.79 (4H, m, 
phth)
5c(50MHz d6-DMSO) 44.2 (t, CH2), 53.6 (d, CHN2), 123.4 (d), 131.5 (s), 134.7 
(d), 167.4 (s, phth C=0), 188.2 (s, ketone)
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/V-Phthaloyl-(L)-phenylalanyl diazomethyl ketone fom JV-phthaloyl-(L)-
phenylalanine
CH2Ph CH2Ph
14.49 g (49.1 mmol)
250 ml
7.5 ml (53.9 mmol)
7.0 ml (54.0 mmol) 
c. 147 mmol
Method
Using the same basic method as that utilised to produce A/-phthaloylglycyl 
diazomethyl ketone, A/-phthaloyl-(L)-phenylalanyl diazomethyl ketone was 
obtained as a yellow oily solid. Product recrystallisation in this case was 
achieved using ethyl acetate/hexane (8.92 g, 57% yield, m.pt. 133-136°C, lit. 
142-144°C[54]). -
Found: C, 67.62; H, 4.16; N, 13.16. C18H13N30 3 requires C, 67.71; H, 4.07; N, 
13.16%
[a ]D22 -221.3 (16.5 mg/1 ml CHCI3)
v m a x (K B r)/c rn '1 3106w (diazo C H ) ,  2101s (diazo), 1779w (imide), 1709s (imide 
C = 0 ) ,  1651m (diazo C = 0 )
m/z 319 (M+, 0.5%), 291 (M - N2, 9.0), 250 (73.2), 91 (25.4), 77 (49.7), 76 (54.9) 
m/z 319.0970 (M+, C18H13N30 3 requires 319.09573)
5h(200MHz d6-DMSO) 5.12 (1H, d of ABq, J 4.9(AB), 11.5 and 13.8, NCH), 6.58 
(1H, s, CHN2), 7.13 (5H, m, Ph), 7.83 (4H, s, phth)
Materials
A/-Phthaloyl-(L)-phenylalanine
THF
Triethylamine 
Isobutyl chloroformate 
Diazomethane (ether solution)
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6c(50MHz d6-DMSO) 33.2 (t, PhCH2), 53.7 (d, CHN2), 57.9 (d, CHN), 123.4 (d),
126.6 (d), 128.3 (d), 128.8 (d), 130.9 (s), 134.8 (d), 137.1 (s), 167.2 (s, phth 
C=0), 190.2 (s, ketone C=0)
5h(200MHz CDCI3) 3.52 (2H, pair of d, J 6.8 and 9.6, PhCH2), 5.09 (1H, dd, J 6.8 
and 9.6, CHN), 5.42 (1H, s, CHN2), 7.14 (5H, m, Ph), 7.65-7.81 (4H, m, phth)
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A/-Phthaloyl-(L)-alanyl diazomethyl ketone from A/-phthaloyl-(L)-alanine
Method
Using the same basic method as that employed to produce A/-phthaloylglycyl 
diazomethyl ketone, A/-phthaloyl-(L)-alanyl diazomethyl ketone was obtained as 
a yellow oil (3.86 g, 94% crude yield with ethyl acetate being indicated as the 
main impurity by 1H NMR spectroscopy). Thin layer chromatography indicated 
the presence of a small amount of a further impurity (Rf 0.57 [product], 0.73 
[impurity], eluent 1:1 ethyl acetate:hexane).
Upon storage at 0°C for several days this material solidified. A slow process of 
recrystallisation from ethyl acetate/hexane was found to be possible when the 
saturated solution was stored at the aforementioned temperature (product m.pt. 
60-63°C).
Found: C, 59.19; H, 3.89; N, 17.23. C12H9N303  requires C, 59.25; H, 3.70; N, 
17.28%
vmax(KBr)/cm' 1 3092m (diazo CH), 2103s (diazo), 1775m (imide), 1705s (imide 
C=0), 1647m (diazo C=0)
m/z 215 (M -N 2, 20.7), 174 (M - COCHN2, 100), 146(2.3) 132(1.9) 
m/z 215.0574 (M - N2, C12H9N 0 3 requires 215.05828)
CH N 2
Materials
A/-Phthaloyl-(L)-alanine
THF
Triethylamine 
Isobutyl chloroformate 
Diazomethane
2.6 ml (18.7 mmol) 
2.4 ml (18.5 mmol) 
c. 50 mmol
3.65 g (16.7 mmol) 
85 ml
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5h(200MHz CDCI3) 1.60 (3H, d, J 7.3, CH3), 4.83 (1H, q, J 7.3, CHN), 5.38 (1H, 
s, CHN2), 7.63-7.83 (4H, m, phth)
6c(50MHz C DC I 3 ) 14.5 (q), 52.1 and 53.7 (both d, CHN and CHN2), 123.4 (d), 
131.7 (s), 134.2 (d), 167.5 (s, phth C=0), 190.1 (s, ketone C=0)
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A/-Phthaloyl-p-alanyl diazomethyl ketone from A/-phthaloyl-p-alanine
OH
Materials
A/-Phthaloyl-p-alanine 
THF
Triethylamine 
Isobutyl chloroformate 
Diazomethane
Method
Using the same basic method as that employed to produce A/-phthaloylglycyl 
diazomethyl ketone, A/-phthaloyl-p-alanyl diazomethyl ketone was obtained as a 
white solid. Recrystallisation from hot ethyl acetate/hexane yielded fine needles 
with a very mild yellow-green colouration (0.37 g, 30% yield, m.pt. 119-122°C).
Found: C, 59.49; H, 3.96; N, 17.01. C12H9N303  requires C, 59.26; H, 3.70; N, 
17.28%
v m a x (K B r)/c rn '1 3088m (diazo C H ) ,  2116s (diazo), 1770m (imide), 1716s (imide), 
1610s (diazo C = 0 )
m/z 215 (M - N2, 22.5%), 202 (M - CHN2, 1.3), 174 (10.3), 160 (100), 146 (4.5),
132 (8 .8), 104 (52.4), 76 (72.8)
m/z 243.0633 (M+, C12H9N30 3 requires 243.06437)
5h(200MHz CDCI3) 2.77 (2H, t, J 7.2, CH2CO), 4.01 (2H, t, J 7.2, CH2N), 5.36 
(1H, s, CHN2), 7.68-7.89 (4H, m, phth)
8c(50MHz CDCI3) 33.6 (t), 38.4 (t), 55.0 (d, CHN2), 123.2 (d), 131.8 (s), 133.9 
(d), 167.9 (s, phth C=0), 191.9 (s, ketone C=0)
1.095 g (5.00 mmol) 
30 ml
0.8 ml (5.8 mmol) 
0.7 ml (0.7 mmol) 
c. 20 mmol
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W-fe/t-Butoxycarbonyl-(L)-phenylalanyi diazomethyl ketone from N-tert-
butoxycarbonyl-(L)-phenylalanine
o o
tB uO . NH ^ ^   ^  tR uO . .N H .
Y  OH Y  Y  "CHNz
O CH2Ph O CH2Ph
Materials
A/-terf-Butoxycarbonyl-(L)-phenylalanine 3.50 g (13.2 mmol)
THF 65 ml
Triethylamine 2.0 ml (14.4 mmol)
Isobutyl chloroformate 1.8 ml (13.9 mmol)
Diazomethane c. 80 mmol
Method
Using the same basic procedure as that employed to produce A/-phthaloyIglycyI 
diazomethyl ketone, A/-terf-butoxycarbonyl-(L)-phenylalanyl diazomethyl ketone 
was obtained as a yellow oil which solidified on standing. Recrystallisation from 
hot ethyl acetate/hexane yielded the desired compound as clear yellow crystals 
(2.54 g, 6 8 % yield, m.pt. 95-97°C, Rf 0.74, eluent 1:1 ethyl acetate:hexane).
Found: C, 62.01; H, 6.67; N, 14.36. C15H19N303  requires C, 62.28; H, 6.57; N, 
14.53%
vmax(KBr)/crn' 1 3328m (carbamate NH), 3127m (diazo CH), 2105s (diazo), 1686s 
(carbamate C=0), 1642s (ketone C=0), 1526s (carbamate) 
m/z 233 (M - [CH3]2C=CH2, 0 .2 %), 220 (M - COCHN2, 9.1) 205 (3.7) 
m/z 220.1329 (M - COCHN2, C13H18N 0 2 requires 220.13372)
§h(200MHz CDCI3) 1.32 (9H, s, [CH3]3C), 2.93 (2H, d of ABq, J 13.8(AB), 6.6  and 
6.7, PhCH2), 4.35 (1H, m, CHN), 5.20 (1H, brd, J 8.5, NH), 5.23 (1H, s, CHN2), 
7.08-7.26 (5H, m, Ph)
5c(50MHz CDCI3) 28.1 (q), 38.3 (t), 54.2 and 58.4 (both d, CHN and CHN2), 79.8 
(s, [CH3]3C), 126.8 (d), 128.4 (d), 129.2 (d), 136.3 (s), 155.1 (s, carbamate NH),
193.4 (s, ketone C=0)
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6h(200MHz d6-DMSO) 1.32 (9H, s, [CH3]3C), 2.89 (2H, d of ABq> J 13.8(AB), 4.4 
and 10.5), 4.19 (1H, m, CHN), 6.13 (1H, s, CHN2), 7.17-7.33 (5H, m, Ph)
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EXPERIMENTAL PART 3: Further Reaction of Diazomethyl Ketones and
Subsequent Halogen Exchange
Triphenylphosphonium bromide from triphenylphosphine
(aq) + PPh3(s) ** PPhaH^Br"^
Materials
Hydrobromic acid (48% aqueous solution)
T riphenylphosphine
Method
To a 250 ml conical flask equipped with a magnetic stirring bar, hydrobromic 
acid was added and heated to 70°C. Triphenylphosphine was then added and 
the mixture stirred for 10 minutes at this temperature. After being allowed to 
cool the solution was transferred to a separatory funnel and extracted four times 
with 30 ml portions of chloroform. The combined organic layers were dried with 
sodium sulfate, filtered and evaporated. The resulting solids were transferred to 
a Buchner funnel where they were purified by washing with warm ethyl acetate. 
The desired product was isolated as a clean white solid and stored below 5°C 
(32.42 g, 95% yield, m.pt. 184-197°C, lit. 185-195°C [861).
70 ml (0.41 mol) 
26.20 g (0.10 mol)
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Af-Phthaloyl-(L)-phenylalanyl bromomethyl ketone from /V-phthaloyl-(L)-
phenylalanyl diazomethyl ketone
N
c h n 2
o CH2Ph
Materials
A/-Phthaloyl-(L)-phenylalanyl diazomethyl ketone 
Dichloromethane
N Br
0.50 g (1.57 mmol) 
30 ml
Triphenylphosphonium bromide 
Xylene
11.0 g (32.1 mmol) 
40 ml
Apparatus
The following were connected in series via plastic tubing:
1. Nitrogen gas cylinder
2. Drying vessel containing calcium chloride.
3. 250ml three necked flask equipped with a glass inlet tube and water 
condenser from the top of which the series connection was continued.
4. Reaction vessel bubbler.
5. Empty catchment trap.
6 . Bubbler filled with an aqueous solution of sodium bicarbonate.
The 250 ml three neck flask was charged with xylene and triphenylphosphonium 
bromide and the reaction vessel with dichloromethane and A/-phthaloyl-(L)- 
phenylalanyl diazomethyl ketone. Nitrogen gas was passed through 
the system at such a rate as to give steady bubbling through all three solutions. 
The xylene vessel was heated to reflux at which point white fumes of hydrogen 
bromide were observed in the nitrogen stream. Effervescence in the reaction 
vessel began almost immediately and the characteristic yellow colouration of the 
starting solution was rapidly lost. Reflux was continued for 30 minutes after the
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effervescence in the reaction vessel ceased and began in the bicarbonate trap. 
The xylene vessel was then allowed to cool and nitrogen gas used to purge the 
system.
Addition of further dichloromethane followed by drying with magnesium sulfate, 
filtration and evaporation gave 0.60 g of a buff coloured solid. Recrystallisation 
of 0.40 g of this material, from ethyl acetate/hexane, yielded colourless needles 
(0.35 g, 0.94 mmol, 87.5% yield from recrystallisation which extrapolates to 90% 
yield for full reaction, m.pt. 108-112°C, Rf 0.86, eluent 1:1 ethyl acetate:hexane, 
Rf 0.75, eluent 10:1 chloroform:ethyl acetate).
Evaporation of the xylene allowed recovery of triphenylphosphine which was 
generally used for the production of further triphenylphosphonium bromide 
without purification.
Found: C, 57.92; H, 3.94; N, 3.69; Br, 21.47. C18H14N 0 3Br requires C, 58.08; H, 
3.76; N, 3.76; Br, 21.50%
[ct]D22 -185.9 (12.1 mg/1 ml CHCI3)
vmax(KBr)/crn’1 1775m (imide), 1744s (ketone C=0), 1713s (imide C=0) 
m/z 373 (M \ 1.3%), 371 (M+, 1.3), 292 (M - Br, 8 .6 ), 278 (0.4), 250 (100) . 
m/z 373.0146 (M+, C18H14N 0 3Br requires 373.01381), m/z 371.0144 (M+, 
C18H14N 0 3Br requires 371.01571)
6h(200MHz CDCI3) 3.42 (2H, d of ABq, J 10.9(AB), 5.1 and 14.1, PhCH2), 3.93 
(2H, s, CH2Br), 5.31 (1H, dd, J 5.1 and 10.9), 7.06 (5H, m, Ph), 7.58-7.74 (4H, 
m, phth)
6c(50MHz CDCI3) 31.3 (t), 33.9 (t), 57.6 (d, CHN), 123.6 (d), 127.0 (d), 128.6 (d),
128.9 (d), 131.2 (s), 134.0 (d), 136.1 (s), 167.4 (s, phth C=0), 196.8 (s, ketone 
C=0)
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A/-Phthaloyl-(L)-alanyl bromomethyl ketone from /V-phthaloyl-(L)-alanyl
diazomethyl ketone
Materials
A/-Phthaloyl-(L)-alanyl diazomethyl ketone 0.50 g (2.06 mmol)
Dichloromethane 30 ml
Triphenylphosphonium bromide 14.0 g (40.8 mmol)
Xylene 45 ml
Method
Using the same basic procedure as that employed to form A/-phthaloyl-(L)- 
phenylalanyl bromomethyl ketone, crude A/-phthaloyl-(L)-alanyl bromomethyl 
ketone was produced as a yellow oil (0.54 g, 87% crude yield). Thin layer 
chromatography indicated the presence of only a small amount of impurity (Rf 
0.81 [product] and 0.03 [impurity], eluent 1:1 ethyl acetate:hexane).
Storage for two weeks at 0°C effected solidification of this material. 
Recrystallisation was found to be possible from ethyl acetate/hexane by storage 
of a saturated solution of the material at the aforementioned temperature. Clean 
white crystals of the desired product were obtained (0.39 g, 64% yield, m.pt. 75- 
78°C, lit. 6 6 °C [132], Rf 0.74, eluent 10:1 chloroform:ethyl acetate).
In this case reflux of the xylene vessel was halted before the generation of 
hydrogen bromide gas was complete. Once cool, further triphenylphosphonium 
bromide and xylene were added to the reflux vessel. The reaction vessel was 
removed, its site thoroughly cleaned, and the remaining apparatus used directly 
in further bromination reactions.
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Found: C, 48.76; H, 3.52; N, 4.73; Br, 27.00. C12H10NO3Br requires C, 48.65; H, 
3.38; N, 4.73; Br, 27.03%
vmax(KBr)/crn' 1 1781m (imide), 1721s (ketone C=0), 1713 (imide C=0) 
m/z 216 (M - Br, 0.3%), 174 (M - COCH2Br, 100), 146 (1.2) 
m/z 216.0680 (M - Br, C12H10N 0 4 requires 216.06601)
5h(200MHz CDCI3) 1.58 (3H, d, J 7.2, CH3), 3.93 (2H, s, CH2Br), 5.13 (1H, q, J 
7.2, CHN), 7.62-7.83 (4H, m, phth)
6c(50MHz CDCI3) 14.4 (q), 30.9 (t), 51.6 (d, CHN, 123.6 (d), 131.6 (d), 134.4 (d), 
167.3 (s , phth C=0), 197.4 (s, ketone C=0)
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A/-Phthaloylglycyl bromomethyl ketone from A/-phthaloylglycyl diazomethyl
ketone
N
O
N Br
Materials
A/-Phthaloylglycyl diazomethyl ketone 0.50 g (2.18 mmol)
Dichloromethane 30 ml
Triphenylphosphonium bromide 10.0 g additional
Xylene 30 ml additional
Method
Additional xylene and triphenylphosphonium bromide were added to the 
apparatus used for the formation of A/-phthaloyl-(L)-alanyl bromomethyl ketone. 
The same basic procedure as that utilised to form A/-phthaloyl-(L)-phenylalanyl 
bromomethyl ketone was employed to yield A/-phthaloylglycyl bromomethyl 
ketone as buff coloured solid (0.63 g). Recrystallisation of 0.40 g of this material 
from ethyl acetate/hexane gave colourless needles (0.33 g, 82% crystallisation 
yield which extrapolates to 84% yield for reaction, Rf 0.75, eluent 1:1 ethyl 
acetate:hexane, Rf 0.61, eluent 10:1 chloroform:ethyl acetate, m.pt. 144-148°C, 
lit. 145-146°C [133] and 147°C [134]).
Found: C, 46.88; H, 2.87; N, 4.86; Br, 28.25. C^HgN 0 3Br requires C, 46.81; H, 
2.84; N, 4.96; Br, 28.37%
v m ax(K B r)/crn"1 1775m (imide), 1732s (ketone C=0), 1721s (imide C=0) 
m/z 283 (M+, 0.6%), 281 (M+, 0.6), 202 (M - B r, 1.7), 188 (0.1), 160 (100) 
m/z 202.0523 (M - B r, C^HgN 0 3 requires 202.05040)
5h(200MHz CDCI3) 3.93 (2H, s, CH2Br), 4.66 (2H, s, CH2N), 7.59-7.78 (4H, m, 
phth)
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8c(50MHz CDCI 3 ) 30.9 (t, CH2Br)t 44.4 (t, CH2N), 123.5 (d), 132.0 (s), 134.1 (d),
167.2 (s, phth C=0), 194.4 (s, ketone C=0)
/
A/-Phthaloyl-(L)-phenylalanyl fluoromethyl ketone from JV-phthaloyl-(L)-
phenylalanyl bromomethyl ketone
CH2Ph
Br
CH2Ph
F
O O
Materials
A/-Phthaloyl-(L)-phenylalanyl bromomethyl ketone 0.200 g (0.538 mmol)
Method
A 10 ml round bottom flask with a side arm was equipped with a magnetic 
stirring bar and a water condenser topped with a nitrogen balloon. To this flask 
was added A/-phthaloyl-(L)-phenylalanyl bromomethyl ketone and chloroform. 
Triethylamine trishydrofluoride was added, the flask flushed with nitrogen and 
the side arm sealed with a septum cap. Using an oil bath held at 80°C, the 
solution was taken to gentle reflux. Carefull monitoring of the reaction by thin 
layer chromatography indicated complete conversion of the material after 31 
hours at this temperature (product Rf 0.62, starting material Rf 0.75, eluent 10:1 
chloroform:ethyl acetate). The reaction was quenched by addition of saturated 
aqueous sodium bicarbonate at room temperature.
The mixture was transferred to a separatory funnel with the aid of 100 ml diethyl 
ether and 100 ml saturated aqueous sodium bicarbonate. The organic layer was 
separated and the aqueous layer extracted with three 100 ml portions of diethyl 
ether. The combined organic layers were washed sequentially with 400 ml 
distilled water, 200 ml hydrochloric acid (2 M), 400 ml distilled water and 200 ml 
saturated aqueous sodium bicarbonate. Following this the organic layer was 
dried with magnesium sulfate, filtered and evaporated to give an off-white solid. 
This material was purified by precipitation from a dichloromethane solution by
Chloroform
Triethylamine trishydrofluoride
5 ml
0.5 ml (3.1 mmol)
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the addition of hexane. Clean white solids were obtained which analysis 
showed to be the desired product (130 mg, 78% yield, m.pt. 110-112°C, lit. 113- 
114°C1901).
Found: C, 69.20; H, 4.60; N, 4.24. C18H14N 0 3F requires C, 69.45; H, 4.50; N, 
4.50%
[a]D22 -2.5 (10.1 mg/1 ml CHCI3)
vmax(KBr)/crn'1 1780m (imide), 1752s (ketone C=0), 1714s (imide C=?0) 
m/z 311 (M+, 1.1%), 292 (M - F, 0.4), 278 (0.8), 250 (100) 
m/z 311.0942 (M+, C18H14N 0 3F requires 311.09461)
5h(200MHz CDCI3) 3.43 (2H, d of ABq, J 14.1(AB), 5.2 and 10.6, PhCH2), 4.92 
(2H, d of ABq, J 15.9(AB) and 47.2, CH2F), 5.21 (1H, ddd, J 1.5, 5.2 and 10.6, 
CHN), 7.11 (5H, m, Ph), 7.62-7.75 (4H, m, phth)
5c(50MHz CDCI3) 33.3 (PhCH2, 57.8 (d, CHN), 82.6 and 86.#(both t, CH2F,
123.6 (d), 127.0 (d), 128.6 (d), 129.0 (d), 131.3 (s), 134.3 (d), 136.1 (s), 167.4 (s, 
phth C = 0 ), 199.9 and 200.3 (both s, COCH2F)
5f (1 88MHz CDCI3) -230.93 (t, J 47.2)
5h(200MHz d6-DMSO) 3.23 (2H, d of ABq, J 13.9(AB), 11.2 and 4.9, PhCH2),
5.37 (1H, dd, J 11.2 and 4.9, CHN), 5.39 (2H, d of ABq, J 16.8(AB) and 46.1, 
CH2-F), 7.15 (5H, m, Ph), 7.85 (4H, m, phth)
5f(188MHz d6-DMSO) -232.7 (t, J 46.1)
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A/-Phthaloyl-(L)-alanyl fluoromethyl ketone from iV-phthaloyl-(L-)-alanyl
bromomethyl ketone
Method
The same general procedure as that used to produce A/-phthaloyl-(L)- 
phenylalanyl fluoromethyl ketone was employed to yield crude A/-phthaloyl-(L)- 
alanyl fluoromethyl ketone as a yellow oil (70 mg, 88% crude yield).
Complete conversion was indicated by thin layer chromatography after a 
reaction time of 48 hours (product Rf 0.60, starting material Rf 0.74, eluent 10:1 
chlorofornrr.ethyl acetate).
Purification by precipitation was found to be possible but inefficient. The desired 
compound precipitated as an off white solid upon storage of a saturated ethyl 
acetate/hexane solution at 0°C (20 mg, 25%yield).
v m a x ( K B r ) / c r n ' 1 1777m (imide), 1745s (ketone C=0), 1713s (imide C=0) 
m/z 235 (M \ 0.1%), 216 (M - F, 0.3), 174 (100), 146 (1.5) 
m/z 235.0660 (M+, C12H10N 0 3F requires 235.06446)
5h(200MHz CDCI3) 1.67 (3H, d, J 7.2, CH3), 5.08 (1H, dq, J 1.4(d) and 7.2(q), 
CHN), 5.00 (2H, d, J 47.1, CH2F), 7.75-7.91 (4H, phth)
5F(188MHz CDCI3) -231.21 (t, J 47.1)
Materials
A/-Phthaloyl-(L)-alanyl bromomethyl ketone 
Chloroform
Triethylamine trishydrofluoride
100 mg (0.338 mmol) 
3 ml
0.32 ml (1.96 mmol)
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/V-Phthaloylglycyl fluoromethyl ketone from /V-phthaloylqlycyl
bromomethyl ketone
Br
O
F
O O
Materials
A/-Phthaloylglycyl bromomethyl ketone 
Chloroform
Triethylamine trishydrofluoride
100 mg (0.355 mmol) 
3 ml
0.35 ml (2.15 mmol)
Method
The same general procedure as that used to produce A/-phthaloyl-(L)- 
phenylalanyl fluoromethyl ketone was employed to yield crude A/-phthaloylglycyl 
fluoromethyl ketone as a buff coloured solid.
Complete conversion was indicated by thin layer chromatography after a 
reaction time of 28 hours (product Rf 0.53, starting material Rf 0.61, eluent 10:1 
chloroform:ethyl acetate).
Off-white crystals were obtained on recrystallisation from ethyl acetate/hexane 
(40 mg, 51% yield).
v m a x ( K B r ) / c r n ' 1  1778w (imide), 1759m (ketone C=0), 1716s (imide C=0) 
m/z 221 (M \ 4.3%), 188 (M - CH2F, 0.7), 160 (100) 
m/z 221.0485 (M+, C ^ N  0 3F requires 221.04878)
5h(200MHz CDCI3) 4.77 (2H, d, J 2.0, CH2N), 5.03 (2H, d, J 47.2, CH2F), 7.27- 
7.92 (4H, m, phth)
8F(188MHz CDCI3) -233.76 (t, 47.2)
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JV-Phthaloyl-(L)-phenylalanyl hydroxymethyl ketone from M-phthaloyl-(L)-
phenylalanyl diazomethyl ketone
CH2Ph CH2Ph
Materials
A/-Phthaloyl-(L)-phenylalanyl diazomethyl ketone 
THF
Sulfuric acid (2 M)
Method
A/-Phthaloyl-(L)-phenylalanyl diazomethyl ketone was suspended as a solid in 
aqueous sulfuric acid. Addition of THF effected partial solution and initiated gas 
evolution. The mixture was heated to boiling by which time solution was total 
and gas evolution had ceased. The mixture was then allowed to cool and 
extracted three times with a total of 90 ml diethyl ether. The combined ether 
layers were dried with magnesium sulfate, filtered and evaporated to give a 
white oily solid. This solid was dissolved in a minimal amount of ethyl acetate 
and slow precipitation effected by addition of hexane thus allowing the isolation 
of the desired compound as a white solid (310 mg, 64% yield, m.pt. 95-105°C, 
lit. 108-112°C [135]).
Found: C, 69.59; H, 4.99; N, 4.26. C18H15N 0 4 requires C, 69.90; H, 4.85; N, 
4.53%
vmax(KBr)/cm'1 3427m (OH), 1779m (imide), 1746m (ketone 0=0), 1711s (imide 
C=0)
m/z 309 (M \ 0.7%), 292 (M - OH, 0.9), 280 (0.9), 250 (100) 
m/z 309.1000 (M+, C18H15N 0 4 requires 309.10010)
0.50 g (1.57 mmol)
30 ml 
25 ml
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5h(200MHz CDGI3) 3.02 (1H, brs, OH), 3.52 (2H, d of ABq, J 14.1(AB), 5.5 and 
10.9, PhCH2), 4.39 (2H, s, CH20), 5.15 (1H, dd, J 5.5 and 10.9, CHN), 7.15 (5H, 
m, Ph), 7.69-7.82 (4H, m, phth)
5c(50MHz CDCI3) 33.5 (t, PhCH2), 57.8 (d, CHN), 66.4 (t, CH2OH), 123.7(d), 
127.1(d), 128.7(d), 128.8(d), 131.2(s), 134.4 (d), 135.8 (s), 167.5 (s, phth C=0),
204.7 (s, ketone C=0)
5h(200MHz d6-DMSO) 3.43 (2H, d of ABq, J 13.6(AB), 4.8 and 11.4, PhCH2),
4.37 (2H, d of ABq, J 18.3(AB) and 6.0, CH2OH), 5.35 (1H, dd, J 4.8 and 11.4, 
CHN), 7.19 (5H, m, Ph), 7.88 (4H, m, phth)
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A/-Phthaloyl-(L)-alanyl chloromethyl ketone from A/-phthaloyl-(L)-alanyl
diazomethyl ketone
N
Materials
A/-Phthaloyl-(L)-alanyl diazomethyl ketone c. 2.5 g (0.01 mol)
Concentrated hydrochloric acid (35% min.)
Method
Concentrated hydrochloric acid was slowly added to a neat sample of N- 
phthaloyl-(L)-alanyl diazomethyl ketone until no further gas evolution or change 
in physical properties was noted. Distilled water and diethyl ether were added to 
the reaction vessel and the whole transferred to a separatory funnel. The 
organic layer was separated, washed with saturated aqueous solutions of 
sodium carbonate and sodium chloride. Following this the organic layer was 
dried with magnesium sulfate, filtered and evaporated to give a yellow oily solid. 
Recrystallisation from diethyl ether/light petroleum yielded a clean white solid 
which, on analysis, was shown to be the desired product (c. 1g, 40% yield, m.pt. 
74-77°C).
Found: C, 57.07; H, 4.06; N, 5.42. C12H10N 0 3CI requires C, 57.25; H, 3.97; N, 
5.56%
vmax(KBr)/cnrf1 1775m (imide), 1752s (ketone C=0), 1709s (imide C=0) 
m/z 216 (M - Cl, 0.5%), 174 (M - COCH2CI, 55.7), 146 (2.2) 
m/z 253.0305 (M+, C12H10N 0 3CI requires 253.03196), m/z 251.0373 (M+, 
C12H10N 0 3CI requires 251.03491)
5h(200MHz CDCI3) 1.67 (3H, d, J 7.2, CH3), 4.20 (2H, s, CH2), 5.13 (1H, q, J 7.2, 
CHN), 7.74-7.92 (4H, m, phth)
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6c(50MHz CDCI3) 14.4 (q), 45.7 (t), 52.0 (d, CHN), 123.7 (d), 131.7 (s), 134.5 
(d), 167.5 (phth C=0), 198.0 (s, ketone C=0)
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EXPERIMENTAL PART 4: Synthesis of Sulfone Coupling Components
2(S)-[(tert-Butoxycarbonyl)amino1-3-(phenyl)propanol from N-tert- 
butoxycarbonyl-(L)-pheny)alanine
Method
A 250 ml three necked round bottom flask was equipped with a magnetic stirring 
bar and nitrogen balloon. The flask was sealed with septum caps and flame 
dried. To this vessel A/-terf-butoxycarbonyl-(L)-phenylalanine and triethylamine 
were added, predissolved in THF, and cooled to -5°C. Ethyl chloroformate was 
added dropwise via syringe resulting in the formation of a white precipitate. After 
being stirred at -5°C for 30 minutes the mixture was filtered by suction and the 
filtered solid washed with a further 40ml THF. The combined filtrates were 
added slowly to a 500ml conical flask containing a slurry of sodium borohydride 
in water at 0°C which resulted in the vigorous evolution of gas. The mixture was 
then stirred for 4 hours at 0°C before being transferred to a separatory funnel 
where extraction was carried out several times with diethyl ether giving a total 
organic volume of 1.5 L. The multiple extraction process was repeated with a 
total of 1.5 L dichloromethane. The diethyl ether and dichloromethane extracts 
were dried separately with magnesium sulfate, filtered and evaporated. A thick 
colourless oil, which solidified as a white solid on standing at room temperature,
o  CH2Ph O CH2Ph
Materials
A/-terf-Butoxycarbonyl-(L)-phenylalanine
THF
Triethylamine 
Ethyl chloroformate 
Sodium borohydride 
Water
11.25 g (42.45 mmol) 
53 ml
5.9 ml (42 mmol)
4.1 ml (43 mmol)
4.02 g (106 mmol)
53 ml
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was obtained from the diethyl ether extracts. A further small quantity of white 
solid was obtained from the dichloromethane extracts.
Recrystallisation from ethyl acetate/hexane yielded the desired compound in 
several crops which were stored in an evacuated desiccator overnight (5.54 g, 
52% yield, m.pt. 81-88°C, lit. 94-96°C11361).
Found: C, 66.96; H, 8.24; N, 5.58. C14H21N 0 3 requires C, 66.93; H, 8.37; N, 
5.58%
vmax(KBr)/crn' 1 3357br,s (OH and NH), 1686s (C=0), 1528, (carbamate) 
m/z 251 (M \ 0.4%), 220 (M - CH2OH, 3.5), 195 (6.0), 164 (12.3), 160 (45.4) 
m/z 251.1516 (M+, C14H21N 0 3 requires 251.15217)
5h(200MHz CDCI3) 1.40 (9H, s, [CH3]3C), 2.83 (2H, d, J 7, CH2Ph), 3.03 (1H, m, 
CHN), 3.58 (2H, d of ABq, J 11 (AB), 3.6 and 5.1, CH20), 4.93 (1H, br s, NH), 
7.17-7.33 (5H, m, Ph)
8c(50MHz CDCI3) 28.2 (q), 37.3 (t, CH2Ph, 53.6 (d, CHN), 63.7 (t, CH20) 79.5 (s, 
[CH3]3C), 126.3 (d), 128.4 (d), 129.2(d), 137.9 (s), 156.1 (s, C=0)
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2(S)-[(te/t-Butoxycarbonyl)amino]-3-(methyl)butanol from N-tert-
butoxycarbonyl-(L)-valine
o
tBuO tRnOtBuOH OH
O
Materials
N-tert-B utoxy ca rbony l-( L)-va I i ne 
THF
Triethylamine 
Ethyl chloroformate
6.1 ml (44 mmol)
4.2 ml (44 mmol)
9.50 g (43.7 mmol) 
54 ml
Sodium borohydride 
Water
4.14 g (109 mmol) 
50 ml
Method
The procedure used to produce 2(S)-[(te/f-butoxycarbonyl)amino]-3- 
(phenyl)propanol was employed with only small alterations in washing and 
extraction solvent volumes (THF wash 50 ml, diethyl ether extraction 1 L in total, 
dichloromethane extraction 1 L in total). The desired compound was obtained 
as a viscous oil (7.62 g, 86% yield). Analysis indicated purity and the material 
was therefore used directly in further reactions.
Found: C, 58.92; H, 10.29; N, 6.99. C10H21NO3 requires C, 59.11; H, 10.34; N, 
6.89%
Vmax(film)/cm‘1 3354br,s (OH and NH), 2968s (CH3-), 1691s (C=0), 1517s 
(carbamate)
m/z 172 (M - CH2OH, 6.0%), 160 (M - [CH3]2CH, 1.5), 130 (6.3), 116 (15,2), 87 
(6.4), 57 (100)
m/z 203.1516 (M+, Cl0H21NO3 requires 203.15217)
8h(200MHz CDCI3) 0.93 and 0.95 (3H and 3H, both d, J 6 .8 , [CH3]2CH), 1.45 
(9H, s, [CH3]3C), 1.83 (1H, m, J possible 6 .8 , CH[CH3]3), 3.28 (1H, br s, OH),
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3.42 (1H, m, CHN), 3.64 (2H, d of ABq, J 11.2(AB), 4.3 and 5.8, CH20), 4.90 
(1H, br d, J 8.1, NH)
§c(50MHz CDCI3) 18.4 and 19.3 (both q, [CH3]2CH), 28.3 (q, [CH3]3C), 29.1 (d, 
[CH3]2CH), 57.9 (d.CHN), 63.7 (t), 79.3 (s, [CH3]3C), 156.7 (s, C=0)
2(S)-[(terf-Butoxycarbonyl)amino]-4-(methyl)pentanol from N-tert-
butoxycarbonyl-(L)-leucine monohydrate
O
Y OH tBuO OH
O
' V
Materials
A/-terf-Butoxycarbonyl-(L)-leucine monohydrate 9.5 g (38 mmol) 
50 mlTHF
Triethylamine 
Ethyl chloroformate 
Sodium borohydride 
Water
5.5 ml (40 mmol) 
7.4 ml (77 mmol) 
3.60 g (95.2 mmol) 
50 ml
Method
The procedure used to produce 2(S)-[(te/f-butoxycarbonyl)amino]-3- 
(phenyl)propanol was employed with only small alterations in washing and 
extraction solvent volumes (THF wash 50 ml, diethyl ether extraction 1 L in total, 
dichloromethane extraction 1 L in total). The desired compound was obtained 
as a viscous oil (6.71 g, 81% yield). Analysis indicated purity and the material 
was therefore used directly in further reactions.
Found: C, 60.66; H, 10.45; N, 6.51. C11H23N 0 3 requires C, 60.82; H, 10.59; N, 
6.45%
vmax(film)/cm' 1 3350br,s (OH and NH), 2958s (CH3-), 1692s (0=0), 1524s 
(carbamate)
m/z 186 (M - CH2OH, 4.8), 160 (M - [CH3]2CHCH2 or M - [CH3]3C, 0.3), 144 (4.8), 
101(1.3)
m/z 217.1698 (M+, H23 N 0 3 requires 217.16776)
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5h(200MHz CDCI3) 0.93 (6 H, d, J 6.5, [CH3]2CH), 1.32 (2H, m, CH2CH[CH3]2), 
1.45 (9H, s, [CH3]3C)f 1.67 (1H, m, CH[CH3]2), 3.46-3.78 (3H, m, CH20  and 
CHN), 4.80 (1H, brd, J 7.5, NH)
5c(50MHz CDCI3) 22.1 and 23.0 (both q, [CH3]2CH), 24.7 (d, CH[CH3]2), 28.3 (q, 
[CH3]3C), 40.5 (t, CH2CH[CH3]), 50.8 (d, CHN), 66.1 (t, CH20), 79.4 (s, [CH3]3C),
156.5 (s, C=0)
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2(S)-[(te/t-Butoxycarbonyl)amino]-1-[(methylsulfonyl)oxy1-3- 
(phenyl)propane from 2(S)-[(teft-butoxycarbonyl)amino]-3-
(phenyl)propanol
tBuO
O CH2Ph O CH2Ph
Materials
2(S)-[(ferf-Butoxycarbonyl)amino]-3-(phenyl)propanol
20.00 g (0.0797 mmol)
Method
A 1 L three necked round bottom flask was equipped with a magnetic stirring bar 
and nirogen balloon, sealed with septum caps and flame dried. To this 2(S)- 
[(terf-butoxycarbonyl)amino]-3-(phenyl)propanol was added predissolved in 
dichloromethane. Triethylamine was added with stirring and the mixture taken to 
0°C where methanesulfonyl chloride was added dropwise. The resulting yellow 
solution was stirred at 0°C for a further 25 minutes before being quenched by 
the addition of 300 ml water. The mixture was transferred to a separatory funnel 
where the organic layer was separated and the aqueous layer extracted several 
times with dichloromethane. The combined organic layers were dried with 
magnesium sulfate, filtered and evaporated to give a yellow solid. 
Recrystallisation from ethyl acetate/hexane yielded the desired compound in 
several crops (25.17 g, 96% yield, m.pt. 110-112°C). The material was stored at 
0°C in a sealed vessel flushed with nitrogen.
Vmax(CHCI3 )/cm- 1 3441m (NH), 3028s (CH3-), 1709s (C=0), 1500s (carbamate), 
1366s (-SO2-O-)
m/z 273 (M - [CH3]2C=CH2, 1.6%), 257 (M - [CH3]3CO, 0.3), 178 (2.6) 
m/z 273.0670 (M - [CH3]2C=CH2> C ^ H ^ O s S ! requires 273.0671)
Dichloromethane 
Triethylamine 
Methanesulfonyl chloride
500 ml
32 ml (0.23 mol) 
15 ml (0.19 mol)
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5h(200MHz CDCI3) 1.41 (9H, s, [CH3]3C), 2.86 (2H, m, CH2Ph), 3.02 (3H, s, 
S02CH3), 4.13 (2H, m, CH20), 4.23 (1H, m, CHN), 4.89 (1H, br d, J 7.2, NH), 
7.20-7.36 (5H, m, Ph)
5c(50MHz CDCI3) 28.2 (q, [CH3]3C), 37.2 (q, S02CH2), 46.1 (t, CH2Ph, 50.8 (d, 
CHN), 69.8 (t, CH20), 79.9 (s, [CH3]3C), 126.9 (d), 128.7 (d), 129.2 (d), 136.6 
(s), 155.0 (s, C=0)
2(SH(terf-Butoxycarbonyl)amino]-3-methyM-[(methylsulfonyl)oxy]butane
from 2(S)-[(tert-butoxycarbonyl)amino]-3-(methyl)butanol
OH To .NIT OSO2CH3
Materials
2(S)-[(te/f-Butoxycarbonyl)amino]-3-(methyl)butanol
Dichloromethane
Triethylamine
Methanesulfonyl chloride
20.05 g (0.099 mol) 
700 ml
42 ml (0.30 mol)
19 ml (0.26 mol)
Method
The general procedure to 2(S)-[(terf-butoxycarbonyl)amino]-1- 
[(methylsulfonyl)oxy]-3-(phenyl)propane was repeated giving crude 2(S)-[(terf- 
butoxycarbonyl)amino]-3-methyl-1-[(methylsulfonyl)oxy]butane as a yellow solid. 
Recrystallisation was performed from dichloromethane/hexane yielding the 
desired product in two crops (27.11 g, 97% yield, m.pt. 64-66°C).
vmax(KBr)/crn' 1 3396s (NH), 2978m (CH3-), 1686s (C=0), 1519s (carbamate), 
1377s (-SO2-O-)
m/z 281 (M+, 0.1%), 266 (M - CH3, 0.7), 238 (4.8), 208 (4.8), 172 (19.6), 116 
(47.3)
m/z 266.1071 (M - CH3, C10H20N 0 5S requires 266.10622)
5h(200MHz CDCI3) 0.96 (3H, d, J 6 .8 , [CH3][CH3]CH), 0.99 (3H, d, J 6.7, 
[CH3][CH3]CH,) 1.45 (9H, s, [CH3]3C), 1.85 (1H, m, [CH3]2CH), 3.04 (3H, s ,
NH)
8c(50MHz CDCI3) 18.3 and 19.2 (both q, [CH3]2CH), 28.2 (q, [CH3]3C), 28.2 (d, 
[CH3]2CH), 37.2 (q, S02CH3), 54.7 (d, CHN), 69.7 (t, CH20), 79.5 (s, [CH3]3C),
155.5 (s,C=0)
S02CH3), 3.63 (1H, m, CHN), 4.27 (2H, d, J 4.4, CH20), 4.79 (1H, br d, J 9.1,
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2(S)-[(fert-Butoxycarbonyl)amino]-4-methyl-1 -[(methylsulfonyl)oxy]pentane 
from 2(S)-[(teft-butoxycarbonyl)amino]-4-(methy))pentanol
tBuO. ..N H .J  OH  ► y  0SO2CH3
o
Materials
r
2(S)-[(terf-Butoxycarbonyl)amino]-4-(methyl)pentanol 5.01 g (23.1 mmol)
Dichloromethane 165 ml
Triethylamine 9.6 ml (69 mmol)
Methanesulfonyl chloride 4.4 ml (57 mmol)
Method
The general procedure to 2(S)-[(terf-butoxycarbonyl)amino]-1- 
[(methylsulfonyl)oxy]-3-(phenyl)propane was repeated giving crude 2(S)-[(terf- 
butoxycarbonyl)amino]-4-methyl-1-[(methylsulfonyl)oxy]pentane as yellow oil. 
Slow recrystallisation was achieved upon storage of a saturated 1:9 ethyl 
acetate:hexane solution of this material at 0°C. The desired product was 
obtained in two crops (5.90 g, 87% yield, m.pt. 74-76°C).
Found: C, 48.56; H, 8.57; N, 4.74. C12H25N 0 5S requires C, 48.81; H, 8.47; N, 
4.74%
vmax(KBr)/cm' 1 3384 (NH), 2978 (CH3-), 1659 (C=0), 1521 (carbamate), 1369 (- 
S02-0-)
m/z 280 (M - CH3, 0.1%), 238 (M - [CH3]2CHCH2 or M - [CH3]C, 0.1), 222 (1.1), 
186(5.6), 116(0.5)
m/z 295.1428 (M+, C12H25N OsS requires 295.14534)
5h(200MHz CDCI3) 0.93 (3H, d, J 6.5, [CH3][CH3]CH), 0.94 (3H, d, J 6 .6 , 
[CH3][CH3]CH), 1.32-1.53 (2H, m, CHCH2CH), 1.44 (9H, s, [CH3]3C), 1.67 (1H, 
m, [CH3]2CH], 3.04 (3H, s, S02CH3), 3.92 (1H, m, CHN), 4.21 (2H, d of ABq, J 
9.9(AB), 3.7 and 4.0, CH20), 4.68 (1H, br d, J 8.3, NH)
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8c(50MHz CDCI3 ) 21.9 and 22.8 (both q, [CH3]2CH), 24.5 (d, [CH3]2CH), 28.2 (q, 
[CH3]C), 37.1 (q, S02CH3), 39.9 (CHCH2CH), 47.7 (d, CHN), 71.6 (t, CH20),
79.6 (s, [CH3]C), 155.2 (s, C=0)
2(S)-[(fert-Butoxycarbonyl)amino]“3-phenyl-1-(phenylthio)propane from
2(S)-[(te/t-butoxycarbonyl)amino]-1-[(methylsulfonyl)oxy1-3-
(phenyl)propane
tBuO.  .NH
OSO2CH3
O CH2Ph O CH2Ph
Materials
2(S)-[(terf-Butoxycarbonyl)amino]-1-[(methylsulfonyl)oxy]-3-(phenyl)propane
5.09 g (0.0155 mol)
Method
A 250 ml three necked round bottom flask was equipped with a magnetic stirring 
bar and a water condenser topped with a nitrogen balloon. The vessel was 
sealed with septum caps and flame dried. The vessel was temporarily opened 
to admit sodium pieces under a flow of nitrogen. By syringe, THF was added 
and the condenser water flow initiated. Methanol was added slowly, with stirring, 
resulting in heat generation. Once no traces of solid sodium remained, 
thiophenol was added rapidly and the mildly yellow solution stirred for 15 
minutes at 25°C. The reaction vessel was opened to admit 2(S)-[(tert- 
butoxycarbonyl)amino]-1-[(methylsulfonyl)oxy]-3-(phenyl)propane as a solid, 
then purged with nitrogen and resealed. Continual nitrogen flow during addition 
was not employed as the starting solid was very light in nature. The reaction 
was stirred at 50°C for 2.5 hours then overnight at room temperature. After 
being diluted with 10% aqueous sodium hydroxide (100 ml), the mixture was 
transferred to a separatory funnel where extraction with dichloromethane was 
carried out several times. The combined organic layers were washed with brine, 
dried with magnesium sulfate, filtered and evaporated to give a yellow oil which 
slowly solidified on standing. This solid was recrystallised thermally from 1:9
Sodium 1.14 g (0.0496 mol)
9.4 ml (0.23 mol)
5.4 ml (0.053 mol) 
37 ml
Methanol
Thiophenol
THF
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ethyl acetate:hexane to give the desired product as a white solid in several crops 
(4.50 g, 85% yield, m.pt. 81-84°C, Rf 0.88 eluent 1:1 ethyl acetate:hexane).
Found: C, 69.87; H, 7.46; N, 3.92; S, 9.15. C20H25N 0 2S requires C, 69.97; H, 
7.29; N, 4.08; S, 9.33%
v max(KBr)/cm'1 3374 (NH), 1694s (C=0), 1526s (carbam ate)
m/z 343 (M+, 4.8%), 287 (0.4), 270 (4.9), 252 (18.0), 220 (6.0), 109 (17.9), 77
(13.0) 91 (53.5), 57 (100), 56 (4.2)
m/z 343.1596 (M+, C20H25N 0 2S requires 343.16060)
5h(200MHz CDCI3) 1.39 (9H, s, [CH3]3C), 2.91 (2H, d, J 6.7, CH2Ph), 3.03 (2H, 
d, J 5.6, CH2S), 4.04 (1H, m, CHN), 4.67 (1H, brd, NH), 7.15-7.37 (10H, m, Ph 
and SPh)
8c(50MHz CDCI3) 28.2 (q, [CH3]3C, 37.6 and 39.4 (both t, CH2S and CH2Ph) ,
51.2 (d, CHN), 79.3 (s, [CH3]3C), 126.2 (d), 126.5 (d), 128.4 (d), 128.9 (d), 129.3 
(d), 129.5 (d), 136.0 (s), 137.4 (s), 155.0 (s, C=0)
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2(S)-[(teff-Butoxycarbonyl)amino]-3-methy 1-1 -(phenylthio)butane from 2(S)- 
[(ferf-butoxycarbonyl)amino]-3-methyl-1-[(methylsulfonyl)oxy]butane
tB uO ^ .N H . tD r>. XTt j
Y  ^ ^ OS° 2CH3  „ *Bu° Y NH^ S P h
Materials
2(S)-[(ferf-Butoxycarbonyl)amino]-3-methyl-1-[(methylsulfonyl)oxy]butane
6 .2g (22.1 mmol)
Sodium 1.61g (70.0 mmol)
Methanol 18ml (0.45 mol)
Thiophenol 7.46ml (72.7 mmol)
THF 53ml + 40ml
Method
The procedure employed to produce 2(S)-[(fe/f-butoxycarbonyl)amino]-3-phenyl- 
1-(phenylthio)propane was repeated using 2(S)-[(terf-butoxycarbonyl)amino]-3- 
methyl-1-[(methylsulfonyl)oxy]butane as a starting material. In this case an extra 
40 ml THF was added to the reaction vessel shortly after the starting material to 
alleviate stirring problems caused by the consistency of the mixture.
2(S)-[(terf-Butoxycarbonyl)amino]-3-methyM-(phenylthio)butane was produced 
as a golden oil which solidified on standing. This material was initially 
precipitated from hot 1:9 dichloromethane:hexane as a white solid (5.84 g, 90% 
yield) and used without further purification as recrystallisation was not achieved. 
A small amount (0.50 g) of material was loaded onto a short column of silica gel 
and washed with 7x15 ml 6:4 dichloromethane:hexane in order to remove the 
impurity (Rf 0.73 with 6:4 dichloromethane:hexane as eluent and 0.85 with pure 
dichloromethane). Flushing the column with 150ml dichloromethane then 
allowed the isolation of a highly pure sample of the desired product (0.45 g, 90% 
column yield, m.pt. 65-67°C, Rf 0.27, eluent 6:4 dichloromethane:hexane, and 
Rf 0.33, eluent dichloromethane).
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Found: C, 64.96; H, 8 .6 8 ; N, 4.65. C16H25N 0 2S requires C, 64.86; H, 8.78; N, 
4.72%
vmax(KBr)/crn’1 3302s (NH), 2974s (CH3-), 1692s (C=0), 1576s (carbamate) 
m/z 295 (M+, 6.4%), 218 (M - Ph, 7.1), 186 (0.5), 179 (3.8), 172 (19.9), 123 
(31.5), 116(52.1)
m/z 295.1594 (M+, C16H25N 0 2S requires 295.16063)
8h(200MHz CDCI3) 0.89 (3H, d, J 6.7, [CH3][CH3]CH), 0.92 (3H, d, J 6.7, 
[CH3][CH3]CH), 1.43 (9H, s, [CH3]3C), 1.92 (1H, m, [CH3]2CH), 3.07 (2H, d, J 5.7, 
CH2), 3.64 (1H, m, CHN), 4.59 (1H, br d, J 9.4, NH), 7.34 (5H, m, Ph)
8c(50MHz CDCI3) 17.7 and 19.3 (both q, [CH3]2CH), 28.2 (q, [CH3]3C), 30.7 (d, 
[CH3]2CH), 37.2 (t, CH2S), 55.0 (d, CHN), 78.9 (s, [CH3]C), 126.0 (d), 129.8 (d), 
129.4 (d), 136.3 (s), 155.5 (s, C=0)
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2(S)-[(teff-Butoxycarbonyl)amino]-4-(methyl)-1-(phenylthio)pentane from 
2(S)-[(teff-butoxycarbonyl)amino]-4-methyl-1-[(methylsulfonyl)oxy]pentane
Materials
2(S)-[(ferf-Butoxycarbonyl)amino]-4-methyl-1-[(methylsulfonyl)oxy]pentane
5.89 g (20.0 mmol)
Method
The procedure utilised to produce 2(S)-[(terf-butoxycarbonyl)amino]-3-phenyl-1- 
(phenylthio)propane was repeated to give 2(S)-[(terf-butoxycarbonyl)amino]-4- 
(methyl)-1-(phenylthio)pentane as a thick yellow oil.
The short column procedure used to purify 2(S)-[(te/'f-butoxycarbonyl)amino]-3- 
methyl-1-(phenylthio)butane was employed here to obtain a highly pure sample 
of 2(S)-[(fe/f-butoxycarbonyl)amino]-4-(methyl)-1-(phenylthio)pentane as a clear 
colourless oil (2.51 g, 41% yield, Rf 0.27 (product), 0.76 (by-product), eluent 6:4 
dichloromethane:hexane and Rf 0.41 (product), 0.85 (by-product), eluent pure 
dichloromethane).
Found: C, 66.08; H, 8.92; N, 4.44. C17H27N 0 2S requires C, 66.02; H, 8.74; N, 
4.53%
Vmax(KBr)/crn‘1 3348m (NH), 2957s (CH3-), 1698s (C=0), 1584s (carbamate) 
m/z 309 (M+, 8.1%), 252 (M - [CH3]2CHCH2 or M - [CH3]3C, 0.5), 236 (3.4), 208 
(0.6), 193 (6.1), 186 (21.2)
m/z 309.1744 (M+, C17H27N 0 2S requires 309.17626)
OS02CH3
Sodium 1.46 g (63.5 mmol) 
22 ml (0.53 mol) 
6.8 ml (66.2  mmol) 
48 ml
Methanol
Thiophenol
THF
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5h(200MHz CDCI3) 0.86 (3H, d, J 6.2, [CH3][CH3]CH), 0.90 (3H, d, J 6.4, 
[CH3][CH3]CH), 1.41 (2H, m, CHCH2CH) 1.41 (9H, s, [CH3]3C), 1.62 (1H, m, 
[CH3]2CH), 3.08 (2H, d, J 4.6, CH2S), 3.90 (1H, m, CHN), 4.56 (1H, br d, J 8 .8 , 
NH), 7.26 (5H, m, Ph)
8c(50MHz CDCI3) 22.0 and 22.9 (both q, [CH3]2CH), 22.9 (d, [CH3]2CH), 28.2 (q, 
[CH3]3C), 39.6 (t, [CH3]2CHCH2), 42.8 (t, CH2S), 48.2 (d, CHN), 79.0 (s, [CH3]C),
125.9 (d), 128.0 (d), 129.0 (d), 136.3 (s), 155.1 (s, C=0)
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2(SH(feff-Butoxycarbonyl)amino]-3-phenyl-1-(phenylsulfonyl)pentane from 
2(S)-[(feff-butoxycarbonyl)amino]-3-phenyl-1-(phenylthio)propane
Materials
2(S)-[(ferf-Butoxycarbonyl)amino]-3-phenyl-1-(phenylthio)propane
1.00 g (2.92 mmol)
Method
In a 100 ml round bottom flask equipped with a magnetic stirrer, 2(S)-[(fe/t- 
butoxycarbonyl)amino]-3-phenyl-1-(phenylthio)propane was placed and 
dissolved in dichloromethane. The solution was taken to 0°C where 3- 
chloroperoxybenzoic acid was added as a solid with stirring. The resulting slurry 
was stirred for 1 hour at room temperature before being transferred to a 
separatory funnel where it was shaken carefully with a saturated aqueous 
solution of sodium bisulfite. After being allowed to stand for 1 hour and 20 
minutes the aqueous layer was removed and the organic layer washed several 
times with a total of 70 ml 10% sodium hydroxide aqueous solution. The 
dichloromethane layer was removed and the combined sodium hydroxide 
washings extracted with a further 75 ml dichloromethane. The combined organic 
layers were washed with a saturated aqueous solution of sodium chloride, dried 
with magnesium sulfate and filtered. Evaporation of the resulting 
dichloromethane solution gave a white solid which was slowly recrystallised from 
hot 1:1 ethyl acetate:hexane giving the desired product in two crops (0.99 g,
90% yield, m.pt. 204-206°C, lit. 215-216“C I751, Rf 0.13 eluent 100% 
dichloromethane).
t H 2Ph
S 0 2Ph
CH2Ph
Dichloromethane
3-Chloroperoxybenzoic acid (57-86%)
22.5 ml
1.61 g (min. 5.32 mmol)
[<x]D22 -25.95 (5.5 mg/1 ml DMSO) lit. -32.7 (5.2 mg/1 ml DMSO at 20°C) 1751
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Found: C, 64.07; H, 6.69; N, 3.62; S, 8.25. C20H25NO4S requires C, 64.00; H, 
6 .6 6 ; N, 3.73; S, 8.53%
vmax(KBr)/cm' 1 3383s (NH), 1693s (C=0), 1521s (carbamate)
m/z 319 (M - [CH3]2[CH2]C, 1.0), 284 (M - PhCH2, 7.6), 141 (M - PhS02,141)
m/z 319.0869 (M+, C16H17N 0 4S requires 319.08780)
5h(200MHz CDCI3) 1.38 (9H, s, [CH3]3C), 2.99 (2H, d of ABq, J 13.5(AB), 6.4 and 
7.2, CH2Ph), 3.34 (1H d of ABq, J 14.4(AB), 4.7 and 7.4, CH2S02), 4.11 (1H, m, 
CHN), 4.90 (1H, br s, NH), 7.13-7.90 (10H, m, Ph and SPh)
8h(200MHz d6-DMSO) 1.19 (9H, s, [CH3]3C), 2.75 (2H, m, CH2Ph), 3.44 (2H, d of 
ABq, J 14.7(AB), 3.8 and 8.5, CH2S02), 4.03 (1H, m, CHN), 7.09-7.87 (10H, m, 
Ph and SPh)
5c(50MHz d6-DMSO) 28.1 (q, [CH3]3C), 40.3 (t, CH2Ph), 47.6 (d, CHN), 58.2 (t, 
CH2S02), 77.7 (s, [CH3]3C), 126.3(d), 127.8 (d), 128.2 (d), 129.2 (d), 129.3 (d),
133.7 (d), 137.7 (s), 139.5 (s), 154.3 (s, C=0)
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2(S)-[(te/f-Butoxycarbonyl)amino]-3-methyl-1-(phenylsulfonyl)butane from 
2(S)-[(tert-butoxycarbonyl)amino]-3-methyl-1-(phenylthio)butane
Materials
2(S)-[(terf-Butoxycarbonyl)amino]-3-methyl-1-(phenylthio)butane
23.1 g (78.3 mmol)
Method
The procedure employed to form 2(S)-[(te/f-butoxycarbonyl)amino]-3-phenyl-1- 
(phenylsulfonyl)pentane was repeated to give a white solid. Initial 
recrystallisation from 1:2 ethyl acetate:hexane yielded a white solid which was 
shown to contain mainly 3-chlorobenzoic acid. The mother liquors were 
therefore washed with further quantities of 10% sodium hydroxide aqueous 
solution. Separation of the organic layer was followed by extraction of the 
aqueous layer with dichloromethane. The combined organic layers were dried 
with magnesium sulfate, filtered and evaporated to give an off-white solid. 
Recrystallisation was initiated by dissolving the material in hot 1:2 ethyl 
acetate:hexane and slowly adding further hexane to the cooled solution. The 
desired product was isolated in this way in two crops (18.9 g, 74% yield, m.pt. 
108-110°C, lit. 103-105°C[75]).
[a]D22 +9.2 (23 mg/1 ml CHCI3) lit. +11.02 (23 mg/ml DMSO at 20°C)[75]
Found: C, 58.63; H, 7.78; N, 4.13. C16H25N 0 4S requires C, 58.71; H, 7.64; N, 
4.28%
v m a x (K B r)/c rn '1 3388m (NH), 2970m (CH3-), 1688s (C=0), 1576s (carbamate) 
m/z 284 (M - [CH]2CH, 7.0%), 250 (M - Ph, 0.2), 223 (0.2), 186 (3.2), 141 (12.1) 
m/z 284.0944 (M - [CH]2CH, C13H18N S 0 4 requires 284.09565)
tBuO
S 0 2Ph
Dichloromethane
3-Chloroperoxybenzoic acid (57-86%)
600 ml
43.22 g (min. 142.8 mmol)
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5h(200MHz CDCI3) 0.86 (3H, d, J 6.3, [CH3][CH3]CH), 0.89 (3H, d, J 6.1, 
[CH3][CH3]CH), 1.42 (9H, s, [CH3]3C), 2.01 (1H, m, [CH3]2CH), 3.27 (2H, d of 
ABq, J 14.5(AB), 8.6 and 2.7, CH2), 3.80 (1H, m, CHN), 4.75 (1H, br d, J 8.7, 
NH), 7.74 (5H, m, Ph)
6c(50MHz CDCI3 ) 17.6 and 18.6 (both q, [CH3]2CH), 28.1 (q, [CH3]3C), 31.9 (d, 
[CH3]2CH), 51.6 (d, CHN), 57.3 (t, CH2S02), 79.1 (s, [CH3]C), 127.8 (d), 129.0 
(d), 133.5 (d), 139.2 (s), 155.0 (s, C=0)
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2(S)-r(te/t-Butoxycarbonyl)amino]-4-methyl-1-(phenylsulfonyl)pentane from 
2IS)-r(te/f-butQxycarbonyl)amino]-4-(methyl)-1-(phenvlthio)pentane
tBuO NH
SPh
tBuO NH
Materials
2(S)-[(ferf-Butoxycarbonyl)amino]-4-(methyl)-1-(phenylthio)pentane
2.1 g (6.80 mmol) 
Dichloromethane 53 ml
3-Chloroperoxybenzoic acid (57-86%) 3.73 g (min. 12.3 mmol)
Method
The general procedure employed to produce 2(S)-[(terf-butoxycarbonyl)amino]- 
3-phenyl-1-(phenylsulfonyl)pentane was repeated to give a white solid (1.94 g, 
84% crude yield). A small quantity (0.50 g) of this was purified by slow 
recrystallisation from hot 1:9 ethyl acetate:hexane for full analysis which 
confirmed the product identity as being the desired material (0.46 g, 92% 
recrystallisation yield, m.pt. 95-97°C, lit. 95-98°C [75]).
[ct]D22 -9.65 (24 mg/1 ml CHCI3) lit. -9.87 (24 mg/1 ml CHCI3 at 20°C)[75]
Found: C, 59.67; H, 7.98; N, 4.01. C17H27N 04S requires C, 59.82; H, 7.92; N, 
4.10%
v m a x ( K B r ) / c r n ' 1 3387m (NH), 2974m (CH3-), 1689s (C=0), 1588s (carbamate) 
m/z 284 (M - [CH3]2CHCH2 or M - [CH3]3C, 1.6%), 268 (M - [CH3]3CO, 1.2), 240 
(1.1), 225(0.5), 186(2.6)
m/z 341.1660 (M+, C17H27N 0 4S requires 341.16660)
5h(200MHz CDCI3) 0.88 (6 H, d, J 6.1, [CH3]2CH), 1.40 (9H, s, [CH3]3C), 1.59 
(3H, m, CHCH2CH) and [CH3]2CH), 3.35 (2H, d of ABq, J 14.3(AB), 6.2 and 4.5, 
CH2S), 4.00 (1H, m, CHN), 4.86 (1H, br d, J 8.1, NH), 7.79 (5H, m, Ph)
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5c(50MHz CDCI3 ) 21.7 and 22.6 (both q, [CH3 ]2 CH), 24.6 (d, [CH3 ]2 CH), 28.2 (q, 
[CHJ3 C), 43.1 (t, [CHakCHCHs), 45.5 (d, CHti), 59.6 (t, CH2 S 02), 78.4 (s, 
[CH3 ]C), 127.7 (d), 129.2 (d), 133.6 (d), 139.9 (s), 154.8 (s, C=0)
EXPERIMENTAL PART 5: Synthesis of Aldehyde Coupling Components 
Methyl 3-[(2-tetrahydropyranyl)oxy]-2(S)-methylpropionate from (S)-methyl-
3-hydroxy-2-methyl propionate
c h 3o o c ^ ^ o ^ o
Ch 3 c h 3
Materials
(S)-Methyl-3-hydroxy-2-methylpropionate
3,4-Dihydropyran
Dichloromethane
Pyridinium p-toluenesulfonate
3.80 g (32.2 mmol) 
3.54 g (42.1 mmol) 
50 ml
0.16 g (0.64 mmol)
Method
(S)-Methyl-3-hydroxy-2-methylpropionate and 3,4-dihydropyran were weighed 
directly into a 250 ml round bottom flask, dissolved in dichloromethane and a 
magnetic stirring bar added. The vessel was immersed in a water bath held at 
approximately 25°C, stirring initiated and pyridinium p-toluenesulfonate added as 
a solid. After being stirred for 3 hours at this temperature the water bath was 
removed and stirring continued for a further 1 hour and 20 minutes. With the aid 
of a little additional dichloromethane the solution was transferred to a separatory 
funnel. In this vessel the solution was washed sequentially with saturated 
aqueous solutions of sodium bicarbonate and sodium chloride. Following this 
the organic layer was dried with magnesium sulfate, filtered and evaporated 
yielding a clear colourless oil (6.51 g, 100% yield).
Found: C, 59.26; H, 8.71. C10H18O4 requires C, 59.40; H, 8.91% 
vmax(film)/crn’1 2945s (CH3- and -CH2-), 2876m (O-CH-O), 1742s (C=0) 
m/z 202 (M+, 0.1%), 187 (M - CH3,0.5), 171 (0.4), 117 (0.8), 85 (100) 
m/z 202.1194 (M+, C10H18O4 requires 202.1251)
201
8h(200MHz CDCI3) 1.19 and 1.20 (3H, both d, J 7.1, ratio 1:1, CHCH3), 1.47-
1.83 (6 H, m, J possible 7.1, CH2CH2CH2), 2.77 (1H, m, CHCH3), 3.40-3.96 (4H, 
m, 2xCH20), 3.70 (3H, 2xs, OCH3), 4.61 (1H, m, OCHO)
5c(50MHz CDCI3) 13.6 (q, CHCH3, 18.9 and 19.1 (t, CH2CH2CH2), 25.2 (t, 
CH2CH2CH2), 30.2 and 30.3 (t, CH2CH2CH2), 39.8 and 40.0 (d, CHCH3), 51.4 (q, 
OCH3), 61.5 and 61.8 (t, OCH2), 68.8 and 69.1 (t, OCH2), 98.1 and 98.6 (d, 
OCHO), 175.1 (s, C=0)
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1 -[(2-Tetrahydropyranyl)oxy]-(c/s)-3-hexene from (c/s)-3-hexen-1 -ol
Materials
10.08 g (0.101 mol)
11.09 g (0.132 mol)
140 ml
0.49 g (1.95 mmol)
Method
The general procedure employed to produce methyl 3-[(2- 
tetrahydropyranyl)oxy]-2(S)-methylpropionate was repeated to give 1 -[(2- 
tetrahydropyranyl)oxy]-(c/s)-3-hexene as a clear colourless oil (17.56 g, 94% 
yield).
Found: C, 71.82; H, 10.82. C ^ c A  requires C, 71.74; H, 10.87%
Vmax(film)/crn' 1 2942s (CH3- and -CH2-), 2872s (O-CH-O), 1652w (C=C) 
m/z 184 (M+, 0.1%), 155 (M - CH3CH2j 0.1), 115(3.6), 101 (8.3), 100 (1.1), 99 
(0.4), 85 (100), 84 (3.7), 83 (12.5) 
m/z 184.1466 (M+, Cu H20O2 requires 184.14630)
5h(200MHz CDCI3) 0.96 (3H, t, J 7.4, CH3CH2), 1.47-1.85 (6 H;, m, CH2CH2CH2),
2.07 (2H, quin, J 7.4, CH3CH2), 2.35 (2H, q, J 6.7, CHCH2CH20), 3.88-3.34 (4H, 
m, 2xCH20) 4.60 (1H, br t, J 3.4, OCHO), 5.29-5.61 (2H, m, CHCH)
6c(50MHz CDCI3) 14.2 (q), 19.5 (t), 20.5 (t), 25.4 (t), 27.7 (t), 30.6 (t), 62.1 (t, 
CH20), 67.0 (t, CH20), 98.6 (d, OCHO), 124.8 and 133.5 (both d, CH=CH)
(c/s)-3-Hexen-1-ol 
Dihydropyran 
Dichloromethane 
Pyridinium p-toluenesulfonate
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2(S)-Methyl-3-[(2-tetrahydropyranyl)oxy]propionaldehyde from methyl 3-[(2- 
tetrahydropyranyl)oxy]-2(S)-methylpropionate
OHC.
0  0  ** 'O ' "O'
C H 3 Ch3
Materials
Methyl 3-[(2-tetrahydropyranyl)oxy]-2(S)-methylpropionate 1.01 g (5.00 mmol)
Dichloromethane 18 ml
Diisobutylaluminium hydride (1.0 M in hexane) 5.3 ml (5.3 mmol)
Method
A 50 ml round bottom flask with a side arm was equipped with a magnetic 
stirring bar and nitrogen balloon. After being flame dried the vessel was charged 
with methyl 3-[(2-tetrahydropyranyl)oxy]-2(S)-methylpropionate predissolved in 
dichloromethane. The vessel and its contents were taken to -78°C where 
diisobutylaluminium hydride was added dropwise, with stirring, via syringe. 
Stirring was continued at -78°C for a further 10 minutes after which the reaction 
was quenched at this temperature by the addition of saturated aqueous 
ammonium chloride. The mixture was allowed to warm to room temperature 
where it was filtered with the aid of a little additional dichloromethane and 
saturated aqueous ammonium chloride. The filtrate was transferred to a 
separatory funnel where the organic layer was separated and washed with 
saturated aqueous sodium chloride. The organic layer was then dried with 
magnesium sulfate, filtered and evaporated to give a clear colourless oil (0.80 g, 
93% crude yield). This material was of sufficient purity to be used directly in 
further reactions. Small amounts of highly pure material could be produced by 
short path distillation (b.pt. 45°C/0.4 mm Hg).
This material was shown to slowly oxidise in air at room temperature to the 
corresponding carboxylic acid. When stored under nitrogen at 0°C this process 
could be prevented.
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vmax(film)/cm' 1 2942s (CH3- and -CH2-), 2873s (O-CH-O), 2728w (aldehyde CH), 
1727s (C=0)
m/z 172 (M+, 0.2%), 153, (M - CH3, 0.1) 143 (0.2), 101 (21.8), 85 (100) 
§h(200MHz CDCI3) 1.14 and 1.15 (3H, 2xd, J 7.1, ratio 1:1, CH3CH), 1.51-1.83 
(6 H, m, CH2CH2CH2), 2.68 (1H, m, CH3CH), 3.48-3.65 and 3.78-4.01 (4H, m, 
2xCH20), 4.62 (1H, m, OCHO), 9.75 (1H, m, CHO)
8c(50MHz CDCI3) 10.5 and 10.5 (q), 18.9 and 19.1 (t, CH2CH2CH2), 25.2 and
25.3 (t, CH2CH2CH2), 30.2 and 30.4 (t, CH2CH2CH2), 46.4 and 46.5 (d, CHCH3),
61.8 and 61.9 (t, CH20), 67.0 and 67.3 (t, CH20), 98.4 and 98.9 (d, OCHO),
203.6 and 203.7 (d, C=0)
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3-[(2-Tetrahydropyranyl)oxy1propionaldehyde from 1-[(2- 
tetrahydropyranyl)oxy]-(c/s)-3-hexene
Materials
1 -[(2-Tetrahydropyranyl)oxy]-(c/s)-3-hexene 11.82 g (6.42 mmol)
Dichloromethane 150 ml
Ozone
Triethylamine 17 ml (122 mmol)
Method
In a 250 ml round bottom flask equipped with a magnetic stirring bar, 1-[(2- 
tetrahydropyranyl)oxy]-(c/s)-3-hexene was placed and dissolved in 
dichloromethane. The solution was cooled to -78°C and a steady stream of 
ozone bubbled through until a mild blue colouration was observed (c. 3 hours). 
After the system was purged with nitrogen triethylamine was added to the blue 
solution at -78°C with stirring. The resulting colourless solution was allowed to 
warm to room temperature where it was flushed with nitrogen, sealed with a 
nitrogen balloon and stirred overnight. With the aid of additional 
dichloromethane the solution, which was now slightly yellow in colouration, was 
washed through a pad of silica and evaporated giving a cloudy yellow oil (13.51 
g, main product Rf 0.60, eluent 100% ethyl acetate). This material was 
adsorbed onto a short column of silica and eluted with ethyl acetate. The 
appropriate ethyl acetate fractions were combined, dried with magnesium 
sulfate, filtered and evaporated giving a clear golden liquid (7.75 g, 76% crude 
yield).
This material was used directly in further reactions as triethylamine was 
identified by 1H NMR spectroscopy as being the main impurity. For full analysis
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a small quantity (0.55 g) was purified by short path distillation (40°C, 0.3 mm Hg) 
giving 0.20  g of the desired product.
vmax(film)/crn' 1 2944s (-CH2-), 2874m (O-CH-O), 1728s (C=0)
m/z 157 (M - H, 1.2%), 101 (41.1), 85 (100)
m/z 157.0878 (M - H, C8H130 3 requires 157.08644)
5h(200MHz CDCI3) 1.51-1.95 (6 H, m, CH2CH2CH2), 2.70 (2H, dt, J 1.9(d) and 
6.0(t), CH2CHO), 3.47-3.58 and 3.71-3.90 and 4.04-4.15 (4H, m, 2xCH20), 4.63 
(1H, m, OCHO), 9.82 (1H, t, J 1.9, CHO)
8c(50MHz CDCI3) 19.2 (t, CH2CH2CH2), 25.2 (t, CH2CH2CH2), 30.3 (t, 
CH2CH2CH2), 43.7 (t, CH2CHO), 61.0 and 62.1 (both t, 2xCH20 ) , 98.6 (d, 
OCHO), 201.3 (s,C=0)
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(±) 2-Methyl-frans-3-pentenoic acid from trans-3-pentenoic acid
o o
^ A OH ^ A , OH
Materials
Diisopropylamine
/7-Butyl lithium (1.47 M in hexane)
Methyl iodide
1.7 ml
7.9 ml (11.6 mmol) 
0.7 ml (11.2 mmol) 
10 mlTHF
frans-3-Pentenoic acid 0.50 g (5.00 mmol) 
1 mlTHF
Method
A 100 ml round bottom flask with side arm was equipped with a magnetic stirring 
bar, fitted with a nitrogen balloon and sealed with a septum cap. This vessel 
was flame dried then charged with diisopropylamine and THF. Stirring was 
initiated, the solution cooled to 0°C and /7-butyl lithium added slowly by syringe. 
After being allowed to stir at 0°C for 30 minutes the solution was taken to -78°C 
where fra/?s-3-pentenoic acid was added, predissolved in THF, by syringe. The 
reaction was stirred at -78°C for 50 minutes before being allowed to warm to 
room temperature where stirring was continued for a further 30 minutes. The 
now yellow solution was taken back to -78°C where methyl iodide was added 
and the resulting mixture stirred for 30 minutes. Over two hours the mixture was 
brought slowly to room temperature where, after a further half hour, the reaction 
was quenched by the addition of a 5% aqueous solution of hydrochloric acid. 
The mixture was extracted several times with diethyl ether, the combined 
organic layers dried with magnesium sulfate, filtered and evaporated yielding a 
brown oil. Dry flash chromatography allowed the isolation of a quantity of 
reasonably pure yellow oil which was shown to be the desired product (Rf 0.39, 
eluent 1:1 ethyl acetate:hexane).
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m/z 114 (M+, 19.3%), 99 (M - CH3, 7.5), 73 (2.8), 69 (83.7), 41 (100)
5h(200MHz CDCI3) 1.26 (3H, d, J 7.0, aCH3), 1.69 (3H, d, J 5.0, terminal CH3), 
3.12 (1H, dq, J 7.0, CHCOOH), 5.54 (2H, m, CH=CH), 10.59 (1H, br s, COOH) 
8c(50MHz CDCI3) 17.1 (q, aCH3), 17.8 (q, CH3CH=CH), 42.7 (CHCOOH), 127.5 
and 129.2 (both d, CH=CH), 181.7 (s, COOH)
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EXPERIMENTAL PART 6: Coupling and Isostere Generation
5(S)-[(ferf-Butoxycarbonyl)amino]-2(R)-methyl-6-phenyl-4-(phenylsulfonyl)- 
1-[(2-tetrahydropyranyl)oxy]-3-hexanol from 2(S)-[(teft- 
butoxycarbonyl)amino]-3-phenyl-1 -(phenylsulfonyl)propane and 2(S)- 
methyl-3-[(2-tetrahydropyranyl)oxy]propionaldehyde
Phf ^  Me
BOCN% - ^ s o 2Ph + OHC'v ^ 'O T H P  ____ „ B o a e ^ j ^ I^ o T H P
CH2Ph 6h3 P1£i i2 o il
Materials
2(S)-[(terf-Butoxycarbonyl)amino]-3-phenyl-1-(phenylsulfonyl)propane
4.36 g (11.6 mmol)
THF 330 ml
Methyl lithium (1.4 M in ether) 18.3 ml (25.6 mmol)
Diisobutylaluminium hydride (1.0 M in THF) 23.5 ml (23.5 mmol)
Methanol 0.95 ml (23.5 mmol)
2(S)-Methyl-3-[(2-tetrahydropyranyl)oxy]propionaldehyde
4.00 g (23.3 mmol)
THF 28 ml
Method
A 1 L three necked round bottom flask (vessel A) was equipped with a magnetic 
stirring bar and nitrogen balloon. A 100 ml round bottom flask with a side arm 
(vessel B) was similarly equipped. Both vessels were sealed with septum caps 
and flame dried.
2(S)-[(terf-Butoxycarbonyl)amino]-3-phenyl-1-(phenylsulfonyl)propane was 
added to vessel A, as a solid, under a flow of nitrogen. THF (330 ml) was added 
by syringe and the suspension heated until complete solution was achieved.
The solution was then taken to -78°C where methyl lithium was added dropwise
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with stirring. The yellow colouration observed on addition of this material 
became permanent once approximately half the specified volume had been 
added. This solution was stirred at -78°C for 30 minutes during which time the 
vessel B reaction was prepared.
In vessel B diisobutylaluminium hydride was taken to 0°C where methanol was 
added dropwise with stirring. After the effervescence ceased the solution was 
taken to -78°C where 2(S)-methyl-3-[(2-tetrahydropyranyl)oxy]propionaldehyde 
was added, predissolved in THF, and stirring continued for a further 2 minutes.
With both solutions at -78°C the contents of vessel B were transferred via 
cannula to the yellow solution in vessel A with stirring. A gradual colour loss in 
vessel A was noted. Once addition was complete the reaction mixture was 
stirred for a further 1 hour at -78°C before being quenched at this temperature 
by the addition of saturated aqueous ammonium chloride. After being allowed to 
warm to room temperature the mixture was filtered and the filtrate extracted 
several times with diethyl ether (total extraction volume 600 ml). The ether 
extracts were then dried with magnesium sulfate and evaporated giving an off- 
white oily solid. The extraction procedure was repeated with dichloromethane 
but no further material was obtained. Addition of diethyl ether (200 ml) to the 
oily solid allowed the isolation of a clean white solid which was shown to be 
unreacted 2(S)-[(terf-butoxycarbonyl)amino]-3-phenyl-1-(phenylsulfonyl)propane 
(0.56 g, 1.5 mmol, 13% recovery). Evaporation of the diethyl ether yielded a 
yellow oil which was considered to contain the many possible diastereomers of 
the desired product (7.19 g.) This material was used directly in the next step 
without purification.
8h(200MHz CDCI3) 1.35 ppm ([CH3]3C, desired product), 1.38 ppm ([CH3]3C, 
recovered starting sulfone).
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5(SH(terf-Butoxycarbonyl)amino]-2(R)-methyl-6-(phenyl)-1-[(2- 
tetrahydropyranyl)oxy]-frans-3-hexene from 5(S)-[(ferf- 
butoxycarbonyl)amino]-2(R)-methyl-6-phenyM-(phenylsulfonyl)-1-[(2- 
tetrahydropyranyl)oxy]-3-hexanol
php  Y e m .
B O C N H ^ ^ A s ^ ^ J x ^ ^ O T H P  _____ ^ B O C N H ^ ^ ^ ^ J v ^ ^ O T H P
PhCH2 OH PhfiH2
Materials
5(S)-[(teAf-Butoxycarbonyl)amino]-2(R)-methyl-6-phenyl-4-(phenylsulfonyl)-1-[(2- 
tetrahydropyranyl)oxy]-3-hexanol 7.19 g (13.14 mmol)
Disodium hydrogen phosphate 7.52 g (52.96 mmol)
Methanol 132 ml
Sodium/mercury amalgam (2% sodium) 59.31 g (51.57 mmol Na)
Method
5(S)-[(ferf-Butoxycarbonyl)amino]-2(R)-methyl-6-phenyl-4-(phenylsulfonyl)-1-[(2- 
tetrahydropyranyl)oxy]-3-hexanol was dissolved in methanol in a 500 ml three 
necked round bottom flask. A magnetic stirring bar was introduced, the vessel 
flushed with nitrogen and sealed with a nitrogen balloon. The solution was taken 
to 0°C where disodium hydrogen phosphate was added followed by 
sodium/mercury amalgam. After being stirred at 0°C for 4 hours and 10 minutes 
the reaction was quenched at this temperature by the addition of water. The 
resulting mixture was allowed to stir overnight at room temperature then carefully 
decanted, with the aid of a little dichloromethane and water, from the residual 
mercury. The mixture was extracted several times with dichloromethane (total 
organic solvent volume 1200 ml) which was then dried with magnesium sulfate, 
filtered and evaporated yielding a virtually colourless clear oil. Dry flash 
chromatography (eluent 3:7 ethyl acetate:hexane) gave a colourless clear oil 
which analysis showed to be the desired product (2.87 g, product Rf 0.75, eluent 
3:7 ethyl acetate:hexane).
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This quantity of product represented a 64% overall yield from 2(S)-l(tert- 
butoxycarbonyl)amino]-3-phenyl-1-(phenylsulfonyl)pentane for the two step 
coupling process.
Found: C, 70.83; H, 9.16; N, 3.77. C23H35N 0 4 requires C, 70.95; H, 9.00; N, 
3.60%
[a]D26 +0.75 (14.3 mg/1 ml CHCI3)
vmax(film)/cm' 1 3442m (NH), 2947s (CH3- and -CH2-), 2873m (O-CH-O), 1706s 
(C=0), 1496s (carbamate)
m/z 298 (M - PhCH2, 1.7%), 214 (M - dihydropyran, 2.9), 158 (13.4) 
m/z 298.1996 (M - PhCH2, C16H18N 0 4 requires 298.20182)
5h(200MHz CDCI3) 0.99 (3H, 2xd, J 6.7, CHCH3), 1.19-1.43 (6 H, m, 
CH2CH2CH2), M 0  (9H, s, [CH3]3C), 2.41 (1H, m, CHCH3), 2.81 (2H, d, J 6.4, 
PhCH2), 3.18-3.82 (4H, m, 2xCH20), 4.36 (1H, m, NHCH), 4.54 (2H, m, NH and 
OCHO), 5.45 (2H, m, J possible 15.6, CH=CH), 7.14-7.31 (5H, m, Ph) 
8c(50MHz CDCI3) 16.9 (q, CH3CH), 19.3 (t, CH2CH2CH2), 25.3 (t, 
OCH2CH2CH2CH2), 28.2 (q, [CH3]3C), 30.4 (t, CH2CH2CH2CH02), 36.4 (d, 
CHCH3), 41.8 (t, CH2Ph), 53.0 (d, CHN), 61.8 (t, CH20), 71.8 and 71.9 (both t, 
CH20), 79.0 (s, [CH3]3C), 98.4 and 98.6 (d, OCHO), 126.1, 128.0, 129.5, 133.4,
133.5 (all d, CH=CH and Ph), 137.5 (s, Ph), 154.9 (s, C=0)
5(SH(te/f-Butoxycarbonyl)amino]-2(R)-methyl-6-methyl-4-(phenylsulfonyl)-
1-[(2-tetrahydropyranyl)oxy]-3-heptanol from 2(S)-f(terf- 
butoxycarbonyl)amino]-3-methy 1-1 -(phenyIsulfonyl)butane and 2(S)-methyI- 
3-[(2-tetrahydropyranyl)oxy]propionaldehyde
PhS°2  Me
BOCNH BOCNH OTHP
Materials
(S)-[(terf-Butoxycarbonyl)amino]-3-methyl-1-(phenylsulfonyl)butane
5.70 g (17.4 mmol) 
THF 270 ml
Methyl lithium (1.4 M in ether) 27.5 ml (38.5 mmol)
Diisobutylaluminium hydride (1.0 M in THF) 35 ml (35 mmol)
Methanol 1.4 ml (34.6 mmol)
2(S)-Methyl-3-[(2-tetrahydropyranyl)oxy]propionaldehyde
6.00 g (34.9 mmol)
THF 40 ml
Method
The general reaction procedure used to form 5(S)-[(terf-butoxycarbonyl)amino]- 
2(R)-methyl-6-phenyl-4-(phenylsulfonyl)-1-[(2-tetrahydropyranyl)oxy]-3-hexanol 
was repeated using the above starting materials. In this case the initial warming 
of vessel A to obtain complete solution was not necessary and the vessel A 
reaction time was increased to 40 minutes before the transference of the vessel 
B material. The crude product was obtained as a yellow oil with a mild yellow 
colouration (11.60 g). The precipitation of unreacted (S)-[(tert- 
butoxycarbonyl)amino]-3-methyl-1-(phenylsulfonyl)butane was not achieved.
5h(200MHz CDCI3) 1.42, 1.44(x2) ([CH3]3C, crude product), 1.42 ([CH3]3C, 
starting sulfone)
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5(S)-[(te/t-Butoxycarbonyi)amino]-2(R)-methyl-6-(methyl)-1-[(2- 
tetrahydropyranyl)oxy]-frans-3-heptene from 5(S)-[(ferf- 
butoxvcarbonyl)amino]-2(R)-methyl-6-methyl-4-(phenylsulfonyl)-1-f(2- 
tetrahydropyranyl)oxy1-3-heptanol
Ph| ° 2 Me Me
BO CN H . .OTHP    BO CN H . X  ^OT
OH
Materials
5(SH(fe/f-Butoxycarbonyl)amino]-2(R)-methyl-6-methyl-4-(phenylsulfonyl)-1-[(2- 
tetrahydropyranyl)oxy]-3-heptanol 11.60 g (32.25 mmol)
Disodium hydrogen phosphate 13.2 g (92.96 mmol)
Methanol 230 ml
Sodium/mercury amalgam (2% sodium) 104.5 g (90.87 mmol Na)
Method
The general procedure used to form 5(S)-[(terf-butoxycarbonyl)amino]-2(R)- 
methyl-6-(phenyl)-1 -[(2-tetrahydropyranyl)oxy]-frans-3-hexene was repeated. 
With the quantity of sodium/mercury amalgam employed here, a mechanical 
stirrer was found to be preferable to a magnetic stirring bar. Positive pressure 
flash chromatography (eluent 1:9 ethyl acetate:hexane) yielded the desired 
product as a colourless clear oil (3.46 g, Rf 0.31, eluent 1:9 ethyl 
acetate:hexane). This quantity of material represents an overall yield of 58% 
from (S)-[(terf-butoxycarbonyl)amino]-3-methyl-1-(phenylsulfonyl)butane for the 
two step coupling process.
vmax(film)/cm' 1 3456m (NH), 2957s (CH3- and -CHr ), 2872s (O-CH-O), 1702s 
(C=0), 1519s (carbamate)
m/z 341 (M+, <0.1%), 298 (M - [CH3]2CH, 3.8), 285 (0.2), 268 (0.1), 256 (0.2), 
240(0.1), 225(0.3)
m/z 298.1993 (M - CH[CH3]2, C16H27N 0 4 requires 298.20183)
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5h(200MHz CDCI3 ) 0.88 (6 H, d, J 6 .8 , [CH3]2CH)f 1.03 and 1.04 (3H, 2xd, J 6 .8 , 
CH3CH), 1.44 (9H, s, [CH3]3C), 1.53-1.84 (7H, m, CH2CH2CH2 and [CH3]2CH), 
2.46 (1H, m, CH3CH), 3.24 (1H, m, CHN), 3.46-3.88 (4H, m, 2xCH20), 4.58 (2H, 
m, NH and OCHO), 5.44 (2H, m, CH=CH)
5c(50MHz CDCI3 ) 17.1, 18.1 and 18.1, 18.2 (all q, CH3CH and [CH3]2CH), 19.2 
and 19.3 (both t, CH2CH2CH2), 25.4 (CH2CH20), 28.3 (q, [CH3]3C), 30.5 
(CH2CH02), 32.4 (d, [CH3]2CH), 36.6 and 36.7 (both d, CHCH3), 56.9 (d, CHN), 
61.8 and 61.9 , 72.0 (all t, 2xCH20), 75.7 (s, [CH3]3C), 98.5 (d, OCHO), 128.5,
133.5 (both d, CH=CH), 154.8 (s, C=0)
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5(S)-[(fert-Butoxycarbonyl)amino1-6-methyl-4-(phenylsulfonvn-1-f.(2- 
tetrahydropyranyl)oxy1-3-heptanol from 2(SH(fert-butoxvcarbonvnaminol- 
3-methvl-1-(phenvlsulfonyl)butane and 3-f(2- 
tetrahydropyranyl)oxy]propionaldehvde
PhS02
BO C N H 'V ^ \S02Ph + ° HC^ -^ 'O rH P  ______
Materials
(S)-[(terf-Butoxycarbonyl)amino]-3-methyl-1-(phenylsulfonyl)butane
5.70 g (17.4 mmol) 
THF 270 ml
Methyl lithium (1.6 M in ether) 24 ml (38.4 mmol)
Diisobutylaluminium hydride (1.0 M in THF) 35 ml (35 mmol)
Methanol 1.4 ml (34.58 mmol)
3-[(2-Tetrahydropyranyl)oxy]propionaldehyde 5.52 g (34.9 mmol)
THF 40 ml
Method
The general reaction procedure used to form 5(S)-[(terf-butoxycarbonyl)amino]- 
2(R)-methyl-6-phenyl-4-(phenylsulfonyl)-1-[(2-tetrahydropyranyl)oxy]-3-hexanol 
was repeated with the above starting materials. In this case the initial warming 
of vessel A to obtain complete solution was not necessary and the vessel A 
reaction time was increased to 35 minutes before the transference of vessel B 
material. The crude product was obtained as a clear golden oil (10.12 g). The 
precipitation of unreacted (S)-[(fe/f-butoxycarbonyl)amino]-3-methyl-1- 
(phenylsulfonyl)butane was not achieved.
5h(200MHz CDCI3) 1.42 and 1.44 ([CH3]3C, crude product), 1.44 ([CH3]3C, 
starting sulfone)
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5(S)-[(fe/f-Butoxycarbonyl)amino]-6-(methyl)-1-[(2-tetrahydropyranyl)oxy]- 
trans-3-heptene from 5(S)-[(tert-butoxycarbonyl)amino]-6-methyl-4- 
(phenylsulfonyl)-1-[(2-tetrahydropyranyl)oxy1-3-heptanol
un
Materials
5(S)-[(ferf-Butoxycarbonyl)amino]-2(R)-6-methyl-4-(phenylsulfonyl)-1-[(2-
The general procedure used to form 5(S)-[(ferf-butoxycarbonyl)amino]-2(R)- 
methyl-6-(phenyl)-1 -[(2-tetrahydropyranyl)oxy]-frans-3-hexene was repeated. 
With the quantity of sodium/mercury amalgam employed here, a mechanical 
stirrer was found to be preferable to a magnetic stirring bar. Positive pressure 
flash chromatography (eluent 3:7 ethyl acetate:hexane) yielded the desired 
product as a colourless clear oil (1.44 g, Rf 0.58, eluent 3:7 ethyl 
acetate:hexane). This quantity of material represents an overall yield of 25% 
from (S)-[(teAf-butoxycarbonyl)amino]-3-methyl-1-(phenylsulfonyl)butane for the 
two step process.
vmax(film)/crn‘1 3345m (NH), 2958s (CHr  and -CHr ), 2872s (O-CH-O), 1702s 
(C=0), 1518s (carbamate)
m/z 284 (M -[CH 3]2C, 1.2%), 172 (1.4), 129 (1.3), 115(1.5), 101 (9.1) 
8h(200MHz CDCI3) 0.89 (6 H, 2xd, J 6 .8 , [CH3]2CH), 1.44 (9H, s, [CH3]3C), 1.51-
BOCNH OTHP
P hS 02
tetrahydropyranyl)oxy]-3-heptanol 
Disodium hydrogen phosphate 
Methanol
Sodium/mercury amalgam (2% sodium)
10.12 g (20.87 mmol) 
12.62 g (88.87 mmol) 
220  ml
100.07 g (87.02 mmol)
Method
1.85 (7H, m, CH2CH2CH2 and [CH3]2CH), 2.34 (2H, q, J 6.7, CH=CHCH2), 3.26- 
3.55 and 3.70-3.93 (5H, m, 2xCH2Q and CHN), 4.52 (1H, br, NH), 4.59 (1H, t, J
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3.2, OCHO), 5.40 (1H, dd, J 15.5 and 6.1, CHCH=CH), 5.55 (1H, dt, J 15.5(d) 
and 6 .8 (t), CH=CHCH2)
8c(50MHz CDCI3) 18.1 and 18.5 (both q, [CH3]2CH), 19.4 (t, CH2CH2CH02) 25.4 
(t, CH2CH2CH20), 28.3 (q, [CH3]3C), 30.6 (t, CH2CH02), 32.4 (d, [CH3]2CH), 32.7 
(t, CH=CHCH2), 57.5 (d, CHN), 62.1 and 66.8 (both t, 2xCH20), 78.8 (s, [CH3]C), 
98.6 (d, OCHO), 127.8 (d, CHCH=CH), 130.8 (d, CH=CHCH2), 151.7 (s, C=0)
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5(S)-[(fer^Butoxycarbonyl)amino]-2(R)-methyl-6-(methyl)-frans-3-heptenoic 
acid from 5(S)-[(ferf-butoxycarbonyl)amino]-2(R)-methyl-6-(methyl)-1 -[(2- 
tetrahydropyranyl)oxy]-frans-3-heptene
Me Me
BO C N H ^ X)THP BOCNHL .
'COOH
Materials
5(S)-[(fe/t-Butoxycarbonyl)amino]-2(R)-methyl-6-(methyl)-1 -[(2- 
tetrahydropyranyl)oxy]-frar?s-3-heptene 2.99 g (8.77 mmol)
Acetone 550 ml
Chromic acid (2 M) 15 ml (30 mmol)
Method
5(SH(terf-Butoxycarbonyl)amino]-2(R)-methyl-6-(methyl)-1-[(2- 
tetrahydropyranyl)oxy]-fra/7s-3-heptene was dissolved in acetone and placed in a 
1 L round bottom flask equipped with a magnetic stirring bar. The solution was 
cooled to 0°C where chromic acid was added dropwise with stirring. The vessel 
was flushed with nitrogen, sealed with a nitrogen balloon and the solution stirred 
at 0°C for 3 hours. The mixture was then diluted with water (200 ml) and 
extracted five times with diethyl ether. The combined ether extracts were dried 
with magnesium sulfate, filtered and evaporated giving an oily material still 
containing a quantity of water. This mixture was taken up in diethyl ether (200 
ml) and transferred to a separatory funnel. The organic layer was decanted and 
the small aqueous layer extracted five times with diethyl ether, (total volume 100 
ml) The combined organic layers were then extracted five times with aqueous 
sodium hydroxide (5%) giving approximately 1.5 L of basic solution. After being 
cooled to 0°C this solution was carefully acidified to pH 2 with hydrochloric acid 
(10%) then extracted twice with diethyl ether. The combined final ether extracts 
were dried with magnesium sulfate, filtered and evaporated yielding the crude 
carboxylic acid product as a colourless clear oil.
220
On standing at room temperature, the crude carboxylic acid solidified. An initial 
attempt at recrystallisation from ethyl acetate/hexane resulted in the precipitation 
of a white solid impurity (90 mg). Evaporation of the mother liquors yielded a 
solid which was identified as the desired product. For ease of manipulation this 
material was taken up in hot ethyl acetate/hexane and allowed to precipitate on 
cooling (0.68 g, m.pt. 68-74°C). Evaporation of the solvent allowed recovery of 
the non-precipitated material (0.59 g). Both samples were of sufficient purity for 
use in further reactions (total 1.27 g, 53% yield). A small amount of the 
precipitated product was recrystallised, from hot hexane containing a minimal 
quantity of ethyl acetate, allowing the isolation of highly pure material.
Found: C, 61.96; H, 9.26; N, 5.01. C14H25N04 requires C, 61.99; H, 9.22; N, 
5.17%
[<x]D22 -16.6 (6.5 mg/1 ml CHCI3)
vmax(KBr)/cnrf1 3308m (NH), 2584br (acid OH), 1728s (acid C=0), 1654s 
(carbamate C=0)
m/z 228 (M - [CH3]2CH, 5.9%), 172 (41.9), 155 (4.9), 116 (1.6), 99 (1.8) 
m/z 228.1228 (M - CH[CH3]2, C^H^N 0 4 requires 228.15353)
5h(200MHz CDCI3) 0.89 (6 H, d, J 6 .8 , [CH3]2CH), 1.29 (3H, d, J 7.0, CHCH3),
I.44 (9H, s, [CH3]3C), 1.76 (1H, m, [CH3]2CH), 1.96 (1H, q, J possible 7.3, 
CHCOOH), 3.16 (1H, q, J possible 7.1, CHN), 4.61 (1H, br, NH), 5.46 (1H, dd, J 
15.2 and 4.8, CH=CHCH[CH3] ) , 5.68 (1H, dd, J 15.2 and 7.3, CH=CHCH[CH3]),
II.61 (1H, brs, COOH)
221
5(S)-[(ferf-Butoxycarbonyl)ammo]-2(R)-methyl-6-(phenyl)-frans-3-hexenoic 
acid from 5(S)-f(fe/t-butoxycarbonyl)amino]-2(R)-methyl-6-(phenyl)-1 -[(2- 
tetrahydropyranyl)oxy]-frans-3-hexene
Me Me
B O C N H ^ ^O TH P BOCNH.
COOH
PhCH2 PhCH2
Materials
5(S)-[(te/f-Butoxycarbonyl)amino]-2(R)-methyl-6-(phenyl)-1-[(2- 
tetrahydropyranyl)oxy]-fra/7S-3-hexene 6.63 g (17.0 mmol)
Acetone 1060 ml
Chromic acid (2 M) 28.5 ml (57 mmol)
Method
5(S)-[(terf-Butoxycarbonyl)amino]-2(R)-methyl-6-(phenyl)-1-[(2- 
tetrahydropyranyl)oxy]-fraA?s-3-hexene was dissolved in acetone and placed in a 
2 L round bottom flask equipped with a magnetic stirring bar. The solution was 
cooled to 0°C where chromic acid was added dropwise with stirring. The vessel 
was flushed with nitrogen, sealed with a nitrogen balloon and the solution stirred 
at 0°C for 3 hours. The mixture was diluted with water (500 ml) and extracted 
three times with diethyl ether (total volume 4.5 L). The ether extracts were 
reduced to 600 ml by evaporation resulting in the separation of more aqueous 
material. The mixture was transferred to a separatory funnel, the organic layer 
separated and the aqueous layer extracted with diethyl ether. The combined 
organic layers (total volume now 1L) were then extracted five times with 
aqueous sodium hydroxide (5%) giving approximately 5 L of basic solution.
After being cooled to 0°C this solution was carefully acidified to pH 2 with 
aqueous hydrochloric acid (10%) then extracted twice with diethyl ether (total 
volume 10 L). The combined final ether extracts were dried with magnesium 
sulfate, filtered and evaporated yielding the crude carboxylic acid as a golden oil 
(3.91 g, 72% crude yield).
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A small amount of material was partially esterified using diazomethane (ether 
solution). Dry flash chromatography (hexane/ethyl acetate polarity gradient) was 
carried out on the product of this reaction and allowed the isolation of a small 
quantity of pure carboxylic acid.
Found: C, 67.66; H, 7.98; N, 4.35. C18H25N 0 4 requires C, 67.71; H, 7.84; N, 
4.38%
vmax(CHCI3)/cm' 1 3440m (NH), 1708s (carbamate C=0 and acid C=0), 1496s 
(carbamate)
m/z 263 (M - [CH3]2[CH2]C, 0.1%), 228 (M - PhCH2, 6.3), 203 (0.7), 116 (1.1) 
m/z 228.1237 (M - PhCH2, C^H^N 0 4 requires 228.12360)
5h(200MHz CDCI3) 1.25 (3H, d, J 6.9, CH3CH), 1.37 (9H, s, [CH3]3C), 2.81 (2H, 
d, J 6.4, CH2), 3.12 (1H, q, J possible 6.9, CH3CH), 4.39 (1H, m, CHN), 4.61 
(1H, br, NH), 5.58 (2H, d of ABq, J 15.6(AB), 6.3 and 4.9, CH=CH), 7.12-7.48 
(5H, m, Ph), 10.38 (1H, br, COOH)
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5(S)-[(feft-Butoxycarbonyl)amino]-6-(methyl)-frans-3-heptenoic acid from 
5(SH(te/f-butoxycarbonyl)amino]-6-(methyl)-1-[(2-tetrahydropyranyl)oxy]-
trans-3-heptene
BOCNH. OTHP BOCNH
Materials
5(S)-[(terf-Butoxycarbonyl)amino]-6-(methyl)-1-[(2-tetrahydropyranyl)oxyKra/7s- 
3-heptene 1.34 g (4.10 mmol)
Acetone 254 ml
Chromic acid (2 M) 6.9 ml (13.8 mmol)
Method
The general procedure employed to produce crude 5(S)-[(tert- 
butoxycarbonyl)amino]-2 (R)-methyl-6 -(methyl)-fra/7s-3-heptenoic acid was 
repeated. Crude 5(S)-[(fe/t-butoxycarbonyl)amino]-6-(methyl)-1 -[(2- 
tetrahydropyranyl)oxy]-frans-3-heptene was obtained as an almost colourless 
clear oil (0.74 g, 70% crude yield).
vmax(filrn)/cm' 1 1712s (carbamate and acid C=0), 1515m (carbamate)
m/z 214 (M - [CH3]2CH, 4.0%), 201 (M - [CH3]2[CH2]C, 1.1), 156 (0.8), 141 (3.4),
85 (2.0)
m/z 214.1101 (M - [CH3]2CH, C10H16NO4 requires 214.10788)
8h(200MHz CDCI3) 0.89 (6 H, d, J 6.7, [CH3]2CH), 1.44 (9H, s, [CH3]3C), 1.76 
(1H, m, [CH3]2CH), 3.11 (2H, d, J 6 .6 , CH2), 3.98 (1H, m, CHN), 4.69 (1H, br, 
NH), 5.50 (1H, dd, J 15.6 and 5.5, CHCH=CH), 5.67 (1H, dt, J 15.6 and 6 .6 , 
CH=CHCH2)
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EXPERIMENTAL PART 7: Evaluation of Alternative Diazomethyl Ketone
Method
A scratch free 150 ml round bottom flask was equipped with a Teflon® coated 
magnetic stirring bar. The ground glass connection of this vessel was well 
greased to allow the later fitting of a nitrogen balloon. To this flask 
diazomethane (diethyl ether solution) was carefully added and cooled to -5°C.
At this temperature isovaleryl chloride, predissolved in diethyl ether, was added 
dropwise. After complete addition, the flask was topped with a nitrogen balloon 
and the yellow solution stirred for two hours. The reaction was quenched by the 
addition of 50 ml water followed by rapid stirring for at least one hour before 
further manipulations were attempted. After being transferred to a separatory 
funnel the organic layer was separated and the aqueous layer extracted with 
diethyl ether. The combined organic layers were then washed sequentially with 
saturated aqueous solutions of sodium bicarbonate and sodium chloride, dried 
with magnesium sulfate, filtered and evaporated. The resulting light yellow liquid 
was characterised by 1H NMR spectroscopy.
Formation Methods
Isobutyryl diazomethyl ketone from isobutyryl chloride
n
Materials 
Isovaleryl chloride 
Diethyl ether
Diazomethane (diethyl ether solution)
c. 0.25 ml (2.05 mmol) 
12 ml
c. 9.6 mmol
5h(200MHz CDCI3) 0.96 (6 H, d, J 6.5, [CH3]2CH), 2.02-2.18 (3H, m, CH2 and 
CH), 5.24(1 H, s, CHN2)
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Af-fert-Butoxvcarbonvl-(D-phenvlalanvl diazomethyl ketone from N-tert-
butoxycarbonvl-(U-phenvlalanine
o  o
tBuO_ ,N Y  __  _ tBuO. NH
•CHN2Y  v 'o "  — ' Y
O CH2Ph 6 CH2Ph
Materials
Sodium hydride (55-65% in oil) 0.175 g (max. 4.74 mmol)
THF 4 ml
A/-terf-Butoxycarbonyl-(L)-phenylalanine 1.33 g (5.02 mmol)
THF 25 ml
Isobutyl chloroformate 0.7 ml (5.4 mmol)
Diazomethane (diethyl ether solution) c. 14.54 mmol
Method
A 25 ml round bottom flask with a side arm was equipped with a Teflon® coated 
magnetic stirring bar and a nitrogen balloon. After being flushed with nitrogen 
and sealed with a septum cap the vessel was flame dried. A 250 ml three 
necked round bottom flask was similarly treated. With this vessel however, the 
ground glass joints were thoroughly greased. Sodium hydride (55-65% in oil) 
was admitted, as a solid, to the 25 ml vessel under a flow of nitrogen. Pentane 
(2 ml) was added by syringe and stirring initiated. After 2 minutes the pentane 
was removed by suction leaving clean sodium hydride. THF was then added to 
this vessel and the sodium hydride suspended. The 250 ml vessel was charged 
with A/-terf-butoxycarbonyl-(L)-phenylalanine dissolved in THF, then taken to - 
78°C. The sodium hydride suspension was transferred to this vessel by syringe 
and the resulting mixture allowed to warm slowly to 0°C. As warming occurred 
the solution became more turbid. The reaction mixture was then taken to -20°C 
where isobutyl chloroformate was added dropwise. After being stirred at -20°C 
for 20 minutes diazomethane (diethyl ether solution) was added to the reaction 
mixture. Stirring was continued at -20°C for 45 minutes after which the reaction
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was allowed to warm slowly to room temperature where it was stirred for a 
further 1 hour. The reaction was then quenched by the addition of water (50 ml) 
with vigorous stirring. The resulting mixture was extracted twice with diethyl 
ether, the combined organic layers washed with saturated aqueous sodium 
bicarbonate, dried with magnesium sulfate, filtered and evaporated. A yellow oil 
was initially obtained which solidified on long term evacuation. The resulting 
yellow solid (0.97 g) was recrystallised from ethyl acetate/hexane at 0°C giving a 
sample of the desired product contaminated with a very small quantity of methyl 
ester (0.39 g, 27% yield, m.pt. 81-85°C).
Vmax(KBr)/cm-1 3327m (NH), 3126m (diazo CH), 2104s (diazo), 1686s 
(carbamate C=0), 1640s (ketone C=0), 1526s (carbamate) 
m/z 233 (M - [CH3]2[CH2]C, 0.1%), 220 (M - COCHN2, 8 .6 ), 205 (2.6), 116 (3.6) 
m/z 220.1365 (M - COCHN2, C13H18N 0 2 requires 220.13376)
6h(200MHz DMSO) 1.34, (9H, s, [CH3]3C), 2.89 (2H, d of ABq, J 13.9(AB), 10.5 
and 4.6), 4.21 (1H, s, CHN), 6.14 (1H, s, CHN2), 7.20-7.43 (5H, m, Ph) 
8h(200MHz CDCI3) 1.41 (9H, s, [CH3]3C), 3.06 (2H, m, CH2), 4.42 (1H, m, CHN),
5.12 (1H, br d, J 7.4, NH), 5.23 (1H, s, CHN2), 7.17-7.36 (5H, m, Ph)
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trans-3-Butenyl diazomethyl ketone from trans-3-pentenoic acid
O O
OH CHN2
Materials
Sodium hydride (55-65% in oil) 
THF
0.74 g (max. 20.04 mmol) 
80 ml
fra/7s-3-Pentenoic acid 
THF
1.99 g (19.9 mmol)
20 ml
2.75 ml (21.2 mmol) 
c. 58.16 mmol + 7.27 mmol
Isobutyl chloroformate 
Diazomethane (diethyl ether solution)
Method
A 500 ml three necked round bottom flask was equipped with a Teflon® coated 
magnetic stirring bar and a nitrogen balloon. The ground glass joints were 
thoroughly greased, the flask sealed with septum caps and then flame dried. 
Under a flow of nitrogen sodium hydride (55-65% in oil) was added to the vessel 
as a solid. Pentane (2 ml) was then added by syringe and stirring initiated. After 
2 minutes the pentane was removed by suction leaving clean sodium hydride. 
THF (80 ml) was added to the vessel and the resulting suspension taken to - 
78°C. At this temperature frans-3-pentenoic acid in THF (20 ml) was added 
slowly by syringe. Once addition was complete the reaction was allowed to 
warm to -20°C where it was stirred for 20 minutes before the dropwise addition 
of isobutyl chloroformate. After a further 10 minutes diazomethane (diethyl ether 
solution, 58.16 mmol) was added and stirring continued at -20°C for 40 minutes. 
The reaction was then allowed to warm slowly to room temperature where 
stirring was continued for a further 1 hour. Water (100 ml) was added with 
vigorous stirring to quench the reaction and the mixture transferred to a 
separatory funnel where the organic layer was removed and the aqueous layer 
extracted twice with diethyl ether. The combined organic layers were then
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washed with saturated aqueous sodium bicarbonate, dried with magnesium 
sulfate, filtered and evaporated yielding a yellow oil.
Dry flash chromatography (hexane-ethyl acetate gradient) allowed isolation of a 
small amount of the desired material (0.19 g, 8% yield, Rf 0.53, eluent 1:1 ethyl 
acetate:hexane). Fractions containing impure samples of the desired product 
were combined, evaporated, then taken up in diethyl ether. This ether solution 
was filtered into a round bottom flask equipped with a Teflon® coated magnetic 
stirring bar. The ground glass connection of this vessel was well greased and 
the solution treated with diazomethane (7.27 mmol) in diethyl ether. The vessel 
was sealed with a nitrogen balloon and the mixture stirred for two hours at room 
temperature before the addition of water. The previously described extraction 
process was repeated after which dry flash chromatography (eluent pure 
dichloromethane) allowed isolation of a further small quantity of the desired 
material (0.18 g, further 7% yield, Rf 0.13, eluent pure dichloromethane).
vmax(filmVcm 1 3088m (diazoCH), 2105s (diazo), 1634s (C=0) 
m/z 124 (M+, <0.1%), 96 (M - N2, 43.9), 83 (1.3), 55 (45.3), 41 (61.9)
8h(200MHz CDCI3) 1.71 (3H, d, J 4.8, CH3), 3.01 (2H, d, J 5.2, CH2), 5.38 (1H, s, 
CHN2), 5.42-5.70 (2H, m, CH=CH)
5c(50MHz CDCI3) 17.7 (q), 44.6 (t), 53.9 (d, CHN2), 123.0 and 130.1 (CH=CH), 
193.4 (s, C=0)
5h(200MHz d6-DMSO) diazomethyl ketone signal 6.02 (s)
trans-3-Butenyl diazomethyl ketone from methyl trans-3-pentenoate
0 O
OCH3 c h n 2
Materials
Methyl trans-3-pentenoate 
THF
1.00 g (8.77 mmol) 
44 ml
Potassium trimethylsilanolate 
Isobutyl chloroformate 
Diazomethane (diethyl ether solution)
1.68 g (13.1 mmol) 
2.8 ml (21.6  mmol) 
c. 33.5 mmol
Method
A 250 ml three necked round bottom flask was equipped with a Teflon® coated 
magnetic stirring bar and nitrogen balloon. The ground glass connections of this 
vessel were thoroughly greased, the vessel sealed with septum caps then flame 
dried. The vessel was charged with a solution of methyl trans-3-pentenoate in 
THF and magnetic stirring initiated. Under a flow of nitrogen potassium 
trimethylsilanolate was added as a solid. The resulting yellow cloudy solution 
was stirred at room temperature for 2 hours and 20 minutes. Isobutyl 
chloroformate was then added dropwise at room temperature and stirring 
continued for a further 4 hours. After being cooled to 0°C, diazomethane (diethyl 
ether solution) was added and the reaction allowed to warm slowly to room 
temperature and stirred overnight. The reaction was then quenched by careful 
addition of water with vigorous stirring. The resulting mixture was extracted 
three times with diethyl ether and the combined organic layers washed with 
saturated aqueous sodium bicarbonate, dried with magnesium sulfate, filtered 
and evaporated. Positive pressure flash chromatography (eluent pure 
dichloromethane) was employed to isolate the desired material as a yellow oil 
(0.25 g, 23% yield, Rf 0.18, eluent pure dichloromethane, Rf 0.54, eluent 1:1 
ethyl acetate:hexane).
vmax(filmVcm 1 3089m (diazo CH), 2105s (diazo), 1640s (C=0)
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m/z 124 (M+, 4.8%), 96 (M - N2, 12.0), 83 (19.2), 69 (26.3), 55 (90.1), 41 (71.9) 
m/z 124.0628 (M+, C6H8N20  requires 124.06370)
8h(200MHz CDCI3) 1.71 (3H, d, J 5.8, CH3), 3.02 (2H, d, J 5.3, CH2), 5.35 (1H, s, 
CHN2), 5.42-5.70 (2H, m, CH=CH)
5c(50MHz CDCI3) 17.8 (q), 44.7 (t), 54.0 (d, CHN2), 123.0 and 130.3 (both d, 
CH=CH), 193.5 (s)
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EXPERIMENTAL PART 8: Further Reaction of Completed Isosteres
Methyl 5(S)-[(tert-butoxycarbonyl)amino]-2(R)-methyl-6-(phenyl)-frans-3- 
hexenoate from 5(S)-[(ferf-butoxycarbonyJ)amino]-2(R)-methyL6-(phenyl)-
trans-3-hexenoic acid
Me Me
'COOH
5(S)-[(terf-Butoxycarbonyl)amino]-2(R)-methyl-6-(phenyl)-frans-3-hexenoic acid
1.00 g (3.13 mmol) 
Diethyl ether 10 ml
Diazomethane (ether solution) c. 10.05 mmol
Method
A 100 ml conical flask was equipped with a Teflon® coated magnetic stirring bar 
and charged with a previously filtered impure solution of 5(S)-l(tert- 
butoxycarbonyl)amino]-2 (R)-methyl-6-(phenyl)-fra/7S-3-hexenoic acid in diethyl 
ether. Diazomethane (ether solution) was carefully added to this with stirring 
and the resulting yellow solution allowed to stir at room temperature for a further 
45 minutes. The reaction was quenched by the addition of water (25 ml) and 
stirred for 30 minutes before being transferred to a separatory funnel. The 
organic layer was separated and the aqueous layer extracted twice with diethyl 
ether. The combined organic layers were dried with magnesium sulfate, filtered 
and evaporated. Positive pressure flash chromatography (eluent 4:6 ethyl 
acetate:hexane) allowed the isolation of a sample of the desired product as an 
off-white solid (0.71 g, 68% crude yield, Rf 0.62 eluent 4:6 ethyl 
acetate:hexane). Further purification was achieved by crushing this material and 
washing thoroughly with hexane giving a clean white solid (0.37 g, m.pt. 63- 
68°C).
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Found: C, 68.46; H, 8.10; N, 4.12. C19H27N 0 4 requires C, 68.47; H, 8.11; N, 
4.20%
[a]D26-11.24 (10.2 mg/1 ml CHCI3)
vmax(KBr)/crn-1 3359s (NH), 1738s (ester C=0), 1678s (carbamate C=0), 1524s 
(carbamate)
m/z 242 (M - PhCH2l 5.8%), 232 (0.2), 217 (1.1), 116 (1.1), 91 (32.6) 
m/z 242.1414 (M - PhCH2, C12H20N 0 4 requires 242.13926)
6h(200MHz CDCI3) 1.21 (3H, d, J 6.9, CH3CH), 1.40 (9H, s, [CH3]3C), 2.82 (2H, 
d, J 6.2, CH2), 3.11 (1H, q, J possible 6.9, CH3CH), 3.65 (3H, s, OCH3), 4.44 
(2H, m, CHNH), 5.54 (2H, d of ABq, J 15.6(AB), 6.3 and 9.4, CH=CH), 7.12-7.33 
(5H, m, Ph)
5c(50MHz CDCI3) 17.1 (q, CH3CH), 28.3 (q, [CH3]3C), 41.7 (t, CH2Ph), 42.3 (d, 
CH3CH), 51.8 (q, OCH3), 52.8 (d, CHN), 79.4 (s, [CjH3]3C), 126.4, 128.2, 129.5, 
129.6, 131.4 (all d, Ph and CH=CH), 137.3 (s, Ph), 155.0 (s, CONH), 174.8 (s, 
COOCH3)
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5(S)-[(feft-Butoxycarbonyl)amino]-2(R)-methyl-6-(methyl)-frans-3-heptenoyl 
diazomethane from 5(SH(terf-butoxycarbonyl)amino1-2(R)-methyl-6- 
(methyl)-frans-3-heptenoic acid
COOH
BOCNH
Me Me
Materials
Sodium hydride (95%) 0.0459 g (max. 1.82 mmol)
THF 4 ml
5(S)-[(terf-Butoxycarbonyl)amino]-2(R)-methyl-6-(methyl)-frans-3-heptenoic acid
0.590 g (2.17 mmol)
THF 9 ml
Isobutyl chloroformate 0.3 ml (2.3 mmol)
Diazomethane (diethyl ether solution) 13.4 mmol
Method
The ground glass connections of a 100 ml three necked round bottom flask were 
thoroughly greased. The vessel was then equipped with a Teflon coated 
magnetic stirring bar and a nitrogen balloon, sealed with septum caps and flame 
dried. Under a flow of nitrogen, sodium hydride (95%) was added to the vessel 
as a solid, THF (4 ml) injected and stirring initiated. The resulting suspension 
was taken to -70°C where 5(S)-[(ferf-butoxycarbonyl)amino]-2(R)-methyl-6- 
(methyl)-frans-3-heptenoic acid in THF (9 ml) was added by syringe. The 
solution was then warmed to -20°C where stirring was continued for a further 20 
minutes. Isobutyl chloroformate was added dropwise at this temperature and 
following a 45 minute stir, diazomethane (diethyl ether solution) was also added. 
After being stirred at -20°C for 1 hour the reaction was allowed to slowly warm to 
room temperature where stirring was continued for a further 1 hour. The 
reaction was quenched by the addition of water (25 ml) with vigorous stirring.
The mixture was then transferred to a separatory funnel where it was extracted 
three times with diethyl ether. The combined organic layers from this process
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were washed with saturated aqueous sodium chloride, dried with magnesium 
sulfate, filtered and evaporated yielding a yellow oil (0.78 g).
Using 0.57 g of the crude material, dry flash chromatography (polarity gradient 
hexane to ethyl acetate) allowed the isolation of the desired compound as a 
thick yellow oil (0.08 g, Rf 0.43, eluent 1:1 ethyl acetate:hexane). Also isolated 
was a sample of the corresponding methyl ester as a colourless oil which 
solidified as a clean white solid on standing (0.22 g, m.pt. 56-63°C, Rf 0.57, 
eluent 1:1 ethyl acetate:hexane). These quantities of material suggest an 
overall reaction yield of 17% for the desired product and 49% for the methyl 
ester by-product.
Diazomethyl ketone: [a]D22 -33.3 (5.2 mg/1 ml CHCI3)
vmax(KBr)/crn"1 3358s (NH), 3078s (diazo CH), 2106s (diazo), 1684s (carbamate 
C=0), 1618s (ketone C=0), 1520s (carbamate)
m/z 252 (M - [CH3]2CH, 2.2%), 239 (M - [CH3]2[CH2]C, 0.5) 224 (0.4), 211 (0.4),
179 (0.8), 172 (0.7), 123 (0.6), 116 (11.0)
m/z 252.1322 (M - CH[CH3]2, C12H18N30 3 requires 252.13478)
5h(200MHz CDCI3) 0.83 (6H, 2xd, J 6.8, [CH3]2CH), 1.16 (3H, d, J 7.0, CH3CH),
1.37 (9H, s, [CH3]3), 1.68 (1H, m, [CH3] 2CH), 3.00 (1H, m, CHCOCHN2), 3.87 
(1H, m, CHNH), 4.59 (1H, br d, J 7.6, NH), 5.35 (1H, s, CHN2), 5.38-5.58 (2H, m, 
J possible 15.5, CH=CH)
5c(50MHz CDCI3) 16.6 (q, CH3CH), 18.1 and 18.6 (both q, [CH3]2CH), 28.2 (q, 
[CH3]3C), 32.2 (d, [CH3]2CH), 47.9 (d, CHCH3), 53.6 and 57.2 (both d, CHNH 
and CHN2), 79.2 (s, [CH3]3C), 130.1 and 131.9 (both d, CH=CH), 155.8 (s, 
CONH), 196.8 (s, COCHN2)
Ester: [a]D22 -23.4 (10.8 mg/1 ml CHCI3)
vmax(KBr)/crn'1 3382s (NH), 1733s (ester C=0), 1684s (carbamate C=0), 1520s 
(carbamate)
m/z 242 (M - [CH3]2CH, 5.1%), 229 (M - [CH3]2[CH2]C, 1.2), 186 (28.7), 172 
(0.3), 169 (4.1), 116(0.9), 113(0.7)
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m/z 242.1400 (M - [CH3]2CH, C 12H 20N 0 4 requires 242.13919)
8h(200MHz CDCI3) 0.81 (6H, d, J 6.7, [CH3]2CH), 1.18 (3H, d, J 7.0, CH3CH),
1.37 (9H, s, [CH3]3C), 1.68 (1H, m, [CH3]2CH), 3.08 (1H, m, CH3CH), 3.59 (3H, s, 
OCH3), 3.87 (1H, m, NHCH), 4.65 (1H, brd, J 9.2, NH), 5.38, (1H, dd, J 15.5 
and 6.0, CH=CHCH[CH3])5.58 (1H, ddd, J 15.5, 7.4, 1.0, CH=CHCH[CH3]) 
5c(50MHz CDCI3) 17.1 (q, CH3CH), 18.0 and 18.5 (both q, [CH3]2CH), 28.2 (q, 
[CH3]3C), 32.4 (d, [CH3]2CH), 42.3 (d, CHCH3), 51.6 (q, OCH3), 57.0 (d, CHN),
79.0 (s, [CH3]3C), 129.7 and 130.7 (both d, CH=CH), 155.3 (s, CONH), 174.8 (s, 
COCHN2)
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5(S)-[(tert-Butoxycarbonyl)amino]-6-(methyl)-fran3-3-heptenoyl 
diazomethane from 5(S)-[(terf-butoxycarbonyl)amino]-6-(methyl)-frans-3-
heptenoic acid
COOH
BOCNH BOCNH
Materials
Sodium hydride (95%) 0.0522 g (max. 2.066 mmol)
THF 4 ml
5(S)-[(ferf-Butoxycarbonyl)amino]-6-(methyl)-fra/7S-3-heptenoic acid
0.56 g (2.18 mmol)
THF 7 ml
Isobutyl chloroformate 0.350 ml (2.699 mmol)
Diazomethane (diethyl ether solution) 16.75 mmol
Method
The ground glass connections of a 100 ml three necked round bottom flask were 
thoroughly greased. The vessel was then equipped with a Teflon® coated 
magnetic stirring bar and a nitrogen balloon, sealed with septum caps and flame 
dried. Under a flow of nitrogen, sodium hydride (95%) was then added as a 
solid, THF (4 ml) injected and stirring initiated. The resulting suspension was 
taken to -70°C where 5(S)-[(te/f-butoxycarbonyl)amino]-6-(methyl)-fraA7s-3- 
heptenoic acid in THF (7 ml) was added by syringe. The solution was warmed 
to -20°C where stirring was continued for a further 15 minutes. Isobutyl 
chloroformate was then added dropwise at this temperature and the mixture 
stirred for 30 minutes before the addition of diazomethane (diethyl ether 
solution). After being stirred at -20°C for 1 hour the reaction was allowed to 
warm slowly to room temperature where stirring was continued for a further 1 
hour. The reaction was quenched by the addition of water (50 ml) with vigorous 
stirring. The mixture was then transferred to a separatory funnel where it was 
extracted three times with diethyl ether. The combined organic layers were dried 
with magnesium sulfate, filtered and evaporated yielding a yellow oil (0.69 g).
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Positive pressure flash chromatography (eluent 1:5 ethyl acetate:hexane) 
yielded a clear yellow liquid which was identified as being the desired compound 
(0.03 g, 5% yield, Rf 0.46, eluent 1:1 ethyl acetate:hexane). Also isolated was 
the corresponding methyl ester as a clear colourless liquid (0.31 g, 52% yield, Rf 
0.72, eluent 1:1 ethyl acetate:hexane).
Diazomethyl ketone: [a]D18 -9.85 (19.6 mg/1 ml CHCI3)
vmax(CHCI3)/cm' 1 3448m (NH), 2109s (diazo), 1709s (carbamate C=0 ), 1652m
(ketone C=0), 1500s (carbamate)
m/z 281 (M+, 0.5%), 238 (M - [CH3]2CH, 7.9), 225 (1.6), 210 (0.6) 
m/z 281.1737 (M+, C14H23N30 3, requires 281.17393)
8h(200MHz CDCI3) 0.83 and 0.84 (6 H, both d, J 6 .8 , [CH3]2CH), 1.37, (9H, s, 
[CH3]3C), 1.71 (1H, m, [CH3]2CH), 2.99 (2H, d, J 6.7, CH2), 3.85 (1H, m, CHN), 
4.50 (1H, brd, J 7.2, NH), 5.36 (1H, s, CHN2), 5.42, (1H, dd, J 15.5 and 5.9, 
CH=CHCH[CH3]), 5.58 (1H, ddt, J 15.4, 6.7(t) and 0.8, CH=CHCH[CH3]) 
5c(50MHz CDCI3) 16.2 and 16.7 (both q, [CH3]2CH), 28.3 (q, [CH3]3C), 32.2 (d, 
[CH3]2CH), 44.4, (t, CH2), 54.3 and 57.5 (both d, CHN and CHN2), 79.3 (s, 
[CH3]3C), 123.4 and 134.5 (both d, CH=CH), 155.5 (s, CONH), 193.1 (s, 
COCHN2)
Ester: [<x]D18 -8.59 (17.7 mg/1 ml CHCI3)
vmax(CHCI3 )/crn' 1 3448m (NH), 1732s (ester C=0), 1718s (carbamate C=0),
1500s (carbamate)
m/z 228 (M - [CH3]2CH, 17.4%), 215 (M - [CH3]2[CH2]C, 3.6), 172 (86.4), 155 
(10.6)
m/z 228.1234 (M - [CH3]2CH, C^H^N 0 4 requires 228.12357)
8h(200MHz CDCI3) 0.81 and 0.82 (6 H, both d, J 6 .8 , [CH3]2CH), 1.37 (9H, s, 
[CH3]3C), 1.68 (1H, m, [CH3]2CH), 3.01 (2H, d, J 6.7, CH2), 3.60 (3H, s, OCH3), 
3.88 (1H, m, CHN), 4.63 (1H, brd, J 8.9, NH), 5.41 (1H, dd, J 15.5 and 5.8, 
CHCH=CH), 5.61 (1H, ddt, J 15.5, 6.7(t) and 1.0, CH=CHCH2)
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5c(50MHz CDCI3 ) 17.9 and 18.4 (both q, [CH3]2CH), 28.1 (q, [CH3]3C), 32.2 (d, 
[CH3]2CH), 32.7 and 37.3 (both d, CH2), 51.3 and 51.5 (both q, OCH3), 57.0 (d, 
CHN), 78.8 (s, [CH3]3C), 122.5 and 133.1 (both d, CH=CH), 155.3 (s, CONH),
171.8 and 173.1 (both s, COOCH3)
239
5(S)-[(ferf-Butoxycarbonyl)amino]-2(R)-methyl-6-(phenyl)-frans-3-hexenoyl 
diazomethane from 5(S)-[(fe/t-butoxycarbonyl)amino]-2(R)-methyl-6-
(phenyl)-frans-3-hexenoic acid
CH2Ph CH2Ph O
BOCNH BOCNH ^C H N 2
Me Me
Materials
Sodium hydride (55-65% in oil) 0.0440 g (max. 1.192 mmol)
THF 2 ml
5(S)-[(te/f-butoxycarbonyl)amino]-2 (R)-methyl-6-(phenyl)-frar7S-3-hexenoic acid
0.38 g (1.19 mmol)
THF 4 ml
Isobutyl chloroformate 0.16 ml (1.23 mmol)
Diazomethane (diethyl ether solution) c. 13.4 mmol
Method
A 100 ml three necked round bottom flask was equipped with a Teflon® coated 
magnetic stirring bar and a nitrogen balloon. The ground glass joints were 
thoroughly greased, the flask sealed with septum caps then flame dried. Under 
a flow of nitrogen sodium hydride (55-65% in oil) was added to the vessel as a 
solid. Pentane (2 ml) was added via syringe and stirring initiated. After 2 
minutes the pentane was removed by suction leaving clean sodium hydride. 
THF (2 ml) was then added and the resulting suspension taken to -78°C where 
5(S)-[(terf-butoxycarbonyl)amino]-2(R)-methyl-6-(phenyl)-frans-3-hexenoic acid 
in THF (4 ml) was added by syringe. The solution was stirred at -78°C for two 
minutes then slowly warmed to -20°C. Isobutyl chloroformate was added 
dropwise at this temperature and, following a 30 minute stir, diazomethane 
(diethyl ether solution) was also added. After being stirred at -20°C for 1 hour 
the reaction was allowed to warm to room temperature where stirring was 
continued for a further 1 hour. The reaction was quenched by the addition of 
water (50 ml) with vigorous stirring. Following this, the mixture was transferred 
to a separatory funnel where the organic layer was separated and the aqueous
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layer extracted twice with diethyl ether. The combined organic layers were dried 
with magnesium sulfate, filtered and evaporated yielding a yellow oil (0.44 g).
Dry flash chromatography (polarity gradient, pure hexane to 1:1 ethyl 
acetate:hexane) yielded a slightly impure sample of the desired product as a 
yellow oil (0.10 g, 25% yield, Rf 0.53 eluent 1:1 ethyl acetate:hexane). A sample 
of the corresponding methyl ester was also isolated as white solid (0.22 g, 56% 
yield, Rf 0.61 eluent 1:1 ethyl acetate:hexane). Recrystallisation attempts, from 
diethyl ether/hexane, gave a small quantity of highly pure ester for analysis (0.03 
g). Purification of the desired diazo compound by precipitating the small impurity 
from diethyl ether/hexane was only partially successful. Removal of the tiny 
amount of remaining impurity by dry flash chromatography (hexane to ethyl 
acetate gradient) gave limited results. Further purification was not attempted as 
only 16.5 mg of product remained.
Diazomethyl ketone: [a]D22 -14.9 (17.0 mg/1 ml CHCI3)
V m ax(C H C I3) /c n Y 1 3441m (N H ) ,  2107s (diazo), 1707s (carbamate C = 0 ) ,  1636m 
(ketone C = 0 ) ,  1496s (carbamate)
m/z 315 (M - N2, 0.2%), 299 (M - [CH3]2[CH2]C, 0.1), 298 (0.6), 282 (0.5), 266 
(0.4), 252 (2.5), 239 (0.1), 220 (0.9)
5h(200MHz CDCI3) 1.17 (3H, d, J 7.0, CH3CH), 1.42 (9H, s, [CH3]C), 2.85 (2H, d 
of ABq, J 13.4(AB), 7.7 and 6.1, CH2) , 4.35 (1H, m, CHN), 4.55 (1H, brd, J 8.2, 
NH), 4.97 (1H, s, CHN2), 5.46 (2H, m, J possible 15.4, CH=CH), 7.15-7.34 (5H, 
m, Ph)
8h(200MHz d6-DMSO) 5.88 (1H, s, CHN2)
8c(50MHz CDCI3) 16.5 (q, CH3CH), 28.3 (q, [CH3]3C), 41.5 (t), 42.4 (d, CH3CH),
48.0 (d, CHN2), 53.5 (d, CHN), 79.6 (s, [CH3]3C), 126.5 (d, Ph), 128.3 (d, 
CH=CH), 128.9 (d, Ph), 129.6 (d, Ph), 132.5 (d, CH=CH), 137.3 (s, Ph), 155.1 
(s, CONH), 195.9 (s, COCHN2)
Ester: vmax(KBr)/crn‘1 3358s (NH), 1738s (ester C=0), 1678s (carbamate C=0), 
1524s (carbamate)
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m/z 277 (M - [CH3]2[CH2]C, 0.1%), 242 (M - PhCH2>11.2), 232 (0.2), 217 (1.5), 
91 (32.6)
m/z 242.1398 (M - PhCH2, C12H20N 0 4 requires 242.13919)
5h(200MHz CDCI3) 1.12 (3H, d, J 7.0, CH3CH), 1.31 (9H, s, [CH3]3C), 2.72 (2H, 
d, J 6.9, CH2), 3.01 (1H, m, CH3CH), 3.54 (3H, s, OCH3), 4.30 (1H, m, CHN), 
4.61 (2H, brd, J 8.7, NH), 5.45 (2H, d of ABq, J 15.5(AB), 6.3 and 4.2, CH=CH), 
7.03-7.22 (5H, m, Ph)
5c(50MHz CDCI3) 17.0 (q, CH3CH), 28.2 (q, [CH3]3C), 41.6 (t, CH2), 42.2 (d, 
CH3CH), 51.7 (q, OCH3), 52.6 (d, CHN), 79.3 (s, [CH3]3C), 126.3 (d, Ph), 128.1 
(d, Ph), 129.4 (d, CH=CH), 129.5 (d, Ph) and 131.5 (d, CH=CH), 137.2 (s, Ph),
155.0 (s, CONH), 174.7 (s, COOCH3)
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Appendix 1: Molecular Mechanics Calculations
Molecular mechanics calculations (Chem-X software, Chemical Design Ltd. 
1994) were carried out on both the amide link and (E)-ethene isostere bearing 
variants of A/-BOC-(L)-Val-(L)-Ala diazomethyl ketone in order to obtain their 
minimum energy conformations.
N -BO C -(L)-V al-(L)-A laC H N 2
s (£)-ethene isostere
CH3
A m ide linked 
Af-BOC-(L)-Val-(L)-AlaCHN2
The results of this study, for the region around the linking groups, are indicated 
on the following diagrams.
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1.052
1.504
1.50- 1.304
1.049
CH(CH3)2 h
0.974 
.N  1.451
.3631.50'
1.207
B ond Lengths (Angstrom s)
119.7 124.7
120.4 119.9
119.2 118.6
120.1
122.2
119.2
Bond Angles (degrees)
Torsion Angles (degrees)
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Appendix 2: Initial Biological Results
For simplicity, the compounds under investigation are assigned the following 
abbreviations:
(EVEthene isosteres
A/-BOC-(L)-Phe-(L)-Ala diazomethyl ketone PAD
A/-BOC-(L)-Phe-(L)Ala methyl ester PAE
A/-BOC-(L)-Val-(L)Ala diazomethyl ketone VAD
A/-BOC-(L)-Val-(L)Ala methyl ester VAE
A/-BOC-(L)-Val-Gly diazomethyl ketone VGD
A/-BOC-(L)-Val-Gly methyl ester VGE
Peptide linked compound
A/-CBZ-(L)-Phe-(L)Ala diazomethyl ketone ZPA
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1. Protease Enzyme Inactivation (SDS-PAGE)
T.
foetus
F2
T.
vaginalis
G3
T.
augusta
G.
lamblia
L
mexicana
(1)*
L.
mexicana
(2)*
PAD no effect no effect no effect no effect no effect
PAE no effect no effect no effect no effect no effect
VAD no effect no effect no effect no effect no effect
VAE no effect no effect no effect no effect no effect
VGD no effect no effect no effect no effect no effect no effect
VGE
some
effect
some
effect
some
effect no effect
strong
effect no effect
* (1) L. mexicana (wild type) stationary phase promastigotes 
(2) L  mexicana (wild type) amastigotes
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2. In vitro Growth Inhibition
Test compound solutions (in water with 2.5% added DMSO) were prepared at 
the following concentrations; 100, 50, 25, 10, 5, 2.5 and 1 pg/ml. Note, 
however, that solubility problems with VGD and VGE prevented testing at 
concentrations greater than 50 pg/ml. Note that with the compound ZPA a test 
solution at 250 pg/ml was also prepared.
The experiments were carried out by treating 180 pi of culture with 20 pi of each 
test compound solution. These mixtures were incubated under the conditions 
specified above each of the following tables of results. A control mixture, which 
consisted of 180 pi culture and 20 pi water/2.5% DMSO with no added test 
compound, was treated similarly.
All mixtures contained, on initiation, 105 parasites/ml as standard.
After incubation, cell counts in 0.1 pi of mixture were taken and compared to 
those of the control. Results are tabulated as a percentage of the control cell 
count. The values quoted are for the maximum concentration of inhibitor 
solution used in cases where growth inhibition was only slight. In cases where 
the effect of the test compound was significant, the concentration giving 
complete inhibition is noted together with the results obtained for the weaker 
solution next in sequence. It should also be noted that all experiments were 
carried out in duplicate and the figures quoted are for the averaged results of 
these.
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T. augusta
Incubated anaerobically for 48 hours at 25°C.
test compound compound concentration 
pg/ml
average cell count 
(%)
PAD 100 92
PAE 100 100
VAD 100 20
VAE 100 104
VGD 50 87
VGE 50 111
T. foetus F2
Incubated anaerobically for 24 hours at 37°C.
test compound compound concentration 
pg/ml
average cell count 
(%)
PAD 100 57
PAE 100 79
VAD 100 67
VAE 100 102
VGD 50 48
VGE 50 34
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T. vaginalis G3
Incubated anaerobically for 24 hours at 37°C.
test compound compound concentration 
pg/ml
average cell count 
(%)
PAD 100 78
PAE 100 92
VAD 100 81
VAE 100 101
VGD 50 83
VGE 50 49
L. mexicana (wild type)
Incubated aerobically for 5 days at 25°C.
test compound compound concentration average cell count
pg/ml (%)
PAD 100 0
50 81
PAE 100 109
VAD 100 115
VAE 100 113
VGD 10 53
VGE 10 o
ZPA 250 99
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L. mexicana (AC10)
Incubated aerobically for 5 days at 25°C.
test compound compound concentration average cell count
pg/ml (%)
PAD 100 0
50 4
PAE 100 103
VAE 100 116
ZPA 250 104
L. mexicana (N53)
Incubated aerobically for 5 days at 25°C.
test compound compound concentration average cell count
pg/ml (%)
PAD 100 0
50 1
PAE 100 120
VAD 100 66
VAE 100 93
ZPA 250 104
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Appendix 3: Second Round Parasite Growth Studies
G. intestinalis
Incubated anaerobically for 48 hours at 37°C
test compound compound concentration average cell count
pg/ml (%) ‘
VGD 50 52
VGE 100 0
50 1
L. mexicana (wild type)
Incubated aerobically for 5 days at 25°C.
test compound compound concentration average cell count
pg/ml (%)
PAD 100 0
50 2
PAE 100 112
VAD 100 <2
50 15
VAE 100 7
VGD 50 102
VGE 50 0
10 7
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L. mexicana (AN8m)
Incubated aerobically for 5 days at 25°C.
test compound compound concentration average cell count
pg/ml (%)
PAD 100 <1
50 32
VGD 50 48
VGE 25 0
10 4
ZPA 25 108
L. mexicana (N53)
Incubated aerobically for 5 days at 25°C.
test compound compound concentration average cell count
pg/ml (%)
PAD 50 0
25 18
PAE 100 127
VAD 100 0
50 8
VAE 100 2
50 49
VGD 50 99
VGE 10 0
5 104
ZPA 25 88
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L. mexicana (AC10m)
Incubated aerobically for 5 days at 25°C.
test compound compound concentration average cell count
pg/ml (%)
PAD 100 2
50 77
VAD 100 7
VAE 100 21
VGD 50 93
VGE 10 0
5 106
ZPA 25 131
J S t
